Stress to progress: learning from antibiotic stress responses to accelerate tuberculosis drug discovery by Boot, M.
  
 
 
 
 
 
 
 
 
 
 
Stress to progress: learning from antibiotic 
stress responses to accelerate tuberculosis drug 
discovery 
 
 
 
 
 
 
 
Maikel Boot 
 
 
 
 
 
 
 
2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doctoral Dissertation Committee: 
 
Prof. dr. F.J. Bruggeman 
Prof. dr. C. Schultsz 
Prof. dr. T.N. Grossmann 
Dr. J.A. Green, MD 
Dr. J.E.M. de Steenwinkel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
promotor:   prof. dr. W. Bitter      
copromotor:  prof. dr. C.M.J.E. Vandenbroucke-Grauls 
 
       
 
 
 
 
 
 
 
 
 
  
 Table of contents 
 
Chapter 1 General introduction  
 
Chapter 2  Exogenous phosphate stress modulates capsular polysaccharide 
composition in mycobacteria. 
  
Chapter 3 iniBAC induction is Vitamin B12- and MutAB-dependent in Mycobacterium 
marinum 
 
Chapter 4 Cell envelope stress in mycobacteria is regulated by the novel signal 
transduction ATPase IniR in response to trehalose  
 
Chapter 5 Induction and secretion of IniB protein is dependent on IniA and IniC in 
Mycobacterium marinum  
 
Chapter 6 Accelerating early anti-TB drug discovery with mycobacterial indicator strains that 
predict mode of action 
 
Chapter 7  A fluorescence-based reporter for monitoring expression of mycobacterial 
cytochrome bd in response to antibacterials and during infection 
 
Chapter 8 Summarizing discussion  
 
 
 
 
 
 
 
 
 
 
  
1. 
 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History of the Mycobacterium tuberculosis complex  
  Tuberculosis (TB) is caused by bacterial species that belong to the Mycobacterium 
tuberculosis complex (MTBC). The first signs of human tuberculosis were traced back to a mummy 
that was buried approximately 9.000 years ago in Israel. From this mummy DNA samples, that very 
closely resemble M. tuberculosis, have been isolated (Hershkovitz et al. 2008) . Interestingly, several 
species that belong to the MTBC complex are also able to cause disease in animals, such as 
Mycobacterium bovis, Mycobacterium pinipedii, and Mycobacterium caprae. The exact origin of 
mycobacterial diseases in animals remains speculative, but the oldest evidence of non-human 
mycobacterial infection comes from a 17.000 year old bison fossil, found in the Natural Trap Cave in 
Wyoming, USA. This bison contained traces of specific mycobacterial lipids that were indicative of 
M. bovis (Lee et al. 2012). Overall, MTBC members contain a very high amount of homologous 
sequences and overall similarity in their genomic DNA. Because members of the MBTC complex 
cause disease in animals and/or humans, it was previously thought that human tuberculosis directly 
evolved from an M. bovis-like progenitor during the first agricultural revolution (10.000 years ago). 
However, genetic research indicated that this scenario is highly unlikely, as several groups have shown 
that M. bovis is in fact part of a younger lineage branch (Brosch et al. 2002; Mostowy et al. 2002). 
Recently, DNA analysis of 259 historical MTBC strains was used to computationally reconstruct the 
evolutionary history of M. tuberculosis in humans. Results from this study indicate that the MTBC 
emerged around 70.000 years ago (Comas et al. 2013). This timing coincides with the out-of-Africa 
migration of anatomically modern humans. This migration eventually led to more densely populated 
areas at different locations in the Neolithic period, possibly explaining the surge of MTBC infections 
in humans (Comas et al. 2013). It is thought that all six lineages of the MTBC group arose after 
undergoing an evolutionary bottleneck that occurred around 20.000-35.000 years ago (Hughes et al. 
2002). Not much is known about the evolution of MTBC before this bottleneck. However, a few 
genomic studies point to an ancient progenitor as the genetic ancestor of the MTBC. This progenitor 
species, commonly known as M. canettii, is thought to have emerged in East Africa as far as 3 million 
years ago (Cristina et al. 2005). A schematic overview of the evolutionary events that followed from 
this ancient progenitor is shown in figure 1. Remarkably, M. canettii isolates are rare as exemplified 
by the fact that they are found highly infrequently and solely in patients in the horn of Africa. (Cristina 
et al. 2005) This probably means that the natural niche or host of this M. tuberculosis progenitor 
species is non-human and yet to be identified.  
 
 
 
 
 
 
  Figure 1. Mycobacterium canettii is likely the ancient progenitor for the current MTBC lineages. Key M. 
canettii progenitor species are labeled A-K. An evolutionary bottleneck forced the species to converge, 
accumulating various mutations in the process (e.g. ∆cobF and PE_PGRS33 mutations). The bottleneck resulted 
in the MTBC offspring lineages 1-6 as indicated by the colors in the figure. Below the geographical origin of the 
lineage, the most notable members of the group are listed. Image adapted from (Boritsch et al. 2016). 
 
  Intriguingly, a recent study indicates that the origin of MTBC isolates could lie within the sea, 
since the group of Stinear et al. presented evidence that a direct predecessor of M. tuberculosis was 
present in a marine sponge (Stinear et al. unpublished). As DNA detection in environmental samples 
and fossil remains improves almost monthly, it is likely a matter of time before a more complete 
picture of the predecessors of human M. tuberculosis will be identified.  
  As human population density increased starting with the out-of-Africa migration, the 
incidence of mycobacterial infections probably increased as well. From the Medieval Ages onwards, 
tuberculosis was known as ‘the white plague’. In total, it has been estimated that tuberculosis caused 
approximately 20% of all deaths between the 17th and 19th century (Chalke 1959; Wilson 2005). In the 
17th century it was the Dutchman Franciscus de la Boë Sylvius who first coupled the characteristic 
tubercle-like lesions in the lungs of patients to the disease tuberculosis (back then known as phthisis). 
Later, Johann Lukas Schönlein introduced the term ‘tuberculosis’ and was subsequently adopted by 
the scientific community. However, it was not until the 19th century that the actual origin of the disease 
was discovered. The first person to show that tuberculosis was not an inherited disease but caused by a 
transferable pathogen was Jean-Antoine Villemin. In 1865, he transferred material from a tuberculosis 
lesion from a cadaver to a healthy rabbit and showed that the rabbit became infected with a strikingly 
similar tuberculosis-like disease. Although he was able to show the contagious nature of the disease in 
these experiments, he could not pinpoint the causative agent. The credit for actually proving the 
existence of a bacterial agent causing tuberculosis went to Robert Koch, whom in 1882 was the first to 
identify, cultivate and characterize Mycobacterium tuberculosis. His findings were published on April 
10th of 1882 in a German medical journal, the “Berliner klinischen wochenschrift”, with the title “Die 
aetiologie der tuberkulose”. Koch’s work spread rapidly across the globe and this cornerstone of 
tuberculosis research won him the Nobel prize in 1905. Because of his work, the world was informed 
on the existence of the bacterium that caused tuberculosis in humans. This crucial discovery oiled the 
works for intervention strategies. Although the scientific community has been aware of the identity of 
the causative agent of TB for more than a century, tuberculosis (TB) still remains one of the severest 
public health problems worldwide.  
 
The global impact and burden of TB  
  The WHO report on tuberculosis, published in 2016, clearly summarizes the severity of the 
tuberculosis pandemic. Over the past 15 years, the incidence of TB has remained relatively stable, 
ranging from 10.2-10.7 million new cases per annum. In 2015, an estimated 10.4 million people 
contracted TB and 1.8 million people died, making it the deadliest infectious disease known to 
mankind (WHO 2016). Of these 1.8 million deaths, 400.000 involved HIV-co-infected individuals. 
Strikingky, the majority of TB cases (>60%) occurred in just six countries: China, India, South-Africa, 
Indonesia, Nigeria and Pakistan (WHO 2016). A worrying development is the spread of multi-drug 
resistant (MDR) and extensively-drug resistant (XDR) M. tuberculosis strains. The highest burden of 
MDR-TB resides within China, Russia, Kazakhstan and several other countries of the former USSR 
(Figure 2). MDR-TB is defined as TB caused by a strain that is resistant for the pivotal first-line 
antibiotics isoniazid (INH) and rifampicin (RIF). Estimates by the WHO suggest that the incidence of 
MDR-TB has tripled between 2009 and 2014 to a staggering total of 480.000 cases reported in 2014 
and over 190.000 deaths. XDR-TB is defined as TB caused by a strain that is not only resistant to INH 
and RIF, but additionally to at least one fluoroquinolone (levofloxacin or moxifloxacin) and to one of 
the second-line drugs (kanamycin, capreomycin or amikacin) (WHO 2016). By the end of 2015, more 
than 115 countries have reported XDR-TB cases and a total of 9.5% of MDR-TB cases were labeled 
XDR-TB.  
 
 
 Figure 2. A global heat map showing the distribution of MDR-TB infections. Data and image are derived from 
the WHO report on tuberculosis (WHO 2016). Colors indicate the percentage of cases, as indicated in the 
legend. 
 
Mycobacterial infection and TB immunology 
  As TB is a disease of the lungs, M. tuberculosis can be readily found in the airways of most 
patients with an active mycobacterial infection. The bacterium becomes airborne when thousands of 
small droplets, called aerosols, are expulsed in the air as a result of coughing or sneezing. These 
aerosols effectively transmit mycobacteria from one host to another, thereby spreading the infection. 
This effectiveness is underscored by the observation that only a very small number of bacteria, 
typically less than 10, are required to establish a successful infection. Some bacteria-containing 
aerosols can reach the alveoli of the lung. There, the bacilli are phagocytized by resident macrophages. 
However, mycobacteria are able to survive the harsh environment within the phagosomal compartment 
of the macrophage by inhibiting the phagolysosomal fusion (Cosma et al. 2003). A specialized type 
VII secretion system, the so-called ESX-1 system, mediates subsequent phagosomal escape through 
secretion of effectors, among which the well-described EsxA and EsxB (van der Wel et al. 2007; Ates 
et al. 2016). Mycobacterial escape to the cytosol is combined with extensive immune modulation, 
which together provides M. tuberculosis with a replication niche (Tufariello et al. 2003). Once 
infected, the macrophages recruit B- and T-cells and other macrophages through a pro-inflammatory 
immune response to the site of infection to form the hallmark of tuberculosis: the granuloma, or 
tubercle (Flynn et al. 2011).  
  The granuloma is a highly organized structure containing a center of infected and uninfected 
macrophages surrounded by lymphocytes. This immune response often results in the inhibition of 
outgrowth of mycobacteria. However, complete eradication of the invading bacteria is thought to be 
rare. Therefore, the tubercle is in fact a cellular deadlock, which can sustain for decades (Saunders & 
Britton 2007). This state is called latent tuberculosis infection, abbreviated to LTBI. LTBI is defined 
as infection with M. tuberculosis without clinical symptoms nor outgrowth of actively replicating 
bacteria (Flynn et al. 2011). An estimated 2 billion people have an LTBI globally (Zumla et al. 2013). 
LTBI diagnosis is difficult, but a positive tuberculin skin test is indicative of M. tuberculosis. This test 
involves the dermal injection of a crude lysate of processed M. tuberculosis, the so-called purified 
protein derivative (PPD). An individual that has previously been in contact with mycobacteria will 
undergo a T-cell mediated immune reaction resulting in a local dermal inflammation (Gedde-dahl & 
Oedde-dahl 1982). The size of the inflammation determines whether the reaction is scored as positive 
or not. However, one should keep in mind that tuberculin positivity solely indicates that the individual 
has developed an immune response against mycobacterial proteins at some point in his life; it does not 
indicate the presence of an active bacterial infection. It has been estimated that only 5-10% of people 
with an LTBI convert to active tuberculosis (WHO 2016). In general, factors such as age, 
malnutrition, stress, smoking or any factor that leads to reduced immunity increases the risk of 
conversion to active disease. Diseases that specifically affect the immune system also increase the risk 
to develop active TB. As indicated previously, a large proportion of TB deaths can be attributed to 
HIV co-infection. The odds of converting from LTBI to active TB, when co-infected with HIV, 
increase from 5-10% to about 50-60% (Selywn et al. 1989). In active TB, the bacilli are not contained 
within the structure of the granuloma, but continue to multiply and form new tubercle foci. This results 
in the destruction of large parts of infected lung tissue. In some cases, the bacteria enter the 
bloodstream and disseminate throughout the body, causing extra-pulmonary TB (Rieder et al. 1990). 
TB is a treatable and curable disease, but historical figures show that up to two thirds of the people 
with active disease will die when the infection is left untreated. 
 
The history of TB treatment 
  After the discovery of the causative agent of tuberculosis by Robert Koch in the late 19th 
century, it took eighty additional years before a treatment regimen was formulated. Reasons for this 
are the apparent resilience and intrinsic resistance that M. tuberculosis displays. The first 
antimycobacterial drug that was discovered came from the group of Selman Waksman, a renowned 
soil microbiologist at Rutgers University in New Jersey. Waksman found that some soil bacteria 
produce compounds that kill other microorganisms. Although he did not coin the term ‘antibiotic’, he 
is accredited for implementing the word in modern science. Waksman isolated the first anti-TB drug 
from Streptomyces griseus and named it ‘streptomycin’. Together with his graduate student Albert 
Schatz, who purified the compound, he published the results in 1944 (Schatz et al. 1944; Wassersug 
1946). This work was the basis for the extensive use of streptomycin as medical agent to combat TB 
and earned Waksman the Nobel prize in 1952. However, streptomycin as monotherapy was soon 
proven to be ineffective during long-term treatment of patients in clinical trials conducted in 1946 by 
the Medical Research Council (MRC) in the UK. Upon conducting the first randomized, controlled 
clinical trial ever, the researchers compared bed rest with a combination of streptomycin and bed rest. 
Although the combination therapy was proven to be superior, the pathology reports were somewhat 
disappointing. Chest X-rays from the treated infected patients demonstrated that only a modest 
improvement could be attributed to streptomycin treatment. The reason for this was the occurrence of 
relapse and drug-resistant mutants after three months of treatment, which indicated that monotherapy 
with streptomycin was not the holy grail to cure TB (Saeed 1971). Scientists and medical doctors soon 
realized that TB can only be cured by administering a multi-drug combination therapy. 
  At almost the same time, a second anti-TB agent was identified in 1943. It was the Danish-
born Swedish Jörgen Lehmann who rationally designed para-aminosalicylic acid (PAS), based on a 
paper of Frederick Bernheim that was published in the journal Science (Bernheim 1940). Bernheim 
showed that salicylic acid could increase the respiratory rate of M. tuberculosis. Based on this work, 
Lehmann hypothesized that a modified structural analogue of the agonist salicylic acid may very well 
have antagonistic properties, thus inhibiting respiration in M. tuberculosis. He drafted two chemical 
entities and contacted Ferrosan, a pharmaceutical company, to synthesize these molecules. One of the 
two chemicals was PAS, and in collaboration with Karl-Gustav Rosdahl large quantities were 
produced in 1943. Soon after, PAS was proven to be effective in animal models and patients suffering 
from TB, and this led to the first combination regimen to treat tuberculosis from 1948 onwards (Ryan 
1992). After the discovery of streptomycin and PAS, two pivotal drugs against TB, the interest in anti-
mycobacterial drug discovery bloomed. This led to the identification of thiacetazone, isoniazid, 
clofazimine, cycloserine, kanamycin, ethionamide, ethambutol, rifampicin and capreomycin in the 
period from1952 to 1963, providing additional options for combination therapy (Wong et al. 2013). 
These years were the golden age of TB drug discovery; whereafter drug discovery waned. It was not 
until 2005 that a novel class of anti-mycobacterial drugs was identified. 
 
TB treatment today 
  Nowadays, patients suspected to have TB are diagnosed with classical culturing methods in 
combination with microscopy or the mycobacterial growth indicator tube assay (MGIT). A recent 
development in diagnosis is the Xpert MTB/RIF assay; a culture-free method of detection that uses a 
PCR-based approach to detect M. tuberculosis. This tool enables rapid diagnosis and simultaneous 
assessment of rifampicin resistance within 2 hours (Lawn et al. 2013).  
  Current treatment of drug susceptible tuberculosis includes a six-month course of several 
different antibiotics: a 2-month intensive phase with isoniazid, rifampin, pyrazinamide (and often 
ethambutol), succeeded by a 4-month period with isoniazid and rifampin. This regimen is based on 
multiple historical clinical trials conducted by the U.S. Public Health Services (PHS) and its 
aforementioned UK counterpart, the MRC. The trials conducted at these institutes between 1948 and 
1986 provided strong evidence that a six-month course could clear TB infection. Moreover, there was 
a low (5-8%) observed relapse rate post treatment (Fox et al. 1999). Most importantly, these trials 
showed that a combination of rifampin (RIF) and isoniazid (INH) allowed shortening treatment from 
18 months (for mono-therapy) to 9 months of combination therapy. For even better cure rates, 
pyrazinamide (PZA) was added during the first two months of this ‘core treatment’ of RIF and INH. 
Additionally, ethambutol (EMB) is included whenever one of the other antibiotics proves ineffective. 
The quadruple combination reduced treatment duration to 6 months. Recent attempts to further reduce 
treatment duration by adding fluoroquinolones have failed. The tested 4-month treatments that 
included gatifloxacin and moxifloxacin led to higher (>13%) overall relapse rates (Gillespie et al. 
2014; Gninafon et al. 2014).  
  During the first two months of the standard six-month treatment regimen the bacilli 
are killed rapidly, leading to a sharp (>99%) decline of the number of viable bacteria and even to total 
clearance of culturable M. tuberculosis from patient sputa (see Figure 3) (Mitchison & Davies 2012). 
The efficacy of early-phase treatment is mostly attributed to the bactericidal activity of INH. However, 
the killing of M. tuberculosis is biphasic, which likely reflects the presence of two populations 
intertwined in human TB infection: a drug-susceptible and actively replicating population, versus a 
more persistent and drug-resistant population that is harder to target. Aborting drug treatment after two 
months, even though the majority of the infection is cleared, can therefore leads to high relapse rates 
(Fox et al. 1999; Lawn et al. 2013). The exact reason for the differential response of bacterial 
populations to treatment is unclear, but localization of bacilli highly influences the ability of 
antibiotics to reach them. Moreover, oxygen tension, nutrient abundance, environmental pH and/or 
bacterial metabolic activity are factors that affect this heterogenic response to treatment (Lenaerts et 
al. 2015).  
  
Figure 3. The biphasic killing of drug susceptible TB during treatment. During the first month, a rapid decline 
can be observed in bacterial survival. This is followed by a phase where mycobacterial numbers slowly decline 
over time as treatment progresses (Mitchison & Davies 2012).  
 
   
A factor that strongly complicates TB treatment is that patients oftentimes feel significantly better 
soon after commencing treatment. Additionally, the antibiotic treatments can have many unpleasant 
side-effects. As a result, patients sometimes discontinue treatment well ahead of the 6-month time 
point. This premature discontinuation of treatment not only leads to a high risk of relapse, it also 
contributes to an increase in the development of bacterial resistance due to mutations. Initially, this 
may lead to strains resistant to one of the first-line drugs. Strains like these have been documented in 
every country on earth so far (WHO 2016). However, further acquisition of mutations as a result of 
incomplete treatment can lead to an increase in the occurrence of MDR and XDR-TB strains. A strong 
increase in MDR-TB and XDR-TB cases has been observed over the last decade. Besides failure to 
comply with therapy, a second cause of the increase in MDR- and XDR-TB cases is the increased 
density and mobility of human populations, which leads to ample opportunity for drug resistant strains 
to directly transmit from patient to patient (Gandhi et al. 2006; Gelmanova et al. 2007). When patients 
are diagnosed with these resistant strains, treatment is extended to 24 months for MDR-TB and 48 
months for XDR-TB, respectively (CDC 2014). The success rate of MDR-TB treatment is around 50% 
and for XDR-TB success rates of treatment are around 40% (WHO 2016). The overall death rates for 
XDR-TB patients rates are 50-80%, and even those who survive have to suffer through extensive drug 
treatment with severe side effects (Mitnick et al. 2008; Pietersen et al. 2014) .  
  These numbers emphasize the dire need for novel anti-TB drugs. A reason for the limited 
availability of successful anti-TB drugs, and the low numbers of new compounds, is that mycobacteria 
are intrinsically resistant to some key antibiotic classes that work against other pathogens. There are 
several reasons for this intrinsic resistance. First, mycobacteria possess β-lactamases. The best well-
described example is BlaC, a β-lactamase that has a broad range of substrates because of its large and 
flexible binding pocket (Chambers et al. 1995). A second reason for extensive intrinsic resistance is 
the low permeability of the highly hydrophobic mycobacterial outer membrane. This makes 
mycobacteria naturally resistant to larger antibiotics, such as vancomycin. Finally, mycobacteria 
contain at least 18 transporters or efflux pumps that, in one way or another, contribute to antibiotic 
resistance. A review that describes these efflux pumps is provided by Da Silva et al. (da Silva et al. 
2011). 
 
Target and mode of action of anti-mycobacterial drugs  
  Most of the targets of currently used antimicrobials and antibiotics used to treat TB have been 
identified. Some of the first- and second-line antibiotics that are effective against mycobacteria are 
also effective against other pathogens. Examples of these are streptomycin, rifampicin and 
ciprofloxacin (or other fluoroquinolones, for that matter). Streptomycin is a broad-spectrum antibiotic 
that inhibits binding of formyl-methionyl-tRNA to the 16S subunit, which leads to an unstable 
interaction between the ribosome and mRNA molecules. As a result, ribosomal translation becomes 
highly inaccurate, forming mistranslated proteins in the process (Sharma et al. 2007). The sheer 
number of mistranslated proteins, and the resulting disruption of cellular function in general, are 
thought to lie at the basis of the bactericidal activity of streptomycin. Resistance mutations in M. 
tuberculosis were mapped more than two decades ago and predominantly found in rpsL, a ribosomal 
protein that is required for translation initiation, and rrs, which encodes the 16S ribosomal protein 
(Finken et al. 1993).  
  A frequently used second-line antibiotic to treat TB infections is ciprofloxacin, a 
fluoroquinolone antibiotic. The fluoroquinolones are broad-spectrum antibiotics, often prescribed to 
treat cases of allegedly resistant bacterial infections. The FDA recommends that fluoroquinolones 
should be reserved for cases where no other options are available (FDA drug safety communication; 
July 26, 2016). Fluoroquinolones inhibit DNA gyrase (Xu et al. 1996), which results in breaks in 
double strand DNA (dsDNA) during the unwinding of DNA. These massive dsDNA breaks cause a 
rapid bacterial cell death. Resistance mutations to fluoroquinolones in M. tuberculosis have been 
mapped to gyrA and gyrB at positions Ala-90 and Asp-94. Promoter mutations influencing expression 
of the gyrase genes have also been identified in M. tuberculosis (Von Groll et al. 2009).  
  Another key antibiotic in TB treatment is rifampicin, a natural compound produced by 
Amycolatopsis rifamycinica. Rifampicin resistance is very common, therefore mono-therapy is not 
advised. Rifampicin inhibits bacterial DNA-dependent RNA biosynthesis by binding in the pocket of 
the β-subunit of RNA polymerase. This steric occlusion results in the prevention of elongation of the 
5’ end of RNA molecules, leading to terminated (m)RNA transcripts (Campbell et al. 2001). 
Resistance mutations in M. tuberculosis are almost exclusively found in the gene encoding the β-
subunit, rpoB (Telenti et al. 1993).  
  Pyrazinamide (PZA), a nicotinamide, was discovered in 1936. It has been used as an anti-TB 
drug since 1952, after it was shown to be highly effective in a murine model of TB infection by 
pharmaceutical companies Lederle and Merck (Malone et al. 1952). PZA is exclusively used to treat 
mycobacterial infections and works particularly well against persistent mycobacterial populations. 
PZA was directly tested in animals for efficacy against M. tuberculosis. It therefore came as a surprise 
that it did not show any bactericidal activity in vitro. The inactivity is overcome when the bacilli are 
grown under acidic conditions (Whitfield et al. 2015). Although the exact mode of action of 
pyrazinamide is still being debated, there are some theories explain that can explain this phenomenon. 
Pyrazinamide is taken up by the host as a pro-drug and is then converted to its active form pyrazinoic 
acid (POA) by the mycobacterial pyrazinamidase (pncA). Several studies by Zhang et al. have shown 
that this intracellular pyrazinoic acid can subsequently diffuse out of the bacteria and become 
protonated. The protonated form (HPOA) is then taken up again by the mycobacteria and accumulates, 
causing pleiotropic effects on bacterial cell homeostasis (Zhang et al. 1999; Zhang et al. 2003; Zhang 
et al. 2013). Where and when protonation of POA occurs is not clear. The intra-phagosomal 
environment could provide the acidic pH. However, work by Raynaud et al. indicates that the pH in 
the phagosome might not be low enough to facilitate the protonation of PZA (Raynaud et al. 1999). In 
addition, other studies also contradict the HPOA theory; work by Peterson et al. indicates that a low 
pH is not essential for the activity of PZA (Peterson et al. 2015). An alternate mode of action has been 
proposed by another group. They found that POA binds to the ribosomal RpsA protein, causing 
inhibition of translation. This observation would explain both the pH-independency and the ability of 
PZA to effectively inhibit persister populations with low metabolic activity (Shi et al. 2011). 
Moreover, the same group identified mutations in the rpsA gene that conferred resistance to PZA. 
However, these findings are also not undisputed, as a recent study contradicts the findings of Shi et al. 
These authors show that the same point mutations in the rspsA gene did not confer resistance (Dillon 
et al. 2017). Although the mode of action is still under debate, it is clear that most clinical resistance 
mutations occur in the gene encoding the (PZA  POA) conversion enzyme, pncA. 
  The most recent breakthrough in antibiotic treatment of TB is the discovery of bedaquiline 
(BDQ), formerly known as TMC-207. It is the first antibiotic to be approved for human use in 40 
years. BDQ is part of a completely new class of antibiotics: the diarylquinolines. BDQ targets 
mycobacterial ATP-synthase and inhibits its AtpE subunit (Andries et al. 2005; Koul et al. 2007). So 
far, BDQ has not been included in the standard treatment regimen, but serves as an FDA-approved last 
resort for treatment of MDR- and XDR-TB cases. Since the discovery of BDQ, the interest in targeting 
the mycobacterial respiratory chain with antibiotics has grown. For most of the components of the 
oxidative phosphorylation complex of M. tuberculosis, inhibitory compounds have been identified. 
For instance, the NADH dehydrogenase (NDH-2), which reduces the menaquinone pool (MK/MKH2), 
can be inhibited by clofazimine (Yano et al. 2011). The cytochrome bc1 complex forms a super-
complex with the cytochrome aa3-type terminal oxidase. The complex transfers electrons onto 
oxygen. Inhibitors of this complex include imidazopyridines, with Q203 as the most promising 
example, and lansoprazol (Pethe et al. 2013; Rybniker et al. 2015). The targets and interactions of 
these drug molecules have been recently reviewed by Bald et al. (Koul et al. 2014; Bald et al. 2017). 
 
The mycobacterial cell wall as a target for antibiotics  
  The unique architecture of the mycobacterial cell envelope not only protects mycobacteria 
against many harmful compounds, it also functions as an excellent target for anti-mycobacterial drug 
discovery. The macromolecules in this cell wall and their biosynthesis routes are unique, which means 
that the compounds that target these processes are often highly specific for mycobacterial species. It 
comes as no surprise that several of the currently used anti-mycobacterial drugs are directed against 
the enzymes that are required for the biosynthesis of the cell envelope (Figure 4). Like Gram-negative 
bacteria, mycobacteria possess both an inner and an outer membrane. The inner- or cytoplasmic 
membrane resembles that of other bacteria and contains classical phosphatidyl-inositol (PI) lipids. In 
addition it also contains several mycobacterial specific lipoproteins and (glyco)lipids (Jackson 2014).  
 
 Figure 4. Sites and mechanisms of action of the four anti-tuberculosis agents ethionamide (ETH), isoniazid 
(INH), ethambutol (EMB) as well as the benzothiazinone (BTZ) in the M. tuberculosis cell envelope. BTZ is an 
experimental compound that is currently being evaluated in phase III clinical trials. MA = mycolic acids, AG = 
arabinogalactan, PG = peptidoglycan, LM = lipomannan, IM = inner membrane. The structures of the drug 
molecules are indicated on the left-hand side of the figure.  
 
Peptidoglycan biosynthesis and antibiotic targets 
  On the outside of the cytoplasmic membrane of mycobacteria, a meshed peptidoglycan layer 
can be found. Peptidoglycan biosynthesis mainly takes place through the Mur pathway 
(MurABCDEF) that collectively synthesizes a muramyl pentapeptide from UDP-GlcNAc and 
phospho-enol pyruvate (Smith 2006). Subsequently, MurX synthesizes Lipid I by addition of a 
decaprenyl phosphate. This molecule is further modified by MurG, that adds a GlcNAc to form Lipid 
II precursors. Lipid II monomers are then translocated over the inner membrane where GlcNAc 
moieties are attached to the muramyl-groups, resulting in the synthesis offunctional PG chains (Hett et 
al. 2010). There are some special modifications of the mycobacterial PG layer that are uncommon in 
other bacteria. For instance, whereas canonical PG contains N-acetylmuramic acid (MurNAc), 
mycobacteria contain an oxidized variant, N-glycolylmuramic acid (MurNGlyc), that provides more 
sites for hydrogen bonds, thereby effectively increasing the rigidity (Mahapatra et al. 2005). The 
muramyl components of the backbone are cross-linked in a mesh-like structure through their 
tetrapeptide side chains. These chains are l-alanyl-d-isoglutaminyl-meso-diaminopimelyl-d-alanine 
cross-linked between meso-diaminopimelic acid (m-DAP) and d-alanine (Lavollay et al. 2008). In 
mycobacteria, the amount of cross-links, and thus the rigidity of the layer in general, can vary. Thus, 
even without novel PG biosynthesis, the mesh structure can be modified by the addition of m-DAP to 
m-DAP linkages. Bacteria in the stationary phase of growth have been shown to harbor a high amount 
(>80% of total linkages) of m-DAP to m-DAP linkages. These linkages probably contributes to the 
increased resistance to endopeptidases of stationary phase bacteria (Jankute et al. 2015). Mutations in 
the Pg modifying enzymes have been associated with amoxicillin resistance. These mutations were 
found to map to ldt an L,D-transpeptidase that generates 3→3 transpeptide linkages in M. tuberculosis 
(Gupta et al. 2010). 
 
Arabinogalactan biosynthesis and antibiotic targets 
  A unique and remarkable property of mycobacterial PG is that it provides a site for the 
attachment of arabinogalactan (AG). This linkage is formed by the anchoring of GlcNAc-1-P to 
decaprenyl phosphatase by WecA and the subsequent addition of rhamnose to the 3 position of 
GlcNAc. This forms α-l-rhamnopyranose-(1→3)-α-d-GlcNAc-(1→P) disaccharide bridges (McNeil et 
al. 1990). The coupling of these layers occurs at some, but not all of the muramyl units that reside 
within the PG. AG is a highly branched structure that is predominantly composed of galactose (Gal) 
and arabinose (Ara) sugar residues, both in the furanose ring form (McNeil et al. 1987). The 
galactofuranose molecules form linear chains of approximately 30 alternating 5- and 6-linked β-d- 
residues (Daffé et al. 1990). The galactan chain is synthesized by GlfT1 and GlftT2 by linking 
galactofuranose units. Arabinofuranose chains are branched chains that contain around 30 residues 
each and are connected to the galactan chain at C5-position of some of the β(1→6) galactofuranose 
residues. This is facilitated by pyrophosphatase synthetase PrsA and decaprenylphosphoryl-5-
phosphoribose synthase UbiA that form decaprenyl-monophosphoryl-d-arabinose (DPA) from 
decaprenyl-monophosphoryl-d-ribose (DPR). The reaction of DPR to DPA is catalyzed by the 
Decaprenylphosphoribose 2′ epimerases DprE1 and DprE2. The identity and number of enzymes 
required for the synthesis of arabinan chains are largely unknown. Deletion studies, however, suggest 
that aftA is involved in biosynthesis of the branched arabinan (Alderwick et al. 2006). Moreover, 
EmbA, EmbB and EmbC play an essential role in catalyzing the arabinan chain polymerization to 
form building blocks for both AG and lipoarabinomannan (LAM) (Alderwick et al. 2005). It is 
thought that two arabinan chains are attached to each galactan chain, resulting in AG (Bhamidi et al. 
2011).  
  An antibiotic that targets the biosynthesis of this layer is ethambutol, a first-line antibiotic that 
is frequently used as the fourth component during the two-month antibiotic intensive phase of 
tuberculosis treatment, as recommended by the WHO. Ethambutol was discovered in 1962. Early 
reports on the effects of the antibiotic swiftly linked its mode of action to cell wall biosynthesis. AG 
synthesis, the target pathway of ethambutol, remained unknown until 1996, when a study by Belanger 
et al. unveiled that ethambutol inhibits the enzymes that polymerize the arabinan chain, EmbA and 
EmbB (Takayama & Kilburn 1989; Belanger et al. 1996). As a result of EmbA and EmbB inhibition, 
both AG and LAM are no longer synthesized, resulting in cell wall malformation. Mutations resulting 
in resistance to ethambutol map to the DPA biosynthetic and utilization pathways with mutations in 
ubiA, aftA, embC, and most predominantly, embB (Safi et al. 2013). A group of candidate compounds 
that can perhaps replace EMB in treatment against TB is the benzothiazinones (BTZ). BTZ has 
entered phase III trials and its clinical efficacy is currently being studied. Benzothiazinones also block 
AG biosynthesisby inhibiting the decaprenylphosphoribose 2′ epimerase DprE1 (Makarov et al. 2014). 
Resistance mutations have already been generated in vitro and were mapped to the dprE1 gene.  
  
Mycolic acid biosynthesis and antibiotic targets 
  Overlaying the AG layer, and covalently linked to it, is a lipid layer that contains the so-called 
mycolic acids. A portion of these long (C60-C90) carbon chain fatty acids are attached to the terminal 
arabinofuranose residues of the arabinan chains. The whole PG, AG and mycolic acid complex 
combined, is referred to as the mycolyl-arabinogalactan peptidoglycan (mAGP) complex. The mycolic 
acids are a major determinant of the fluidity and impermeability of the mycobacterial cell envelope 
(Liu et al. 1996). Mycolic acids are synthesized by fatty acid synthases (FAS). Three different types of 
mycolic acids can be distinguished: the alpha (α), keto (k) and methoxy (m) variants. The most 
abundant types are theα-mycolic acids. They are produced from short-chain (C16-C24) fatty acids, and 
produced de novo by FAS-I. These chains can either form the α-alkyl moiety (C24) or can be extended 
by FAS-II to form the mero-chain (C56). To extend the fatty acid chain, the reaction is initiated by a 
β-ketoacyl-ACP synthase, called FabH. This enzyme uses palmitoyl-CoA and malonyl-AcpM to form 
β-ketoacyl-AcpM. Further processing occurs when MabA reduces the β-ketoacylated AcpM to a β-
hydroxyacyl-AcpM. Then, a dehydration reaction by HadAB/BC dehydrogenase complexes produces 
a trans-2-enyol AcpM, which in turn is reduced by InhA (an enoyl-ACP reductase). This condensation 
reaction, catalyzed by KasA and KasB (both β-ketoacyl-ACP synthases), elongates the acyl-AcpM by 
two carbons, resulting in a longer chain length every cycle (Takayama et al. 2005). When the length of 
the saturated acyl chain is between C42-C62 long, further modification by either cyclopropanation (by 
CmaA1 and CmaA2), addition of a keto-moiety (via MmaA1 through MmaA4) or addition of 
methoxy groups (via PcaA enzymes) can take place (Yuan et al. 1995; Glickman 2003). Additional 
modifications can occur through FadD32 (a fatty acyl-AMP ligase) and the polyketide synthase Pks13. 
Together these proteins can link C22-C24 α-alkyl short chain fatty acids to produce α-alkyl-β-keto 
(C60-C90) mycolic acids. Figure 5 summarizes the biosynthesis of mycolic acids. 
 
 Figure 5. Schematic representation of mycolic acid biosynthesis adapted with permission from Jankute et al. 
2015. The types of mycolic acids (alpha, methoxy and keto) produced via this pathway can be found in the box 
in the upper left corner. Antibiotics that can intervene in this pathway are indicated in the red boxes (ETH/INH 
and SQ109). Upon the formation of TDM from two TMM molecules, trehalose (blue ball) is produced.  
 
  Antibiotics that target mycolic acid biosynthesis are isoniazid and ethionamide. Isoniazid is 
short for isonicotinic acid hydrazide and is pivotal in TB treatment. The molecule was discovered by 
three independent pharmaceutical companies, but introduced by Roche in the 1950s. The mechanism 
of action, however, was only discovered 50 years later. Isoniazid is a pro-drug that enters the cell 
through passive diffusion. The isoniazid molecules are then activated by the catalase peroxidase KatG 
(Timmins & Deretic 2006). KatG peroxidizes INH, which can then react with NAD+ adducts. 
Although these INH-NAD+ adducts bind to at least 18 mycobacterial proteins, their predominant target 
is thought to be the NADH-specific-InhA protein (see figure 5), which is required for mycolic acid 
production (Argyrou et al. 2006). The effect of INH is thought to be dependent on the growth phase of 
mycobacteria. Fluctuations in the levels of KatG, or so-called pulses, have been shown to influence the 
efficacy of INH treatment at the single cell level in M. smegmatis (Wakamoto et al. 2013).  
Ethionamide is also a pro-drug with a similar mode of action as INH. However, ethionamide is 
activated by the mono-oxygenase EthA (Baulard et al. 2000). Mutations that cause resistance to INH 
or ethionamide include mutations in the genes encoding the activating enzymes, katG and ethA, 
respectively. Moreover, mutations in inhA confer resistance to both drugs (Zhang et al. 1992; Pym & 
Cole 2008).   
Not all mycolic acids are esterified to AG; they can also be linked to trehalose to form 
trehalose mono (TMM)- or trehalose dimycolates (TDM). These trehalose-containing glycolipids form 
an important structural component of the outer layer of the outer membrane. The building block for 
these mycolic-acid containing structures is TMM, which is transported over the inner membrane via 
the TMM-flippase MmpL3 (Xu et al. 2017). After crossing the periplasm. the TMMs are either used 
as a mycolic acid donor for building mAG or used to form TDM. The latter reaction results in the 
release of free trehalose and is performed by one of the mycolyl-transferases, collectively known as 
the Ag85 family proteins. There are three mycolyl-transferases (Ag85A, B and C) and these proteins 
show redundancy in the ability to convert TMM into TDM. Only a combined inhibition of all three 
proteins results in bacterial cell death (Belisle et al. 1997). There is active interest in targeting the 
transport of TMMs with antibiotics. An example of such an antibiotic is SQ109, a 1,2-ethylenediamine 
analogue that was derived from ethambutol. SQ109 was originally shown to target MmpL3 (see figure 
5), effectively inhibiting its flippase activity (Tahlan et al. 2012). However, these results are not 
undisputed, as another study indicates that SQ109 disturbs the PMF. The authors state that the 
inhibitory effect on MmpL3 is not due to direct binding of SQ109 to the flippase (Li et al. 2014). 
Regardless of the exact mode of action, mutations in MmpL3 have been found to result in SQ109 
resistance (Tahlan et al. 2012). SQ109 is currently tested in phase II trials.  
 
Biosynthesis of other predominant mycobacterial (glyco-)lipids  
  In addition to TMM and TDM the mycobacterial cell wall contains several other trehalose-
containing lipids, including sulfolipids (SL-1) (only found in M. tuberculosis), diacyltrehaloses 
(DATs), triacyltrehaloses (TATs) and poly-acyltrehaloses (PATs) (see Figure 6). Many mycobacterial 
species also produce the trehalose-containing lipooligosaccharides (LOSs). However, this lipid is 
absent in M. tuberculosis. All these trehalose-containing lipids are all long-chain methyl-branched 
fatty acids that are produced by polyketide synthetases. A major difference with FAS biosynthesis is 
that, instead of malonyl-CoA, methyl-malonyl CoA is utilized as a substrate for the biosynthesis of 
these methyl-branched lipids (Angala et al. 2014). The trehalose-containing glycolipids are important 
constituents of the outer membrane. Since trehalose is crucial for cell wall biosynthesis, it is not 
surprising that mycobacteria possess several routes to synthesize or salvage trehalose. First, is the 
OtsA-OtsB pathway, which forms trehalose from glucose-6-phosphate. A second biosynthesis route is 
the TreY-TreZ pathway in which an α(1,4) linkage in a glucose polymer is converted to a trehalose-
containing an α(1,1) linkage. Lastly, the TreS pathway can reverse the α(1,4) linkage in maltose to an 
α(1,1) linked trehalose (Kaasen et al. 1992; Nakada et al. 1995; Maruta et al. 1996).  
  Another important group of cell wall glycolipids that do not contain trehalose are the 
mannosyl-phosphatidyl-myo-inositol (PIM) glycolipids, and the structurally closely related 
lipomannan (LM) and lipoarabinomannan (LAM). LM and LAM both have an α(1,6) mannan 
backbone. These glycolipids are non-covalently attached to either the inner or the outer membrane via 
their phosphatidyl-D-myo-inositol moiety (Pitarque et al. 2008). Many varieties and modifications of 
these lipids can be found in mycobacteria. In slow-growing mycobacteria LAM molecules can be 
capped with up to three α(1,2) mannose residues to form ManLAM (Gilleron, Martine et al. 2008) 
  Finally, there are many other unique (glyco)lipids in the cell envelope of M. 
tuberculosis and they all seem to play a role in pathogenesis and virulence. Well-studied virulence 
determinants are the glycolipids phthiocerol dimycocerosates (PDIMs) and phenolic glycolipids 
(PGLs) (Jackson et al. 2007; Guilhot et al. 2008). The molecular composition of these lipids is 
complex, a fact that is also reflected by the size of the PDIM biosynthesis locus. In total, a 73kb 
region, spanning from tesA to mmpL7 in M. tuberculosis, is deemed responsible for PDIM production. 
To synthesize PDIMs, a fatty-acyl AMP ligase, FadD26 loads C22-C24 fatty acids onto PpsA. 
Subsequently, these substrates are elongated with methylmalonyl-CoA by PpsA-PpsE to produce 
phtiocerol or phenolphtiocerol (Siméone et al. 2010). The mycocerosic acid moieties for phtiocerol 
and phenolphtiocerol are synthesized from C16 and C20 fatty acids that are transported to the 
polyketide synthase Mas by FadD28. Mas then serves as a scaffold to elongate these fatty acids with 
methyl-malonyl-CoA, which produces methyl-branched mycocerosic acids. The resulting 
macromolecule is loaded onto PapA5 that connects the phtiocerol or phenolpthiocerol groups to the 
mycocerosic acids in an esterification step (Trivedi et al. 2005). A large part of this biosynthesis 
pathway is also used for PGL production. Although unconventional, attempts to block and inhibit 
PDIM or PGL synthesis with chemical compounds have been made. For example, one study identified 
fadD22 as important cofactor for PGL biosynthesis and describes a small molecule that inhibits 
production of this lipid (Ferreras et al. 2008). Several important mycobacterial glycolipids are 
depicted in figure 6.  
 
 Figure 6. Schematic representation of the M. tuberculosis cell envelope. Abbreviations: α, alpha; AG, 
arabinogalactan; DAT, diacyltrehalose; k, keto; m, methoxy; MOM, mycobacterial outer membrane; PAT, 
penta-acyltrehalose; PDIM, phthiocerol dimycocerosate; PG, peptidoglycan; SGL, sulfoglycolipid; TAT, 
triacyltrehalose. Lipid molecule images are a courtesy of Monika Jankute (Jankute et al. 2015). 
 
The mycobacterial capsular layer 
  The mycobacterial capsule was discovered in 1959 when Chapman and coworkers noticed a 
space between the phagosomal membrane and the cell wall of mycobacteria in coupes obtained from 
cell infection studies (Chapman et al. 1959). The authors referred to this space as the ‘capsular space’. 
Subsequently, studies utilizing electron microscopy confirmed the presence of the ‘electron 
transparent zone’ (ETZ) in pathogenic mycobacteria (Hanks 1961). More recently, Sani et al. 
confirmed these observations with cryo-EM. These authors found that, unlike other bacteria, 
mycobacteria contain a capsular layer that is loosely attached to the cell surface. This instability partly 
arises from the non-covalent interactions between the glycans (Sani et al. 2010). With the use of 
detergents, the contents of the layer were isolated and analyzed. In M. tuberculosis, the capsule mainly 
consists of polysaccharides formed by one of three oligosaccharides: α-glucan, D-arabinomannan or 
D-mannan (Ortalo-Magne et al. 1995; Lemassu et al. 1996). The dominant constituent of the layer is 
α-glucan, comprising up to 80% of the total capsular content. The capsular α-glucan is a large polymer 
of linear α-D-1-4 linked glucose units that have core substitutions at position 6 (α-1-6 linked). A 
complicating factor in studying α-glucan is its high structural similarity with cellular glycogen. It is 
therefore challenging to chemically distinguish, detect and measure mycobacterial α-glucan 
specifically. Since the capsular layer is the outermost barrier of mycobacteria, α-glucan is the first 
molecule that comes into contact with host cells during infection. Therefore, it should come as no 
surprise that this layer plays a significant role in immune-modulation as well as virulence (Sambou et 
al. 2008; Angala et al. 2014). A large array of enzymes is required for the biosynthesis of the 
mycobacterial capsular layer. The general genetic blueprint of the biosynthesis route, however, 
resembles that of the ones present in other Gram-negatives like E. coli. The glg genes are responsible 
for synthesis of both glycogen and the capsular α-glucan. Enzymes encoded by this cluster include 
GlgA, GlgB, GlgC/GalU and the GlgE pathway, involving OtsA/B and TreS (Stadthagen et al. 2007). 
The latter pathway is used to synthesize trehalose, which is subsequently converted to maltose via 
TreS and utilized by glucosyltransferase GlgE to form the end-product: capsular α-glucan (Elbein et 
al. 2010; Kalscheuer et al. 2010). Although biosynthesis has been studied extensively, it is unknown 
how these large biomolecules are transported to the outer leaflet of the outer membrane in 
mycobacteria. 
 
Envelope stress responses in relation to antibiotics  
  The previous paragraphs describe the complexity of the mycobacterial cell envelope, but also 
illustrate the success of the mycobacterial cell wall as a target for antibiotics, as well as the multitude 
of essential enzymes that can be targeted. To continue to find new, and possibly even better drugs, it is 
crucial that we fully understand the dynamics of cell wall biogenesis. Moreover, insights into the 
repair routes that bacteria entail during different stages of infection or the different physiological 
niches that they occupy are also essential. Regulation of cell wall biogenesis and the processes that are 
involved in repairing cell wall damage or the pathways that are activated upon damage caused by 
antibiotic treatment are important research topics in our quest to discover novel drugs against this 
persistent foe.  
  Whereas many research groups are now focusing on mycobacterial cell wall composition and 
biosynthesis, the induction and function of mycobacterial envelope stress responses (ESRs) remains 
largely unaddressed. Studying these responses might lead to the discovery of chinks in the bacterial 
armor. It may also help to address the observed heterogenic responses that are observed within patients 
as a result of antibiotic treatment (Sun et al. 2012). In addition, understanding the layers of regulation 
of key players in stress responses can lead to the discovery of synergistic compounds, such as the ones 
identified by Peterson et al. (Peterson et al. 2016). Targeting the adaptive strategies that mycobacteria 
deploy upon antibiotic treatment to overcome resistance has been successful already. A striking 
example is the recently characterized EthR2-inactivating agent spiroisoxazoline that allows bacteria to 
circumvent EthA-mediated ethionamide resistance (Blondiaux et al. 2017). The spiroisoxazoline 
molecule works by binding to the ethionamide repressor. This alleviates repression of transcription of 
EthA2. EthA2 can subsequently serve as a target for ethionamide, effectively making the bacterial cell 
susceptible again to ethionamide therapy. 
  A big hurdle in mycobacterial stress response research is the limited amount of data that is 
available on the transcriptional profiles of M. tuberculosis responses to cell-wall targeting agents. 
Most studies have focused on single compounds, such as INH (Wilson et al. 1999; Boshoff et al. 
2004; Waddell et al. 2004). Comprehensive time-point studies that compare cell-wall targeting agents 
or comparative studies with a more sensitive technique like RNA sequencing are still lacking. Besides 
by transcriptomics, another way to understand these processes could be by comparing the cell wall 
stress systems of mycobacteria to the ones found in Gram-negative species. Because the cell wall 
stress responses of Gram-negative species have been studied extensively, perhaps parallels can be 
drawn to aid our understanding of the adaptability of the mycobacterial cell wall.  
  In Gram-negative species several cell wall systems can respond to a variety of stresses: 
disrupted proton motive force (PMF), altered protein folding, changes in membrane homeostasis and 
altered efflux/influx rates (Rowley et al. 2006; Kohanski et al. 2008). Most of these stress systems 
also respond to sublethal, non-toxic levels of antibiotics (Andersson & Hughes 2014). In total, five 
main envelope stress responses or ESRs can be distinguished: The Cpx, σE, Bae, Rcs, and Psp systems 
(Ades 2004; Majdalani & Gottesman 2006; Leblanc et al. 2011; Raivio 2014; Flores-Kim & Darwin 
2016). An overview of these ESRs in gram-negatives is shown in figure 7(A-E).  
 
Gram negative envelope stress responses  
 The Cpx system is a two-component system with a regulator (CpxR) and a sensor histidine 
kinase (CpxA). The system is activated in response to protein misfolding. These processes inactivate 
the system inhibitor CpxP. This causes CpxA to phosphorylate CpxR (Figure 7A). The downstream 
events range from the expression of protein foldases to upregulation of transporter proteins and from 
the induction of envelope biosynthesis pathways to an increase in efflux pumps. Overexpression of the 
Cpx system was found to cause resistance to (fluoro)quinolones and aminoglycosides in Escherichia 
coli (Hirakawa et al. 2003). The Cpx response was also found to be induced by some β-lactam 
antibiotics (Laubacher & Ades 2008) or adhesion of bacteria to surfaces through the outer membrane 
protein NlpE. A mycobacterial counterpart of the Cpx system has not been described yet.  
 The sigma factor E (σE) was the first described ESR. The response is triggered by the detection 
of misfolded outer membrane proteins due to perturbations of the outer membrane (Ades 2004). These 
misfolded proteins are then detected by the periplasmic protease DegS. Activation of the pathway can 
also be the result of decoupling of RseB from RseA in response to defects in OM biosynthesis, and 
specifically, as a consequence of LPS accumulation (Figure 7B). LPS molecules can bind and release 
RseB from RseA, making RseA susceptible to cleavage by DegS. Free RseB activates the stress 
system (Figure 7B). When RseA is released, regulated intra-membrane proteolysis occurs. This leads 
to the release of cytosolic σE from a membrane-bound anti-sigma factor. The response that follows 
upon activation of σE varies from the upregulation of efflux pumps, chaperones and proteases to the 
downregulation of the production of membrane proteins (Lima et al. 2013; Kim 2015). The σE 
response is also present in mycobacteria and plays a similar role as in other Gram-negatives, 
responding to detergents, heat shock and alkaline pH (Donà et al. 2008). However, in mycobacteria it 
is regulated by the two-component system MprAB (He et al. 2006). The σE was proven to be essential 
for virulence of mycobacteria in mice (Manganelli et al. 2004). A direct role for the σE and antibiotic 
treatment has not been established in mycobacteria.  
 
Figure 7A/7B. Gram-negative Envelope Stress Responses Cpx (A) and σE (B). Induction of the systems comes 
from a variety of envelope stresses, including antibiotics, toxic metabolites and bacteriocins. The Cpx response 
is induced by β-lactam antibiotics and misfolded proteins. The σE response is activated upon detection of 
unassembled OMPs by DegS or RseB. Green arrows indicate activating signals, red arrows indicate inhibiting 
signals. 
 
  The Bae ESR is a two-component system comprised of sensor kinase BaeS and the regulator 
BaeR (Figure 7C). It is activated by antimicrobial compounds of a variety of sources (plants, bacteria, 
funghi) as well as β-lactams. Activation of the Bae response results in the transcription of chaperones 
and efflux pumps that counteract the antimicrobial compounds by removing them from the 
intracellular milieu (Baranova & Nikaido 2002;Leblanc et al. 2011). Well-studied examples of these 
pumps are AcrD, MdtABC and TolC (Raffa & Raivio 2002). Overexpression of the Bae system leads 
to resistance to β-lactam antibiotics as described by Hirakawa et al. (Hirakawa et al. 2005). So far, no 
orthologous system has been identified in mycobacteria. However, there are many efflux pumps 
present in mycobacteria. The function of most of these efflux systems has yet to be elucidated. 
Moreover, the regulation of these efflux pumps has not been studied in detail either (Li et al. 2007; 
Louw et al. 2009). 
  The Rcs response is a two-component phosphorelay consisting of two sensor kinases: RscC 
and RscD. Both are associated to the inner membrane, together with a cytoplasmic regulatory element, 
coined RscB (Majdalani & Gottesman 2006). The Rcs system can sense outer membrane stress via the 
lipoprotein RcsF. RcsF is usually associated with beta-barrel outer membrane proteins such as OmpA 
(Majdalani & Gottesman 2006). However, when RcsF cannot be inserted in outer membrane proteins 
correctly, it accumulates in the periplasm. As a consequence, RscC and RscDphosphorylate RscB2 
and RscAB (Figure 7D). Subsequently, genes that encode enzymes for capsule biosynthesis are 
upregulated by RscAB and genes involved in motility or biofilm formation are repressed by RscB2. 
The Rcs response is activated by several antimicrobial agents and confers resistance to β-lactam 
antibiotics (Hirakawa et al. 2005; Laubacher et al. 2008; Farris et al. 2010). The Rcs system does not 
have direct orthologues in mycobacteria.  
 
Figure 7C/7D. Gram-negative Envelope Stress Responses Bae (C) and Rcs (D). The Bae response is induced by 
β-lactam antibiotics, metals and flavonoids. The Rcs response is activated in response to envelope stress 
(reduction of insertion of RcsF) and β-lactam antibiotics. Green arrows indicate activating signals, red arrows 
indicate inhibiting signals. 
 
  A final, well-described ESR is the phage shock protein (Psp) response. This response is set in 
motion by conditions that disrupt the inner membrane and thus abolish the PMF (Darwin 2005). One 
condition that activates the system is when there is an overproduction and stalling of complexes that 
should localize to the outer membrane. These stresses are sensed by PspC and PspB, which transduce 
the signal to the cytoplasmic PspA by binding it. As a result, transcriptional regulator PspF is released 
from PspA and this leads to transcription of genes that are involved in cell wall repair and general 
survival (Flores-Kim & Darwin 2016). The Psp response has been associated with the response to 
antimicrobials in Gram-positive species Bacillus subtilis; deletion of Psp causes susceptibility to 
lantibiotics (Wolf et al. 2010; Kingston et al. 2013). M .tuberculosis also have a Psp system that is 
homologous to the Gram-negative system (Datta et al. 2015). Moreover, direct evidence for the 
activation of the system in response to anti-cell wall antibiotics has been provided by Provvedi et al., 
who showed that the Psp system is induced upon treatment with vancomycin (Provvedi et al. 2009). 
Intruigingly, in Gram-negative bacteria PspA plays a role in rescuing the proton motive force, whereas 
in mycobacteria it seems to play a role in lipid droplet formation (Armstrong et al. 2016). 
 
Figure 7E. Gram-negative Envelope Stress Response Psp. Induction of this system is in response to loss of PMF 
or certain antimicrobial compounds. As a result, efflux pumps are upregulated. There is not apparent 
downregulation in the Psp response. Green arrows indicate activating signals, red arrows indicate inhibiting 
signals. 
   
 
 
Scope of this thesis 
  The aim of our research was to gain insight into the adaptive strategies and stress response 
systems that mycobacteria deploy when challenged with antibiotics that have proven to be successful 
in the treatment of TB. We used this knowledge to develop genetic tools that will allow for a more 
rapid identification and assessment of new compounds in vitro, as well as in vivo using the zebrafish 
embryo infection model.  
  In Chapter 2 we set out to unravel the genetic network involved in the biosynthesis of the 
capsular α-glucan by performing transposon mutagenesis. In doing so, we identified capsule-deficient 
as well as capsule-overproducing mutants and discovered novel members that play a role in the 
production of this capsular layer during stress conditions. In this work, we link the overproduction of 
capsular α-glucan to the stringent response, which is normally induced by nutrient starvation. In 
addition, we constructed stress reporters that respond to low-phosphate states, to address the formation 
of a capsular α-glucan as a result of phosphate limitation in Mycobacterium marinum. We used these 
tools in vivo to address the relevance of phosphate limitation that mycobacteria encounter during 
infection. 
  In Chapter 3 we present work on the major antibiotic stress operon in mycobacteria: the 
iniBAC operon. This operon is induced by ethambutol and isoniazid in M. marinum. We investigated 
the origin of the stress signal that leads to induction of the operon by constructing a stress reporter, in 
which the production of a fluorescent reporter is coupled to the iniBAC promoter. We used this 
reporter to identify transposon mutants with constitutive IniBAC production. Interestingly, we found a 
clear and strong link between IniBAC induction and vitamin B12 production, and the methylmalonyl 
CoA pathway. We also attempted to identify the metabolic cue that is responsible for the induction of 
the operon. 
  In Chapter 4 we describe the identification of the regulator of the iniBAC operon, IniR. We 
show that IniR belongs to a novel class of transcriptional regulators in both M. marinum and M. 
tuberculosis. IniR can activate iniBAC transcription and induction is abolished in knockout mutants. 
Finally, we show that iniBAC can be directly induced by free trehalose. This induction is amplified 
when cell wall permeability is increased.  
  In Chapter 5 we set out to characterize the role of the IniBAC proteins and address the 
question whether these proteins form a functional complex. We performed localization studies and 
showed that both IniA and IniC can be found in the cytosol and that IniA partially associates with the 
cell membrane. IniB appeared to be present in large amounts in bacterial culture upon treatment with 
EMB or INH. Analysis of ∆iniA and ∆iniC mutants showed that the production and secretion of IniB is 
dependent on the presence of IniA and IniC. We used ESX-1-, ESX-5-, and SecA2-deficient mutants 
to show that secretion of IniB is independent of these alternative secretion systems.  
  In Chapter 6 we present the first comprehensive overview of the mycobacterial stress 
responses that are induced in M. tuberculosis and M. marinum after treatment with first-line antibiotics 
ethambutol, isoniazid, streptomycin and rifampicin and the second-line antibiotic ciprofloxacin. RNA 
sequencing experiments showed that M. marinum displays very distinct ‘stress fingerprints’, which we 
could utilize to distinguish antibiotics by mode of action. We then generated stress reporters to study 
whether mode of action prediction was possible with these stress reporters. We screened a compound 
library of 190 compounds and identified three compounds that likely cause cell wall damage. 
 In Chapter 7 we describe the development of a reporter strain that can be used to measure 
cytochrome bd expression in mycobacteria. Since cytochrome bd is an important survival factor in 
vivo, studying its expression could lead to new insights into the dynamics of complexes that are crucial 
for energy metabolism. In this chapter, we show that the cydA reporter can be activated in culture by 
several antibiotics that target the respiratory chain: bedaquiline (BDQ), clofazimine (CFZ) and Q203. 
This activation is concentration dependent. We also address the induction levels of the CydA marker 
in infection studies and in a zebrafish embryo infection model to determine the importance of cytBD 
during infection.  
  In Chapter 8, we reflect on the work presented in this thesis. 
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Abstract 
Mycobacterium tuberculosis is protected by an unusual and highly impermeable cell-envelope that is 
critically important for the successful colonization of the host. The outermost surface of this cell 
envelope is formed by capsular polysaccharides that play an important role in modulating the initial 
interactions once the bacillus enters the body. Although details on the bio-enzymatic steps involved in 
the production of the capsular polysaccharides are revealed, information regarding the ability of the 
bacterium to modulate the composition of the capsule is still lacking. Here, we study the mechanisms 
involved in regulation of mycobacterial capsule biosynthesis using a high throughput screen for gene 
products involved in capsular α-glucan production. Utilizing this approach we identified a group of 
mutants that all carried mutations in the ABC phosphate transport locus pst. These mutants 
collectively exhibited a strong overproduction of capsular polysaccharides, including α-glucan and 
arabinomannan, suggestive of a role for inorganic phosphate (Pi) metabolism in modulating capsular 
polysaccharide production. These findings were corroborated by the observation that growth under 
low Pi conditions as well as chemical activation of the stringent response induces capsule production 
in a number of mycobacterial species. This induction is, in part, dependent on sigma factor E. Finally, 
we show that Mycobacteruim marinum, a model organism for M. tuberculosis, encounters Pi-stress 
during infection, which shows the relevance of our findings in vivo.  
 
  
Introduction 
  Despite enormous research efforts in global public health consortia, Mycobacterium 
tuberculosis, the causative agent of tuberculosis (TB), continues to represent a major health problem 
that causes up to 1.5 million deaths annually. The chronic character of M. tuberculosis infection, 
covering one-third of the world’s population, coupled to the increasing insensitivity of the bacillus to 
many classes of antibiotics calls upon innovative strategies to combat this devastating disease. The 
unique and complex cell envelope of M. tuberculosis is not only a major virulence factor, but also an 
attractive target for anti-TB drug discovery. The mycobacterial cell envelope is composed of two 
membranes: a relatively normal plasma membrane and a membrane that resembles the outer 
membrane of Gram-negative bacteria. This outer membrane is composed of mycolic acids, partly 
linked to the arabinogalactan-peptidoglycan layer, in the inner leaflet and a variety of intercalating 
lipids and glycolipids in the outer leaflet (1-3). The outermost cell surface of mycobacteria is formed 
by a thick but loosely attached capsular layer that is mainly composed of polysaccharides and a minor 
amount of proteins and (glyco)lipids (4-8). The main capsular polysaccharide of M. tuberculosis is α-
glucan, a polymer of linear α-D-1-4 linked glucose units with core substitutions at position 6 on every 
5 or 6 residues by α-D-1-4 linked oligoglucosides (7, 9, 10). Recent studies have indicated that 
capsular α-glucan might play an important role in immune modulation upon entry into the host. For 
example, capsular α-glucan was shown to block CD1 expression in dendritic cells, suppress IL-12 
production, and stimulate IL-10 production in a CD80-dependent manner (11). Additionally, capsular 
components have antiphagocytic properties that prevent uptake by macrophages (12) and abolish 
dendritic cell function, a process dependent on C-type lectin DC-SIGN(13). Furthermore, α-glucan 
interacts with complement receptor 3 (CR3) (14) and inactivation of glycogen/α-glucan 
glycosyltransferase GlgA impairs virulence of M. tuberculosis in mice (10). Collectively, these 
findings suggest that M. tuberculosis capsular α-glucan has an important role in host-pathogen 
interaction and virulence. However, the exact function of capsular α-glucan in virulence as well as 
how the production of capsular polysaccharide is modified by the bacillus in response to stress signals 
is not known.  
  In our ongoing efforts to elucidate the capsular α-glucan biosynthesis routes and transport 
system, we recently developed a monoclonal antibody-based screening and quantification method that 
allows for the comprehensive analysis of large libraries of mutants (n>40.000) (15). Using this 
method, we identified several strongly induced capsular α-glucan mutants in the ATP-binding cassette 
phosphate transport pst locus of Mycobacterium smegmatis and M. tuberculosis (15). The Pst system 
is important for Pi acquisition in mycobacteria (16, 17). Rifat et al. showed upregulation of the 
phosphate stress response (PSR) via the pst system of M. tuberculosis (16). Several studies showed 
that the two-component system (2CS) SenX3-RegX3 is involved in Pi-stress signaling (16), in which 
downstream signaling occurs via the MprAB-SigE-Relmtb pathway (18). Recently, Chuang et al. 
showed that Pi-stress increases the cell envelope thickness (19). Taken together, these reports and our 
own findings link Pi limitation in mycobacteria with capsular biosynthesis regulation.  
  In this study, we aimed to further characterize the panel of pst mutants that show strongly 
induced capsular α-glucan production. We demonstrate that Pi-starvation upregulates the capsular α-
glucan production in a SigE-dependent manner, but not via the stringent response (SR). Furthermore, 
we provide evidence that also amino acid starvation can induce the production of capsular α-glucan.  
Material & methods 
Bacterial strains and growth conditions 
  M. smegmatis mc2155, M. tuberculosis strains mc26020, H37Rv; CDC1551; and 
Mycobacterium marinum strains E11 and M-USA were grown at 37°C or 30°C, respectively, in 
Middlebrook 7H9 liquid medium supplemented with 10% albumin-dextrose-catalase (ADC; BD 
Biosciences) and 0.05% Tween 80 or in modified 7H9 medium (Pi medium) supplemented with 
different concentrations of exogenous Pi (0-25mM) and 10% ADC as described (16). For the serine 
hydroxomate (SHX) experiments the bacterial strains were grown in modified 7H9 medium with or 
without ADC or supplemented with albumin or dextrose (both from Sigma) or a combination of those. 
When needed, the bacterial strains were grown on 7H10 solid medium supplemented with 10% ADC 
and Tween-80. For bacterial strains that required selective pressure, kanamycin, hygromycin, or 
streptomycin was added at a concentration of 50 µg/ml. Escherichia coli strain DH5α was grown at 
37°C on LB agar (Difco).  
Transposon mutagenesis and capsular α-glucan mutant screen  
  Transposon mutagenesis and the capsular α-glucan screen were performed as described 
previously (15). Briefly, the obtained transposon mutant libraries of M. smegmatis and M. tuberculosis 
(mc26020) were screened in a double filter assay for altered expression of capsular α -glucan by 
utilizing the anti-glucan antibody (IV58B6)(20). Colonies that showed more or, alternatively, less 
capsular α -glucan versus wild-type strain were selected and rescreened for their capsular α -glucan 
profile using the colony-based immunoblot approach as described earlier (15). Then, the transposon 
insertion sites of the mutant strains were identified by using ligation-mediated (LM) PCR as described 
previously (21). For the primer sequences used in the LM-PCR see supplemental Table S2. 
 
Genetic constructs and complementation of pstS::tn  
  The genetic knock-out strains of M. tuberculosis H37Rv ∆sigE, and ∆relA and complemented 
strains were constructed as described previously (22, 23). M. smegmatis MSMEG_pstS::tn strain was 
constructed as described previously (15) and complemented with M. smegmatis pstS. In short, primers 
were designed (see supplemental Table S2) and the gene was amplified from M. smegmatis genomic 
DNA by PCR. The PCR products were purified and digested with PstI and HindIII. pSMT3 E. coli-
Mycobacterium shuttle vector was purified from E. coli strain DH5α and digested with PstI and 
HindIII. The digested plasmid and the insert (pstS) were ligated by T4 ligase and subsequently 
transformed into E. coli XL-10 by heat shock. Next, the transformants were selected on hygromycin-
containing LB plates and the pSMT3 complementation plasmid was confirmed by sequencing. 
Subsequently, the plasmid was transformed into M. smegmatis pstS::tn by electroporation. The 
complemented strain was confirmed by PCR (table S2). For the construction of the M. marinum 
phosphate marker strains the putative promoters of genes ppk1, senX3 and phoS2 were cloned in front 
of the fluorescent reporter gene mCherry. The promoter regions of ppk1, senX3, phoS2 were amplified 
by PCR from M. marinum E11 genomic DNA with forward and reverse primers containing an XbaI 
and BamHI site, respectively. The XbaI and BamHI digested insert and pSMT3 vector was ligated by 
T4 ligase (Fermentas) to generate the genetic constructs; pSMT3::PRv2983-mCherry, pSMT3::Pppk1-
mCherry, pSMT3::PsenX3-mCherry and pSMT3::PphoS2-mCherry. The constructs were introduced 
into wild-type M. marinum M-USA by electroporation. To quantify the bacterial infection in the 
zebrafish experiments, mEos3.1 was integrated in the genome using L5 integrase. A vector containing 
mEos3.1 was obtained from Zhang et al. (24) and amplified by PCR with flanking regions 
corresponding to the target vector. The primers were designed to amplify hsp60-mEos3.1, with 15 bp 
overlapping the target vector (supplemental Table S2). The vector pMV361 was digested with PmlI 
and NsiI. Subsequently, the insert was introduced into the digested vector by In-Fusioncloning 
(Clontech) to produce the integrative plasmid pMV-hsp60-mEos3.1, as described previously (25). The 
plasmid was subsequently transformed to M. marinum M-USA containing the genetic constructs as 
describe above. All primers that were used are listed in supplemental Table S2. 
Serine hydroxamate experiments  
  M. smegmatis mc2155 and M. tuberculosis mc26020 and H37Rv were grown as described 
above and at the early log phase (OD600 = ±0.5), 100-150 µg/ml or a concentration series of 0-250 
µg/ml SHX (Sigma) was added for the induction of the stringent response. At different time points, 
capsular polysaccharides were extracted and analyzed as described below.  
 
Capsule polysaccharide extraction  
  M. smegmatis, M. tuberculosis (H37Rv, CDC1551 and mc26020) and M. marinum strains 
were grown in liquid or solid medium as described above and capsular extraction was performed as 
described previously (15). Briefly, cells were diluted to equal amounts of OD600 units in liquid 
medium and 900 µl of cell suspension was collected and supplemented with 100 µl 5% tyloxapol 
(Sigma) to a final concentration of 0.5%. Bacterial cells from agar plates were collected and 
subsequently suspended at a concentration of 20.0 mg/ml in PBS supplemented with 0.5% tyloxapol. 
The capsular polysaccharides were extracted using a Bead Beater (Biospec products) (without beads) 
by vigorous shaking (1 min) and subsequently centrifuged for 10 min at 2,000 x g. The capsular 
extracts (supernatants) were collected and filtered (0.45 µm, Millipore) to remove remaining bacterial 
cells, and subsequently, the capsular polysaccharides were analyzed by using an immunodot-blotting 
or sandwich ELISA assay. 
 
Capsular polysaccharide quantification by immunodot-blotting and sandwich ELISA  
  The capsular extracts of the diverse mycobacterial strains were obtained as described above 
and immunodot-blotting and sandwich ELISA were performed as described earlier (15). In short, for 
the immunodot-blotting, 5.0 µl of the capsular polysaccharide extracts was spotted onto nitrocellulose 
sheets (Millipore) in a 3-fold dilution series and the sheets were baked for 1h at 70°C and blocked in 
PBS supplemented with 4.0 % skimmed milk (Nutricia) for 1h at room temperature. Next, the sheets 
were immunolabeled with anti-α-glucan mAb at 1.5 µg/ml (20) or anti-arabinomannan (AM) mAb 
(F30.5)(8) for 1.5 or 3h, respectively at room temperature. Subsequently, the sheets were washed three 
times with phosphate buffered saline Tween 80 (PBST) and incubated with a horseradish peroxidase 
(HRP) secondary antibody in PBST for 1.5 h. The capsular polysaccharides were visualized by 
coloring agent 3,3’-diaminobenzidinetetrahydrochloride/4-chloro-1-napthol (DAB/4CN). For the 
sandwich ELISA, ELISA plates (Greiner, 655001) were coated with anti-α-glucan antibody at a final 
concentration of 5.0 µg/ ml and incubated overnight under gentle shaking at room temperature. Next, 
the plates were washed four times with 200 µl PBST and subsequently blocked with 200 µl of 1 % 
bovine serum albumin (BSA, Sigma) for 1 h at room temperature. Then, 100 µl of capsular extracts or 
a glycogen reference (Sigma) dilution series (1.0 - 1.95 ng/ml) was incubated for 1.5h at room 
temperature. Then, the plates were washed four times with PBST and 50 µl of the preincubated 
secondary antibody solution was incubated for 1.5 h at room temperature, as described previously 
(15). Subsequently, the plates were washed six times with 200 µ ofl PBST visualized by adding 100 µl 
of ortho-phenylenediamine dihydrochloride (Sigma) coloring solution (10 mg of ortho-
phenylenediamine dihydrochloride, 10 ml of ortho-phenylenediamine dihydrochloride buffer 
(0.1 M citric acid; 0.2 M Na2HPO4, pH 5.5), and 5.0 µl of 30% H2O2) for 4 min and subsequently 
stopped by adding 50 µl of 10% H2SO4. Next, the optical density was measured at 492 nm with an 
ELISA plate reader (Epoch, Biotek, SN253854) and analyzed by Gen 5, version 1.11, software. 
 
Electron Microscopy and immunogold visualization of capsular α-glucan and AM  
  The immunogold labeling and visualization of capsular polysaccharides α-glucan and AM by 
electron microscopy were performed as earlier described (15). Briefly, the bacterial strains were grown 
as described above and fixed as described previously (15). The fixed bacteria (3.0 µl, 0.55 OD/ml) 
were spotted onto carbon-coated EM grids (EMS, #15800) and dried for 15 min at 37°C. Then, EM 
grids were incubated two times for 2 min with 0.15% glycine (Sigma) in PBS and blocked for 10 min 
at room temperature in PBS with 1 % BSA (Aurion). Next, The EM grids were immunolabeled for 3 h 
at room temperature using anti- α-glucan mAb (IV58B6) or anti AM mAb (F30.5), both at a 
concentration of 10 µg/ml. The EM grids were washed three times for 3 min at room temperature in 
PBS with 0.1% BSA and incubated with secondary antibody biotinylated goat anti-mouse IgM (0.1 
µg/ml Zymed, #62-6840) in 1.0% BSA/PBS for 45 min at 37°C. The EM grids were washed three 
times for 3 min in 0.1% BSA/PBS at room temperature and immunogold labeled with 10 nm-gold 
particle labeled tertiary antibody goat anti biotin (1:20 dilution, Aurion, # 810.088) in 1.0% BSA PBS 
for 30 min at 37°C. Subsequently, the grids were washed and incubated with 1% glutaraldehyde 
(Zymed)/PBS for 5 min at room temperature and washed six times for 1 min with H2O, dried 
overnight and subsequently stored in a grid-box for EM analysis. The EM pictures were obtained by 
an electron microscope (CM100 BIOTRIM, Philips) and digital camera (Morada 9.2, Olympus) with 
ITEM imaging software (version 5.2).  
 
Flow cytometry analysis of phosphate stress markers in M. marinum  
  M. marinum strains were grown to an OD600 of 0.6-0.9 in modified Pi limitation 7H9 medium 
with or without hygromycin for the controls as described above. Pellets of 1 ml cultures were collected 
by centrifugation. The pellets were washed with PBS and resuspended in 500µl of PBS + 0,05% 
Tween-80. Flow cytometry analysis was subsequently performed on a BD Accuri C6 flow cytometer 
(BD Biosciences) equipped with a 488 nm laser and 585/40 nm filter. 20.000 gated events were 
collected per sample and data were analyzed using BD CFlow software.  
 
Zebrafish embryo experiments and bacterial infection  
  M. marinum M-USA wild-type expressing the fluorescent marker mEos3.1 and M. marinum 
strains containing the genetically engineered promoter-mCherry fusion constructs (see above) 
expressing the fluorescent marker mEos3.1 were grown to the logarithmic phase and microinjected 
into Danio rerio zebrafish embryos. Subsequently, the bacterial infection was followed over time and 
analyzed as described previously (26). For the confocal microscope imaging, embryos were fixed 
overnight in 4% (V/V) paraformaldehyde (Electron Microscopy Sciences, 100122) dissolved in PBS 
and stored in 100% methanol at -20°C. Subsequently, embryos were embedded in 1% low melting 
point agarose (Amresco, 0815) dissolved in egg water (60 µg/ml instant ocean sea salts (Sigma) in an 
8-well microscopy µ-slide (Ibidi). Next, the bacterial infection (mEos3.1) and the phosphate marker 
constructs (mCherry) were visualized with a confocal laser scanning microscope (Leica TCS SP8 X, 
microscope: Leica DMI6000) and analyzed with LAS (Leica Application Suite) AF 2.6.3 software. All 
zebrafish experiments were done according to the guidelines stated by the Dutch animal welfare laws.  
 
Results 
Inactivation of the Pst phosphate transporter system induces capsular α-glucan and AM 
production  
  In an ongoing effort to gain insight into the molecular mechanisms underlying capsular α-
glucan biogenesis in mycobacteria, we created transposon mutant libraries in M. smegmatis and 
screened for mutants with an altered capsular α-glucan profile using our double-filter assay, as 
described previously (15). In this species, we identified several mutants that carried transposon 
insertions in ABC phosphate transport locus pst (table S1). Using the same approach, we also 
identified these Pi transporter mutants in M. tuberculosis, which suggests a role for Pi metabolism in 
capsular α-glucan regulation in both these mycobacteria (Table S1). As shown in supplemental table 
S1, strains carrying mutations in genes coding for this high-affinity Pi transport system, expressed 
higher levels of capsular α-glucan.  
  Next, we complemented the pstS::tn mutant of M. smegmatis with a plasmid containing an 
intact copy of the pstS gene and analyzed the capsular α-glucan content by using an immunodot-
blotting assay. As shown in figure 1, capsular α-glucan production was strongly upregulated in the 
pstS::tn mutant as compared with the wild-type strain, whereas complementation of this mutant 
restored capsular α-glucan production to wild-type levels (Figure 1, left panel). In addition to α-
glucan, mycobacteria also produce capsular AM. To investigate whether inactivation of the Pst system 
also affected the production of this polysaccharide, we analyzed the expression of capsular AM in the 
pstS::tn and complemented strains using an AM-directed immunodot-blotting experiment. We found 
that AM production, similar to α-glucan production, was strongly increased in the pstS::tn mutant in 
comparison with the wild-type strain, whereas the complemented strain displayed normal AM 
production (Figure 1, right panel). Taken together these results demonstrate that inactivation of the Pst 
transport system in M. smegmatis and probably also in M. tuberculosis translates to elevated capsular 
α-glucan and AM production/secretion during growth in vitro.  
Exogenous Pi levels modulate capsular polysaccharide production in various mycobacterial 
species 
  The results above suggest that capsular α-glucan levels are regulated by exogenous Pi levels. 
To further elucidate this, we first investigated the consequence of Pi starvation on capsular α-glucan 
production in M. smegmatis. Wild-type M. smegmatis was grown in a modified 7H9 medium with Pi 
concentrations ranging from 25 mM to zero (Figure 2). As expected, reducing the exogenous Pi 
concentration showed a stepwise reduction in mycobacterial growth. To investigate the effect of 
exogenous Pi levels on capsular polysaccharide production, capsular α-glucan levels were analyzed at 
the early stationary phase using immunodot-blotting (Figure 2A, 48 hr). As shown in figure. 2B, an 
inverse correlation between Pi concentration (25 mM to 0µM) and capsular α-glucan production was 
observed. To examine whether other mycobacterial species behaved in a similar manner, capsular α-
glucan levels produced by M. marinum (strain E11) and M. tuberculosis (both the auxotrophic strain 
mc2 6020 and strain CDC1551) when grown under Pi-rich (25 mM) or Pi-limiting (25 µM) growth 
conditions were compared. In both species, we detected strongly upregulated capsular α-glucan 
production under Pi limiting conditions (Figure 2C and Figure 3). To analyze capsular α-glucan 
production over time, produced capsular α-glucan was also quantified using a sandwich ELISA 
(Figure 3B). Reducing the levels of exogenous Pi correlated with a stepwise induction of capsular α-
glucan, clearly visible at days 8, 11 and 16 (Figure 3B). These results demonstrate that various 
mycobacterial strains and species, including the clinical isolate M. tuberculosis CDC1551, upregulate 
capsular α-glucan production under Pi-limiting conditions.  
 
Chemical activation of the stringent response induces capsular polysaccharide production  
  To elucidate the pathway(s) involved in the Pi-dependent capsular polysaccharide production, 
we investigated the potential role of the stringent response in this process. Previously, Rifat et al. 
showed upregulation of ppk1 and relA expression under Pi-limiting conditions, which is consistent 
with inorganic polyphosphate accumulation and stringent response activation (16). To investigate 
whether activation of the stringent response could play a role in Pi-dependent capsular polysaccharide 
production, we induced the stringent response by growing M. smegmatis in Pi medium supplemented 
with serine hydroxymate (SHX). As shown in figure 4A, growth of M. smegmatis was inhibited by the 
addition of SHX, presumably by activating the stringent response. Similar results were previously 
observed for Pseudomonas aeruginosa, where supplementation of SHX induced a strong growth arrest 
(27). However, our results are in contrast with previous attempts to study an SHX-induced stringent 
response in M. tuberculosis (23). An explanation for the observed differences is the use of a different 
growth medium, i.e. 7H9 medium (Primm et al.) vs Pi medium (this study). To further sort out this 
difference, the effect of SHX supplementation on M. smegmatis growth in Pi versus 7H9 medium was 
tested (Figure 5A). Consistent with what was observed by Primm et al., addition of SHX to 7H9 
medium did not result in a growth arrest of M. smegmatis. One important difference between these two 
media is the supplementation of ADC. To test the effects of ADC supplementation on SHX activity, 
bacteria were grown in 7H9 medium supplemented with or without ADC and SHX. Indeed, in the 
absence of ADC, bacteria grown in 7H9 displayed an SHX-dependent growth arrest (Figure 5B). 
Reversely, in an experiment where M. smegmatis was grown in Pi medium supplemented with ADC, 
addition of SHX no longer demonstrated an inhibition of growth (Figure 5C). These results clearly 
demonstrate that ADC has an inhibiting effect on the SHX-induced growth arrest. To further sort out 
which components of ADC are responsible for this effect, we tested Pi medium supplemented with or 
without albumin. As shown in figure 5C, albumin had no effect on SHX-induced growth arrest. 
Because dextrose is added to both media, these results indicate that the catalase component in ADC is 
probably responsible for the inhibiting effect.  
  Next, we investigated the effect of chemically induced stringent response activation on the 
production of capsular polysaccharides. For this, capsular extracts obtained at different time points 
during growth were analyzed for capsular α-glucan levels and AM by using immunodot-blotting 
(Figure 4). Three hours after addition of SHX, M. smegmatis produced elevated levels of both α-
glucan (Figure 4B) and AM (Figure 4C). These levels further increased after 17 hours, as both 
polysaccharides were strongly overexpressed. To confirm these results, we also visualized and 
subsequently quantified capsular polysaccharides using immunogold labeling and electron microscopy 
(Figure 4D). These experiments showed that, upon addition of SHX, both capsular α-glucan (Figure 
4D+E) as well as AM (Figure 4D+F) were highly upregulated. Finally, to investigate whether M. 
tuberculosis exhibits a similar phenotype, the stringent response was induced in M. tuberculosis 
auxotrophic strain mc26020 by addition of SHX to a log-phase culture for 4 days. As shown in figure. 
4G, 48 hours after SHX supplementation M. tuberculosis demonstrated a dose-dependent increase in 
capsular α-glucan production. Taken together, these results strongly suggest that SHX-mediated 
activation of the stringent response is linked to an induction of capsular polysaccharide production in 
both M. smegmatis and M. tuberculosis.  
Pi-mediated capsular α-glucan production is dependent on σ factor SigE  
  Previous studies reported the involvement of alternative σ factor SigE in downstream nutrient 
stress signaling, including Pi-stress, via polyphosphate-MprAB-SigE (16, 18) and induced expression 
of RelA (18, 28). Therefore, we investigated the consequence of SigE deficiency on the Pi-mediated 
induction of capsular polysaccharides. Wild-type M. tuberculosis H37Rv, ∆sigE and ∆sigE 
complemented with an integrated wild-type sigE were grown under Pi-rich (25 mM (+)) or Pi-limiting 
(25 µM (-)) conditions and capsular polysaccharide expression was analyzed over time by immunodot-
blotting. As shown in figure 6A, wild-type M. tuberculosis showed a Pi-dependent upregulation of 
capsular α-glucan production at day 15 post inoculation. In contrast, the ∆sigE strain failed to induce 
α-glucan production during the course of the experiment (26 days), a phenotype that was partially 
restored by complementation with an intact sigE copy.  
  Next, wild-type M. tuberculosis, ∆sigE and the complemented strains were incubated with 
SHX to directly activate the stringent response downstream of SigE. As expected, addition of SHX 
bypassed the need for SigE and induced capsular α-glucan production in all 3 strains (Figure 6B). To 
further elucidate the pathway of Pi-mediated upregulation of capsular α-glucan, we investigated 
stringent response initiator RelA. Importantly, RelA in M. tuberculosis is a unique enzyme, in that it 
can both synthesize and hydrolyse (p)ppGpp. To highlight these two enzyme activities, M. 
tuberculosis RelA is designated as RelMtb. Wild-type M. tuberculosis, ∆relmtb derivative and 
complemented strains were grown under Pi-rich (25 mM (+)) or Pi-limiting (25 µM (-)) conditions and 
analyzed for capsular α-glucan by immunodot-blotting assay. As shown in figure 6C, both the wild-
type and complemented strains showed normal Pi-mediated induction of capsular α-glucan. However, 
strikingly, the ∆relMtb strain demonstrated the same α-glucan induction under Pi-starved conditions, 
indicating that RelMtb activity is not needed for the increase in capsular α-glucan production. These 
data suggest that Pi-stress signaling in M. tuberculosis induces capsular α-glucan in a SigE-dependent 
manner, but independently of RelMtb.  
M. marinum experiences phosphate-limiting conditions in vivo  
  Phosphate limitation is believed to be a relevant physiological condition encountered by M. 
tuberculosis in vivo. In a previous study, Rifat et al. showed that expression levels of gene clusters 
involved in the phosphate stress response (PSR), including the phosphate-specific transport operon 
pstS3-pstC2-pstA1, were induced in mouse lungs during infection (16). Furthermore, several reports 
show that the two-component regulator SenX3-RegX3 is directly involved in the mycobacterial PSR 
(16, 29, 30) and that ppk1 expression is RegX3 dependent (16, 31). In order to investigate whether Pi 
limitation is a relevant condition encountered by mycobacteria in vivo, three reporter strains were 
constructed. These reporter strains are transcriptional fusions of a promoter region of interest in front 
of an mCherry gene, so that gene activation could be monitored by a fluorescence readout. Promoter 
regions of known phosphate-stress related genes ppk1, senX3 and phoS2 (ortholog to pstS3 in M. 
tuberculosis) were selected. First, these phosphate-stress sensing reporter strains were grown under Pi-
rich (25 mM) or Pi-limiting (25 µM) conditions and subsequently analyzed by flow cytometry to see 
whether phosphate stress could be detected in vitro. Comparison of M. marinum strains containing the 
stress-marker constructs revealed that the senX3-mCherry fusion was only 1.6 fold induced after 24 
hours under Pi-limiting condition (Figure 7A and 7B). Over time, this induction was slightly increased 
on day 2 and peaked on day 3, indicating that the Pi-stress occurs within 24 hours and stably increases 
(Figure 7C). Surprisingly, the ppk1-mCherry reporter construct showed no significant difference 
between high or low Pi growth conditions over a 4-day period of time (Figure 7D and 7E, 
respectively). The phoS2-mCherry fusion showed constitutive activity and no difference was observed 
between high and low Pi (Figure 7 F and G) . Therefore, the phoS2-mCherry fusion was excluded as a 
phosphate stress marker and was used as a positive control.  
  The in vitro induction of Pi stress might be different from the in vivo situation, therefore, all 
three constructed reporter strains were also analyzed in zebrafish embryos. First, an additional 
(integrative) plasmid harboring the hsp60 promoter and fluorescent protein-encoding gene mEos3.1 
(GFP) was introduced in the reporter strains, to allow the detection of the bacteria. Subsequently, 
zebrafish embryos were infected with these M. marinum promoter-fusion mCherry/mEos3.1 strains 
and a control strain that only contained the hsp60-mEos3.1 construct. The bacterial infection in the 
zebrafish embryos was analyzed from 1 to 4 days post infection (dpi). At 3 dpi the phosphate stress 
marker senX3 is gradually induced, increasing even further at 4 dpi (Figure 8A). This clearly indicates 
that Pi stress is sensed by M. marinum in vivo. This result is consistent with our in vitro data 
(Figure7A and B) and with the previous findings that the expression of senX3 is elevated under Pi 
stress in M. tuberculosis in vivo (16). In addition, the ppk1 Pi-stress marker strain now also showed 
induction of ppk1 at 4 dpi, an indication that the ppk1 promoter-fusion construct is expressed in vivo, 
as reported previously by Rifat et al. (Figure 8A).  
  To examine possible differences in induction between bacterial populations, we analyzed these 
reporter strains by confocal microscopy. In all reporter strains we detected similar severity of bacterial 
infection from 3 dpi onward (Figure 8C). The senX3 promoter-fusion construct is induced at 3 dpi and 
the merged fluorescence pictures indicate induction of the senX3 reporter, a clear sign that Pi limitation 
is sensed at 3 dpi in vivo (Figure 8C). Furthermore, the ppk1 Pi-stress indicator is clearly detectable at 
3 dpi and suggests ppk1 induction in vivo ( Figure 8C). As observed in vitro, the phoS2 promoter-
fusion was constitutively induced (Figure 8C) in vivo. In conclusion, these data show that Pi- 
limitation is encountered by M. marinum in vivo.  
Discussion 
M. tuberculosis is a well-adapted human pathogen that encounters multiple stress conditions during 
infection. To survive these harsh environments, the bacillus deploys a variety of strategies to adapt its 
complex cell envelope composition. The mycobacterial capsule, the outermost cell envelope layer, is 
expected to be important. The capsular polysaccharides have previously been associated with 
virulence and immune modulation (10, 13), which might be key for bacterial adaptation within the 
host. The purpose of this study was to investigate mechanisms involved in mycobacterial capsular 
polysaccharides α-glucan biogenesis under exogenous Pi starvation and to pinpoint the biological 
relevance of Pi-starvation in vivo.  
  In this study, we show that the Pst system is involved in the regulation of the capsular 
polysaccharides α-glucan in both M. smegmatis and M. tuberculosis. The Pst system is a high affinity 
inorganic Pi ABC transporter important for the acquisition of Pi (17). This is in line with previous data, 
which showed that expression of pstS3 is significantly upregulated under Pi depletion, suggesting an 
important role for the Pst system in bacterial survival at low Pi conditions (32). Consistently, the Pst 
system is linked via SenX3-RegX3to the ESX-5 system in which Pi limitation controls the 
overexpression of ESX-5 genes and hypersecretion of its substrates EsxN and PPE41 (33). The ESX-5 
system is essential for virulence in M. tuberculosis and it is also suggested to have an important role in 
the Pst system in virulence (33).  
  We hypothesized that blocking the Pst system by transposon inactivation would lead to Pi 
starvation in M. tuberculosis and result in the upregulation of the capsular polysaccharides. Indeed, we 
show an upregulation of capsular α-glucan at low levels of Pi in M. tuberculosis. These results strongly 
indicate that Pi stress modulates the immunomodulatory capsular α-glucan. In contrast to α-glucan 
levels, the AM levels were not significantly induced upon Pi stress in M. tuberculosis (data not 
shown). This result is inconsistent with our findings in M. smegmatis where an MS_pst::tn mutant 
showed elevated levels of AM (Figure 1). This suggests a different regulation of AM production under 
Pi starvation in M. smegmatis in comparison with M. tuberculosis. Interestingly, the capsular α-glucan 
production is detectable from the early stationary phase onward, suggesting that some form of stress 
(other than low phosphate) can initiate the production of capsular α-glucan (Figure 3). Interestingly, 
the stringent response is activated as the metabolic state of mycobacteria is changed due to various 
nutrient starvations. Consistently, Primm et al. reported a mild activation of the stringent response and 
(p)ppGpp production in the early stationary phase (23). Here, we have used chemical activation of the 
stringent response by SHX, which elevated the α-capsular glucan production. So, these findings 
suggest a strong link between the stringent response and capsular α-glucan upregulation in M. 
tuberculosis. Interestingly, inactivation of the Pst system is associated with immune modulation and 
reduced virulence of M. tuberculosis in mice (34, 35). This effect might be due to high capsular α-
glucan levels, which have also been associated with immunomodulation, in these strains (11, 13, 14, 
33). Because we identified upregulation of capsular α-glucan production in three different 
mycobacterial species, M. smegmatis, M. marinum and M. tuberculosis upon Pi starvation, this 
phenotype seems to be a conserved feature. In this study we also show that SHX-mediated activation 
of the stringent response in M. smegmatis causes bacterial growth arrest and upregulation of α-glucan 
and AM. Therefore, our study clearly demonstrates that SHX is a useful tool to investigate the 
stringent response in mycobacteria. Previous attempts by Primm et al. were unsuccessful, and we 
show here that this is probably due to the presence of catalase, which may inactivate SHX in the 
medium.  
  A full understanding of the stringent response pathway is difficult, due to a highly dynamic 
interplay of sigma and anti-sigma factors, RelA
 
activity (levels of (p)ppGpp), and different nutrient 
stresses(36-43). The situation in M. tuberculosis is no different. To further complicate matters, several 
of the sigma factors involved in this process, like SigE, are also capable of activating genes not related 
to the stringent response (22, 44). In the context of Pi-starvation, SigE is of particular interest, as 
previous reports link SigE to the signal transduction pathway activated under Pi stress(16, 18). In this 
study, we show that the phosphate stress-mediated upregulation of capsular glucan is SigE-dependent. 
To our surprise, inactivation of relMtb had no influence on the Pi-stress mediated induction of capsular 
α-glucan (Figure 6). This strongly suggests that the pathway for the upregulation under Pi-starvation is 
initiated by SigE and is primarily not stringent response dependent. In contrast, downstream SHX-
mediated activation of RelMtb clearly induces the capsular α-glucan levels. These results highlight the 
complexity of capsular α-glucan production and regulation mediated by different stress conditions and 
divergent activated pathways, at least for amino acid versus Pi starvation. Based on our findings and 
the current literature, we suggest a model of the capsular α-glucan production under stress conditions 
in M. tuberculosis (Figure 9). This model shows that different stresses can activate the SigE stress 
regulon and/or the stringent response via RelMtb to modulate capsular α-glucan levels. The Pst system 
senses low Pi and activates the SigE regulon via downstream signaling via the SenX3-RegX3-MprAB-
SigE pathway to elevate capsular α-glucan production. In addition, amino acid stress via chemical 
activation of RelMtb by SHX induces (p)ppGpp production, activates the stringent response stress 
regulon, and subsequently leads to higher levels of capsular α-glucan (Fig. 9, green arrows). 
Furthermore, SigE and RelMtbcan be activated by various stresses encountered by M. tuberculosis in 
vivo that could therefore also up-regulate capsular α-glucan (Fig. 9, black arrows).   
  Finally, we have revealed that Pi limitation is encountered by M. marinum in vivo in zebrafish 
embryos. These findings are consistent with several reports suggesting that Pi-limitation is 
encountered by M. tuberculosis in vivo (16, 18, 33). However, in our hands the ppk1 promoter-fusion 
construct was not induced in vitro, apparently additional stimuli that only occur in vivo are necessary 
for induction of this gene. A full comprehension of both capsular polysaccharide and lipid changes, 
especially in multiple stresses that mimic the in vivo condition, might be the key to a better 
understanding of the pathogenesis of M. tuberculosis. In this context, our work provides a first glimpse 
that the outermost capsule layer, i.e., capsular α-glucan is modified under stress conditions. The 
identification of possible routes in stress-mediated biosynthesis regulation of capsular α-glucan might 
lead to novel ways to intervene with the capsular polysaccharide biosynthesis in M. tuberculosis. 
Finally, the discovery how to activate the stringent response in mycobacteria with SHX is of great 
practical value and might therefore boost our understanding of this essential in vivo stress pathway in 
M. tuberculosis. 
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Figure 1. Immunodot-blotting analysis of capsular polysaccharides α-glucan and AM in M. 
smegmatis pstS::tn and complemented strains. Mycobacterial capsular extracts of liquid cultures (t 
= 48 h) were spotted in 3-fold serial dilution steps (Dil) onto nitrocellulose filters and immunostained 
with IgM anti-α-glucan (IV56B6) and anti-AM (F30.5) antibodies, respectively. Data shown are 
representative for three independent experiments. 
 Figure 2. Capsular α-glucan production of Pi stressed M. smegmatis, M. marinum and 
auxotrophic M. tuberculosis. The mycobacterial strains M. smegmatis mc2155, M. marinum E11, and 
auxotrophic M. tuberculosis mc26020 were grown in 7H9-based liquid medium supplemented with 
different concentrations of Pi, and cells were collected at various time points (see below). The bacterial 
cells were “shaved” with a detergent, and the obtained capsular extracts were subsequently assayed by 
immunodot-blotting to analyze the capsular α-glucan level using anti-glucan mAb (IV56B6). A, 
growth curves of M. smegmatis grown in different concentrations of Pi show a Pi concentration-
dependent growth arrest. B, immunodot-blotting analysis of capsular α-glucan of A at 48 h revealed Pi 
stress-mediated induction of α-glucan in M. smegmatis. C, immunodot-blotting analysis of capsular α-
glucan in M. marinum (left panel) and M. tuberculosis (right panel) grown under low and high Pi at 
days 5 and 6, respectively. In both mycobacterial strains, the capsular α-glucan levels are elevated 
under low Pi. The data presented here are representative for four independent experiments. Dil, 
diluted/dilutes. 
Figure 3. M. tuberculosis induces capsule polysaccharide α-glucan under Pi starvation. M. 
tuberculosis CDC1551 was grown in 7H9 medium supplemented with different concentrations of Pi 
ranging from 25 mM to 0, and bacterial growth was monitored by measuring OD600 for 16 days. At 
several time points, indicated with numbers 1–5, samples were collected, and capsular extracts were 
made to analyze the α-glucan content. A, growth curves of M. tuberculosis grown in different 
concentrations of Pi. B, detection of capsular α-glucan during growth of A at several days by sandwich 
ELISA utilizing anti-glucan antibody (IV56B6). Data are representative for three independent 
experiments. Error bars represent S.D. 
 
 Figure 4. Chemical activation of the stringent response by SHX upregulates the capsule 
polysaccharides α-glucan and AM in M. smegmatis and α-glucan in M. tuberculosis. M. smegmatis 
(mc2155) and M. tuberculosis (mc26020) strains were grown in 7H9-based liquid Pi medium without 
ADC, and SHX was added at 6.5 h and 4 days, respectively. Bacterial cells were collected at different 
time points and shaved with a detergent. The obtained capsular extracts were subsequently assayed by 
immunodot-blotting to analyze the capsular polysaccharides α-glucan or AM using specific anti-
glucan (IV56B6) or anti-AM (F30.5) mAb. A, M. smegmatis challenged with 100 µg/ml SHX showed 
strong reduction in growth in comparison with bacteria grown without SHX. Error bars represent S.D. 
The cells grown in A were used to determine α-glucan (B) and AM (C) levels. A strong induction of 
α-glucan and AM is observed after 3 and 17 h of SHX addition. D, direct visualization of capsular 
polysaccharides α-glucan (upper panel) and AM (lower panel) in M. smegmatis WT by immunogold 
labeling. Cells were cultured in liquid, fixed 2 days after SHX addition, and labeled with IV56B6 
(upper panel) or F30.5 (lower panel) mAb. Quantitative evaluation of the EM analysis of α-glucan (E) 
and AM (F) is shown. Values represent means of three experiments ±S.E.M. G, M. tuberculosis 
(mc26020) strain treated with SHX (50,100, 150, and 200 µg/ml) showed dose-dependent upregulation 
of capsular α-glucan after 48 h. Data are representative for three independent experiments. Dil, 
diluted/dilutes or dilutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5. Mycobacterial growth medium 7H9 supplement ADC inactivates activity of stringent 
response activator SHX in M. smegmatis. M. smegmatis mc2155 strain was grown in liquid 7H9 or 
in 7H9-based Pi medium. The 7H9 and Pi media were supplemented with or without ADC, and Pi 
medium was supplemented with albumin. The bacterial growth of M. smegmatis was monitored by 
OD600 over time; at 4 h after inoculation, the bacterial cultures where supplemented with or without 
100 µg/ml SHX. A, bacterial growth is arrested in Pi medium upon addition with SHX in comparison 
without SHX, indicative for SHX-dependent activation of the stringent response. In 7H9 medium 
supplemented with SHX, bacterial growth arrest is not observed, a clear sign that this compound is not 
active. B, removal of ADC from 7H9 medium shows SHX-mediated growth arrest in M. smegmatis, a 
strong indication that ADC supplement is responsible for inactivation of compound SHX. C, ADC 
addition to Pi medium shows no activity of SHX on bacterial growth in M. smegmatis, and Pi medium 
supplemented with or without albumin (A) shows SHX-mediated bacterial growth arrest. This 
indicates that dextrose and/or catalase is responsible for inactivation of compound SHX. Data are 
representative for six independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6. Capsular α-glucan upregulation under Pi starvation is SigE-dependent. M. tuberculosis 
H37Rv wild-type, targeted knock-out (sigE and relMtb), and complemented (C_sigE and C_relMtb) 
strains were collected from liquid 7H9-based Pi medium supplemented with normal Pi (+; 25 mM) or 
low Pi (−; 25 µM) concentrations. To activate the stringent response, SHX was added at a final 
concentration of 250 µg/ml. Cell suspensions were normalized on OD600 values at days 6, 11,15,19, 
and 26 and subsequently shaved with detergent to liberate the capsular polysaccharides. The capsular 
extracts were spotted in 3-fold serial dilutions (Dil) onto nitrocellulose sheets and subsequently 
analyzed for the amount of capsular polysaccharides α-glucan by immunodot-blotting with antibody 
directed against α-glucan (IV56B6). A, immunodot-blotting analysis of Pi stress-related capsular α-
glucan regulation by SigE in M. tuberculosis. Upon Pi stress, capsular α-glucan is upregulated in WT 
strain over time, whereas in the sigE mutant no Pi stress-mediated upregulation is observed. The 
upregulation of capsular α-glucan is restored by complementation with the sigE gene. B, immunodot-
blotting analysis of capsular α-glucan regulation by SigE where the stringent response, downstream of 
SigE, is activated by SHX. WT, mutant sigE, and the complemented sigE strains showed induced 
capsular α-glucan levels by activation of the stringent response at day 15. C, In WT, mutant relMtb, and 
the complemented relMtb strains, normal Pi stress-related induction of α-glucan levels is observed. 
Experiments are representative for two, and all other data are representative for three independent 
experiments. 
 Figure 7. Upregulation of senX3 promoter fusion in M. marinum under Pi starvation in vitro. A, a 
plot of FACS data for the senX3-mCherry construct under high phosphate conditions. A representative 
WT fluorescence curve (black line) is plotted with senX3-mCherry after 1 (in red), 2 (in blue), 3 (in 
green), or 4 days (in orange) in high phosphate-containing medium. B, a plot of FACS data for the 
senX3-mCherry construct under low phosphate conditions. A representative WT fluorescence curve 
(black line) is plotted with senX3-mCherry after 1 (in red), 2 (in blue), 3 (in green), or 4 days (in 
orange) in low phosphate-containing medium. C, quantification of the -fold induction per day 
compared with WT M. marinum. Mean fluorescence intensity of the low phosphate cultures was 
divided by the mean fluorescence intensity of the high phosphate cultures, leading to a -“fold 
induction.” D, a plot of FACS data for the ppk1-mCherry construct under high phosphate conditions. 
A representative WT fluorescence curve (black line) is plotted with ppk1-mCherry after 1 (in red), 2 
(in blue), 3 (in green), or 4 days (in orange) in high phosphate-containing medium. E, a plot of FACS 
data for the ppk1-mCherry construct under low phosphate conditions. A representative WT 
fluorescence curve (black line) is plotted with ppk1-mCherry after 1 (in red), 2 (in blue), 3 (in green), 
or 4 days (in orange) in low phosphate-containing medium. F, a plot of FACS data for the phoS2-
mCherry construct under high phosphate conditions. A representative WT fluorescence curve (black 
line) is plotted with phoS2-mCherry after 1 (in red), 2 (in blue), 3 (in green), or 4 days (in orange) in 
high phosphate-containing medium. G, a plot of FACS data for the phoS2-mCherry construct under 
low phosphate conditions. A representative WT fluorescence curve (black line) is plotted with ppk1-
mCherry after 1 (in red), 2 (in blue), 3 (in green), or 4 days (in orange) in low phosphate-containing 
medium. Data are representative for three independent experiments. 
 Figure 8. In vivo activation of M. marinum low Pi reporter strains. M. marinum strains containing 
the mCherry promotor-fusion constructs (phoS2, ppk1, and senX3) and constitutive mEos3.1 
expression were injected into zebrafish embryos. As a control, we used a strain expressing only 
mEos3.1. A, bright field (left panel) and fluorescence images of 3- and 4-dpi embryos with the Pi 
stress promotor-fusion constructs in red and total infection in green. The bacterial injection inocula for 
strains phoS2, control, ppk1, and senX3 were 57, 243, 32, and 139, respectively. B, bright field image 
of zebrafish embryo indicating the region that was analyzed by confocal microscopy imaging. C, 
confocal microscopy imaging showing mEos3.1 (bacterial infection; left panel) and mCherry (Pi stress 
indicator; middle panel) expression. Data are representative for three individual experiments. 
 Figure 9. Model of capsular α-glucan regulation routes in M. tuberculosis. The model is based on 
our finding of capsular induction under Pi starvation and SHX-mediated amino acid stress as well as 
the current literature on stress signaling pathways in M. tuberculosis. Low Pi is sensed by the Pst 
system and downstream signaling via the SenX3-RegX3-MprAB-SigE pathway. SigE activates the 
SigE-dependent stress regulon, which ultimately induces the capsular α-glucan (green arrows). SigE 
signaling to RelMtb occurs in Pi starvation, but the capsular α-glucan is not elevated via a RelMtb-
dependent manner (red arrow with cross). Mimicking amino acid starvation by SHX activates the 
stringent response via RelMtb-mediated induction of (p)ppGpp and upregulates the capsule 
polysaccharide α-glucan (green arrows). Nutrient stress as seen in the stationary phase cultured M. 
tuberculosis leads to induced capsular α-glucan levels mediated by RelMtb and/or SigE (black arrows). 
SigE and RelMtb communicate via feedforward and feedback loops and therefore might influence 
each other in the capsular α-glucan production (black arrows with question mark). Furthermore, M. 
tuberculosis encounters in vivo various stress conditions, like carbon, iron, hypoxia, or other stresses 
(marked Other stresses) that might upregulate capsular α-glucan in a similar way via SigE and/or 
RelMtb. TCS, two-component system; Poly-P, polyphosphate. 
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 Abstract 
Tuberculosis can be treated with a 6-month regimen of antibiotics. Although the targets of most of the 
first-line antibiotics have been identified, less research has focused on the intrabacterial stress 
responses that follow upon treatment with antibiotics. Studying the roles of these stress genes may 
lead to the identification of crucial stress-coping mechanisms that can provide additional drug targets 
to increase treatment efficacy. A three-gene operon of unknown function that is strongly up-regulated 
upon treatment with isoniazid and ethambutol is the iniBAC operon. We have reproduced these 
findings and show that iniBAC genes are also induced in infected host cells, although with higher 
variability. Next, we set out to elucidate the genetic network that results in iniBAC induction 
in Mycobacterium marinum. By transposon mutagenesis, we identified that the operon is highly 
induced by mutations in genes encoding enzymes of the vitamin B12 biosynthesis pathway and the 
vitamin B12-dependent methylmalonyl-CoA-mutase MutAB. Lipid analysis showed that 
a mutA::tn mutant has decreased phthiocerol dimycocerosates levels, suggesting a link 
between iniBAC induction and the production of methyl-branched lipids. Moreover, a similar screen 
in Mycobacterium bovis BCG identified that phthiocerol dimycocerosate biosynthesis mutants show 
up-regulation of iniBAC genes. Based on these data, we propose that iniBAC is induced in response to 
mutations that cause defects in the biosynthesis of methyl-branched lipids. The resulting metabolic 
stress caused by these mutations or caused by ethambutol or isoniazid treatment may be relieved 
by iniBAC to increase the chance of bacterial survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Mycobacterium tuberculosis, the causative agent of tuberculosis, is responsible for 1.5 million deaths 
annually, making it the most deadly bacterial pathogen known to mankind (1). Although tuberculosis 
can be treated effectively with a long term multidrug regimen, failure to complete treatment has led to 
increasing occurrence of drug resistance, which in turn complicates treatment (1, 2). Therefore, the 
need to develop new anti-mycobacterial compounds is evident. An attractive target for drug therapy is 
the mycobacterial cell wall, which is composed of non-canonical elements providing the opportunity 
to specifically target mycobacteria (3). In the past several antibiotics that target the mycobacterial cell 
wall have been identified and have proven to be effective in treatment of tuberculosis. Well known 
examples of specific anti-cell wall antibiotics for mycobacteria are ethambutol (EMB) and isoniazid 
(INH). Ethambutol targets the polymerization of arabinan, an essential component of the 
mycobacterial cell wall involved in covalently linking the peptidoglycan layer to the outer membrane 
(4). The prodrug isoniazid is activated by the peroxidase KatG and subsequently forms adducts with 
NAD+ to inhibit InhA, a NADH-dependent enoyl-ACP (acyl carrier protein) reductase (5). As a 
consequence, biosynthesis of mycolic acids, the most abundant lipid of the mycobacterial outer 
membrane, is inhibited, causing an aberrant and lethal deformation of the cell wall (6). Recent 
research efforts have emphasized that also other essential steps in the biogenesis of the mycobacterial 
cell wall can serve as new targets for anti-tuberculosis interventions (7, 8). 
  Although our knowledge on cell wall biosynthesis in mycobacteria has greatly increased over 
the last decades, the bacterial stress responses that follow after treatment with antibiotics targeting the 
mycobacterial cell wall have yet to be elucidated. By mapping the intra-bacterial responses upon 
treatment with antibiotics, key pathways that are necessary to cope with antibiotics or with antibiotic-
induced stress can be identified. Moreover, mapping bacterial stress levels may help to explain the 
observed heterogeneity, displayed by bacterial subpopulations, to antibiotic treatment within patients 
(9). Together, these findings might pave the way for novel drug targets that sensitize or enhance 
currently used antibiotics. 
  Despite the availability of gene expression data after exposure of mycobacteria to anti-
tuberculosis drugs, there is no comprehensive map of the stress response pathways that follow upon 
treatment. Moreover, antibiotic stress regulation pathways were not addressed in general. Insights into 
the pathways that mycobacteria deploy when confronted with antibiotic treatment will lead to a better 
understanding of the bacterial adaptive strategies and may consequently pinpoint drug-induced blind 
spots that can be targeted by novel compounds. Some individual genes or gene clusters that are 
regulated in response to antibiotic treatment have been well characterized. For instance, the acyl 
carrier protein kasA has been found to be up-regulated in response to isoniazid (10). Another set of 
genes that was found to be highly induced by sublethal concentrations of ethambutol and isoniazid 
in M. tuberculosis and Mycobacterium bovis BCG is the iniBAC operon (11, 12). This operon was 
found to be induced specifically by these two cell wall targeting antibiotics, but not by general cell 
wall stress caused by disruption of the membrane integrity through the activity of granulysin or 
lysozyme (12). Further studies by the same group showed that overexpression of iniA seemed to 
confer tolerance to INH treatment in M. bovis BCG but not in M. tuberculosis (13). This suggests a 
function for iniA in coping with the stress that is induced by INH or EMB treatment in M. bovis BCG. 
Despite these early studies, not much is known about the pathways that lead to induction of these three 
genes of unknown function. In Escherichia coli, disruption of cell wall biosynthesis can be sensed by 
extracytoplasmic function sigma factor E (14). Similarly, mycobacterial sigE has been shown to 
respond to heat-shock and oxidative stresses (15). Although sigE is not a specific sensor for cell wall 
stress, other sigma factors may play a role in the stress network that is activated 
upon iniBAC induction. A few publications have addressed the regulation of the iniBAC operon. 
Colangeli et al. (16) have shown that lsr2, among regulating a large set of other genes, negatively 
regulates iniBAC expression, whereas recent studies have also implicated operon regulation 
by mtrA and the alleged INH binding regulation element inbR (17, 18). 
  In this study we aimed to elucidate the genetic network that revolves around the induction of 
the iniBAC operon. We found that the operon can be induced by mutations in vitamin B12 
biosynthesis or the vitamin B12-dependent methylmalonyl-CoA mutase MutAB in Mycobacterium 
marinum. Mutants in mutAB show decreased phthiocerol dimycocerosate (PDIM) and phenolic 
glycolipid (PGL) levels, but are not altered in their antibiotic susceptibility. 
Results 
The iniBAC operon is induced upon EMB and INH treatment in M. marinum  
  To investigate the response of the iniBAC operon to stress, we generated a reporter gene 
construct by placing the gene encoding green fluorescent protein mEos3.1 under control of the M. 
marinum iniB promoter region, optimized as previously reported for M. tuberculosis (12). The reporter 
construct was transformed into M. marinum cells and activity was assessed using the inducing 
antibiotics INH or EMB. The initial induction experiments were carried out by the addition of the 
antibiotics EMB or INH at their minimal inhibitory concentration (MIC) followed by flow cytometry 
analysis. Starting from day 1, we observed a strong induction of the iniBAC reporter construct after the 
addition of the antibiotic, as compared with the non-treated M. marinum cells; fluorescence was 114-
fold (EMB) and 121-fold (INH) higher. The induction increased over time and reached a 357-fold 
difference by day 5 for EMB and 643-fold for INH (Fig. 1A). 
  Next, we tested reporter activity in cell infection experiments. Carp leukocyte cells (CLC) and 
THP-1 macrophages were infected with M. marinum harboring the iniBAC reporter construct and 
analysis of induction kinetics was tracked by flow cytometry. To differentiate between infected and 
non-infected macrophages and to assess which proportion of the infected cells expressed 
the iniBAC reporter construct, the red fluorescent protein crimson E2 was constitutively expressed on 
an episomal construct. We combined this with an integrative version of the stress marker containing 
the iniB promoter and mEos3.1. As such, we could determine which proportion of the total pool of 
infected, crimson-positive cells was also iniBAC-induced and, thus, mEos3.1 positive. After infection, 
the phagocytized bacteria were challenged with 1× MIC of EMB or INH, and flow cytometry was 
used to measure induction of the iniBAC reporter on days 0, 1, 2 and 3. Fig. 1B shows a representative 
measurement of an experiment performed in triplicate. In THP-1 cells the population of macrophages 
that contained bacteria with induced iniBAC increased to 41.6% (S.D. 0.4%) on day 3 for ethambutol. 
Isoniazid showed a faster induction pattern in THP-1 cells with 13.4% (S.D. 0.4%) becoming 
mEos3.1-positive on day 1, increasing to 38.6% (S.D. 0.7%) on day 3 (Fig. 1, B and C). In CLC 
infection assays, similar patterns were observed (Fig. 1, B and C).   
  In summary, the induction of the iniBAC reporter during intracellular infection seems to 
increase over time but does not seem to affect all bacteria, which was observed in culture. THP-1 cells 
were also analyzed by confocal imaging on days 1 and 2 (Fig. 2). Confocal imaging confirmed the 
observations of flow cytometry assays. Moreover, the EMB- and INH-treated macrophages showed a 
clear pattern of heterogeneity from day 2 onward, coinciding with the significant increase in induction 
seen by flow cytometry for both antibiotics. In conclusion, we have confirmed that M. 
marinum expresses iniBAC upon treatment with EMB and INH. Furthermore, this induction is 
observed in culture and in two different cell types using a cell infection assay. However, induction is 
more variable during cell infection as compared with culture. 
 
Mutations in vitamin B12 biosynthesis and the vitamin B12-dependent mutAB cause up-
regulation of iniBAC in M. marinum  
  Next, we set out to probe which genes and regulation networks play a role in iniBAC 
induction. For this, a wild type M. marinum MUSA containing an exosomal variant of the iniBAC stress 
marker was used as a parent strain to create a transposon library. The resulting mutants were plated out 
and selected for high fluorescence. Analysis of the transposon insertion site was performed for a total 
of 50 positive mutants. Strikingly, 32 of the 50 transposons insertions were identified in genes that are 
responsible for cobalamin synthesis, the so-called cob family genes (Fig. 3A). These genes are part of 
the set of 25 genes that are required for vitamin B12 biosynthesis in mycobacteria (19). Furthermore, 
12 mutants were identified in methylmalonyl-CoA-mutase encoding genes MutAB or in the gene 
coding for its alleged foldase, meaB (20). The MutAB enzyme plays a role in propionate metabolism, 
converting (S)-methylmalonyl-CoA, a precursor for methyl-branched lipids, to (R)-methylmalonyl-
CoA, which is further processed to succinyl-CoA to enter the tricarboxylic acid or glyoxylate cycle 
(Fig. 3B). The methyl-branched lipids synthesized from (S)-methylmalonyl-CoA include PDIM, 
diacyl trehalose/penta-acyl trehalose, and SL-1 (21). MutAB is vitamin B12-dependent, suggesting 
that the mutants affected in vitamin B12 biosynthesis were most likely identified because of their 
downstream effect on MutAB. Besides identification of most known cobalamin biosynthesis genes, 
this screen also confirms that MMAR_4563, is probably coding for the vitamin B12 biosynthesis 
enzyme CobF (data not shown), and MeaB is indeed functionally linked to MutAB. Other mutants that 
showed induction, albeit to a lesser extent, include mutations in pks16, mshD, or mas, genes that are 
all involved in cell wall lipid biosynthesis (Table 1).  
 
iniBAC induction in vitamin B12 biosynthesis mutants can be rescued by exogenous vitamin B12  
  To confirm that the effects seen on the induction of the iniBAC stress marker were due to 
abrogated vitamin B12 biosynthesis, we compared the induction of three mutants, mutA::tn, mshD::tn, 
and cobN::tn. Without the addition of vitamin B12, both mutA::tn and cobN::tn showed clear 
expression of mCherry (Fig. 4A). As expected, the cobN transposon mutant clearly reverts from 
high iniBAC induction to a near background expression level by the addition of 10 µg/ml vitamin B12 
(Fig. 4B). We also tested which concentration of vitamin B12 was required to phenotypically 
complement the cob mutants. Lowering the concentration to <100 ng/ml vitamin B12 abrogated 
complementation, which was also confirmed by flow cytometry (data not shown). Because usually 
only trace amounts of vitamin B12 are required, this means that M. marinum does not efficiently 
transport vitamin B12 under these conditions. The other two mutants, mutA::tn and mshD::tn, were 
unaffected by the addition of vitamin B12, as confirmed by fluorescence microscopy (data not shown). 
  Besides complementation with vitamin B12, a genetic complementation was also performed 
for three mutants, i.e. cobB::tn, mshD::tn, and mutA::tn. The resulting complemented strains were 
analyzed by flow cytometry for fluorescence induction of the stress marker as compared with their 
mutant parent strain. This confirmed that complementation of cobB::tn and mshD::tn was achieved by 
introducing an intact copy of the respective gene (Fig. 4C). The mutA::tn mutant did not complement 
when only mutA was reintroduced in the mutant strain, suggesting that the transposon mutant we 
obtained in mutA likely also disturbs expression of the downstream genes mutB and MMAR_2304 
(meaB orthologue). Complementation was achieved when we introduced mutA, mutB, 
and MMAR_2304, as fluorescence induction was restored to wild type levels. 
 
Addition of acetic acid or propionic acid to transposon mutants in mutA or cobB does not affect 
viability or iniBAC induction – To assess whether we could find the metabolic cue that 
induces iniBAC, we performed an experiment on HdB minimal medium plates containing only acetic 
acid, propionic acid, or valeric acid as carbon source. Because acetic acid and propionic acid are both 
major players in the pathways in which MutAB operates, we suspected that the addition of these fatty 
acids could influence either bacterial growth of some of our mutants or iniBAC induction. Glucose and 
glycerol served as a growth control. However, we did not observe any significant growth differences 
upon the addition of 0.1% acetic acid, propionic acid, or valeric acid when comparing 
a cobB::tn and mutA::tn mutant versus a WT M. marinum (Fig. 5A). We also analyzed 
the iniBAC induction of the bacteria that grew on these plates by flow cytometry. Also in this 
experiment, we did not observe any significant changes in induction (Fig. 5B). These results suggest 
that the induction of the iniBAC operon is probably not directly dependent on the level of metabolic 
intermediates or fluxes in the routes outlined in Fig. 3. 
Analysis of M. marinum mutants in vivo reveals a temporary iniBAC induction phenotype 
independent of vitamin B12 availability 
  To assess whether vitamin B12 availability can complement the cob mutants in vivo, three 
different mutants (cobN::tn, mutA::tn, and mshD::tn) were selected for analysis in a zebrafish embryo 
hindbrain infection model using WT as a control. All four strains contained a constitutive, integrated 
hsp60-mEos3.1 construct for visualization of infection and an episomal version of the 
mCherry iniB stress marker. After 24 h of infection, a homogeneous induction of iniBAC was seen for 
all three mutants, indicating that the induction had not changed in this period of time (Fig. 6). This is 
not unexpected because the bacteria were already highly expressing mCherry and the protein is 
relatively stable. However,120 h post infection (hpi), a clear reduction of mCherry was observed in 
all three mutants, whereas the green fluorescent signal, i.e. mEos3.1, was still present or even 
increased. 
In summary, we show that iniBAC induction is declining in vivo, with virtually no induction after 120 
h. The decrease in induction was seen for all tested mutants and, therefore, seems to be independent of 
vitamin B12 availability. 
 
Mutants in mutA and cobB have decreased levels of methyl-branched lipids PDIM and PGL  
  Because MutAB mediates the isomerization of (R)-methyl-malonyl-CoA to succinyl-CoA, we 
hypothesized that a mutA transposon mutant could have an excess amount of (R)-methylmalonyl-CoA. 
Consequently, this could influence the amount of methyl-branched lipids that are synthesized, such as 
PGLs/PDIMs (Fig. 3B). To assess whether this was the case, we performed TLC analysis to detect 
both PDIM and PGL variants for WT MUSA and transposon mutants in genes mas, mutA, and cobB. 
Strikingly, when comparing the amount of PDIMs of the mutA and cobB transposon mutants, a 
significant reduction in PDIM types A, B, and C can be distinguished (Fig. 7A). This reduction is 
phenotypically similar to a mas transposon mutant, which is known to be strongly affected in PDIM 
production (22). Moreover, PGL production was also severely decreased 
in mutA::tn and cobB::tn compared with WT, whereas the mas mutant, as expected, showed a null 
phenotype for this lipid (Fig. 7B). In conclusion, abrogation of vitamin B12 biosynthesis or mutation 
of mutAB caused a decrease in methyl-branched lipids PGL and PDIM in M. marinum. 
 
The antibiotic susceptibility of mutAB and cobB mutants to first-line antibiotics is unchanged  
  To see whether the mutations that induce iniBAC are also changed in antibiotic susceptibility, 
we determined the MIC values of mutA::tn, mutB::tn, mshD::tn, and cobB::tn upon exposure to five 
first-line antibiotics. There were no differences observed for the four mutants tested, indicating that, 
although differences in PDIM and PGL can be seen for mutA::tn and cobB::tn, this does not seem to 
affect antibiotic susceptibility (Table 2). This finding seems to contradict the previously published 
results by Colangeli et al. (13), where they stated that up-regulation of iniA in M. tuberculosis caused 
a moderate but significantly increased resistance phenotype against ethambutol. 
 
The induction of iniBAC is not caused by general cell wall stress  
  The array of mutants that show an increased induction of the iniBAC operon seem to revolve 
around methyl-branched lipid biosynthesis. To see whether a defect in lipid biosynthesis and cell 
envelope integrity in general would also cause induction of the operon, we transformed 
a kasB::tn mutant, a mutant known to produce truncated mycolic acids, with the iniBAC stress marker 
(23). This mutant shows reduced growth and is attenuated in zebrafish embryos. Comparison of 
induction on plate to a mutA::tn and mshD::tn mutant revealed that the kasB::tn mutant does not seem 
to be highly induced on plate (data not shown). 
  Subsequent analysis by flow cytometry revealed that the iniBAC operon is indeed only 1.4-
fold induced in this mutant, comparable with a mshD::tn mutant, whereas a mutA transposon mutant 
showed a 14.2-fold induction compared with a WT expressing the stress marker (Fig. 8). Therefore, 
not all genes that cause cell wall alterations contribute equally to the induction of the iniBAC operon. 
 
Mutants in PDIM biosynthesis operon show induction of iniBAC in M. bovis BCG  
  Although most genes coding for vitamin B12 biosynthesis enzymes are present in species 
belonging to the M. tuberculosis complex, research by Warner et al. (24) has shown that M. 
tuberculosis does not seem produce vitamin B12 in vitro. This bacterium, therefore, seems to depend 
on the import of exogenous vitamin B12 (24, 25). Because of this difference, we wondered what 
genes would affect iniBAC induction in these species. To explore this, we created a transposon 
mutant library in an M. bovis BCG Copenhagen strain containing the iniBAC stress reporter. In total, 
we identified 29 mutants that showed a high induction of the stress reporter. Genetic analysis of these 
mutants showed that we did not obtain any transposon insertion in genes involved in the vitamin B12 
biosynthesis pathway, as expected. Most of these mutants were affected in the PDIM biosynthesis 
operon, including tesA, ppsB-E, papA5, and mas, similar to what had been found for M. marinum. A 
list of the unique mutants identified in this screen can be found in Table 3. 
  To determine whether these mutations had an effect on bacterial viability, MIC values for five 
first-line antibiotics were determined for the M. bovis BCG transposon 
mutants papA5::tn and mas::tn. Both mutants were compared with their WT parent strain harboring 
the stress marker. No differences of >2-fold were observed when comparing mutant to parent, again 
indicating that there is no correlation between iniBAC up-regulation and antibiotic susceptibility 
(Table 4), as was also observed in M. marinum. Together, these data show that mutants in two 
different mycobacterial species mutations or changes in PDIM biosynthesis induce the iniBAC operon, 
further supporting the link between iniBAC induction and the biosynthesis of methyl-branched lipids. 
 
Discussion 
  In this work we show that the induction of the iniBAC operon as a result of EMB or INH 
treatment takes place both in cultured M. marinum and in intracellular bacteria, confirming previous 
observations of iniBAC induction in Mycobacterium smegmatis and M. bovis BCG by Alland et 
al. (12). We also show that the induction seems to be heterogeneous within THP-1 macrophages. 
Heterogeneity upon antibiotic treatment is a phenomenon that is well-known for mycobacteria, and 
this phenotype plays an important role in patient treatment outcomes (9). Therefore, the observed 
variation in iniBAC induction underlines the importance of studying antibiotic response networks. 
  Previously, induction of the iniBAC operon was defined as a general cell wall stress operon 
that was induced upon the addition of cell wall biogenesis antibiotics EMB and INH (12, 13). In this 
study we show that the induction of iniBAC seems to be more specific and linked to the biosynthesis 
of methyl-branched lipids. M. marinum transposon mutants in mutAB or cob genes responsible for 
vitamin B12 biosynthesis caused strong induction of iniBAC. Moreover, these strains showed a strong 
decrease in the amount of PDIM and PGL lipids but no altered antibiotic susceptibility. Interestingly, 
in M. bovis BCG, mutations in the PDIM biosynthesis operon cause induction of the iniBAC operon 
and, therefore, point to a similar induction signal as the PDIM-deprived M. marinum transposon 
mutants. 
  One theory that could explain why the iniBAC operon is highly induced in both species is that 
one of the lipid precursors (S)-methylmalonyl-CoA, (R)-methylmalonyl-CoA, or propionyl-CoA 
accumulates. Mycobacteria are highly sensitive to increases in the pool of intermediates of fatty acids 
but also propionyl-CoA and propionyl-CoA itself. High levels of propionyl-CoA have been found to 
be toxic unless detoxified by the methyl citrate cycle (26). Because the methyl citrate cycle is intact in 
the iniBAC-inducing mutants, the accumulation of (S)-methylmalonyl-CoA or (R)-methylmalonyl 
seem to be the most likely accumulating candidates. In M. marinum, prevention of conversion of (R)-
methylmalonyl-CoA to succinyl-CoA causes induction of the iniBAC operon, whereas M. bovis BCG 
probably does not have MutAB activity in culture due to an incomplete vitamin B12 biosynthesis 
pathway. Subsequently, M. marinum shows lowered PDIM levels upon mutations in the methyl-
malonyl pathway, and M. bovis BCG shows induction of the operon when PDIM biosynthesis is 
disturbed, possibly leading to accumulation of a toxic intermediate. When we assessed growth of 
WT M. marinum and its isogenic cobB::tn and mutA::tn mutants on minimal medium, there was no 
clear difference in growth or iniBAC induction for any of the carbon sources used. This suggests that 
metabolites of the different pathways indicated in Fig. 3 do not seem to play a direct role in iniBAC 
stress. 
  Another hypothesis is that a misbalance occurs between the methyl-malonyl pathway because 
of disturbance of outflow due to mutations in PDIM biosynthesis or blocking of MutAB and the 
methyl citrate cycle. This is supported by work from Lee et al. (27), where it was found that the 
relative abundance of acetyl-CoA determined the toxicity of propionyl-CoA or its three-carbon 
intermediates. Because in M. marinum both pathways are constitutively active in vitro, a blockade can 
lead to an overflow of the methyl-citrate cycle and may cause iniBAC induction. The iniBAC operon 
might be involved in rescuing the bacterium from these otherwise toxic intermediates. It seems that the 
outflow of possibly accumulated (S)-methylmalonyl-CoA and (R)-methylmalonyl-CoA is not simply 
managed by conversion to methyl-branched lipids. As we did not assess the relative balance of these 
two intermediates, it might be worthwhile to investigate the relative abundance of acetyl-CoA and 
propionyl-CoA by metabolomics. Surprisingly, the M. marinum mutAB mutants have lower PGL and 
PDIM levels, confirming research by Jain et al. (28) who showed that a mutAB overexpression strain 
has increased PDIM levels. Therefore, a regulation pathway may be in place that reduces the 
methylmalonyl pathway when toxic metabolites in this cycle reach a certain threshold. Alternatively, 
another unidentified outflow of these metabolites is present, as some of these enzymes in the pathway 
are duplicated in M. marinum. The function of the iniBAC operon has been previously addressed by 
Colangeli et al.(13). They predicted that IniA might serve as an efflux pump that leads to tolerance to 
EMB and INH treatment (13). We also tested this hypothesis using our overexpression mutants. In our 
system iniBAC overexpression took place under more natural conditions and, therefore, possibly 
included overexpression of accessory genes that have not been identified yet. Based on the antibiotic 
susceptibility assays with high expressing iniBAC mutants in M. marinum and M. bovis BCG, we 
notice that induction of the operon did not alter antibiotic susceptibility. Our results, therefore, do not 
support the hypothesis that this operon forms an efflux pump that influences bacterial resistance to 
EMB and INH. 
  In line with this, sequence analysis shows that both iniA and iniC contain a GTPase domain 
that shows a high similarity to dynamin family proteins. This suggests that these proteins might have a 
function that allows them to vesiculate possible toxic intermediates. Bacterial dynamin-like proteins 
(DLPs) have first been discovered in a cyanobacterium, Nostoc punctiforme (29). It was shown that 
an N. punctiforme DLP could form tubulations in lipid bilayers and facilitate both fission and fusion of 
vesicles in a GTP-dependent manner (30). More recently, E. coli has been shown to contain a triplet of 
DLPs, leoABC, that mediate toxin release via membrane vesicles. It is worth noting that bacterial 
DLPs are often found in tandem, like E. coli leoA and leoC, and mycobacterial iniA and iniC (31). It is 
tempting to hypothesize that the iniBAC genes are dynamin-like proteins that allow vesiculation of 
toxic molecules in mycobacteria, and this is definitely something that future research can address. 
Recently, it has been suggested that DLP of Bacillus subtilis is involved in membrane stress (32). 
Perhaps overproduction of some mycobacterial lipids, such as PDIM, could also trigger membrane 
stress. 
  In this work we established that M. marinum produces vitamin B12 in vitro and 
that MMAR_4563 is indeed a functional gene in this biosynthesis route, as previously suggested by 
Weerdenburg et al. (33). Therefore, we propose to call this gene cobF. The vitamin B12 mutants that 
we identified seem to have reduced PDIM levels. Although we did not confirm reversion of PDIM 
levels upon vitamin B12 supplementation by TLC, we assume that this is the case. Because PDIMs are 
important for virulence in mycobacteria (34), this may suggest a direct link between vitamin B12 
biosynthesis, cell homeostasis, and virulence. Evidence for the effect of vitamin B12 homeostasis and 
virulence was presented by Weerdenburg et al. (33), where it was shown that mutations in the vitamin 
B12 biosynthesis genes caused an increased fitness for M. marinum in Acanthamoeba infection 
experiments. Although there are two enzymes in M. marinum that need vitamin B12 as a cofactor, 
methionine synthase MetH and methylmalonyl-CoA mutase MutAB (24, 25), based on our results the 
absence of MutAB could explain the observed virulence effects because the mycobacterial lipid profile 
is altered. In this paper and a previous study by Gopinath et al. (25), it was shown that mycobacteria 
are able to take up vitamin B12 in vitro. Because vitamin B12 is present in the host (35), there is a 
reservoir for vitamin B12 that can be scavenged during infection, thereby altering lipid expression. 
  Although our in vivo experiments show that iniBAC induction is absent after 120 hpi 
independent of vitamin B12 availability, we cannot rule out that vitamin B12 plays a role in vivo. In 
light of this we find it interesting that both mutA::tn and cobN::tn mutants showed a significantly 
milder infection phenotype than mshD::tn and WT M. marinum, indicating that abrogation of the 
MutAB pathway or vitamin B12 biosynthesis may influence the outcome of infection. 
  Future experiments should be performed to elucidate the role of the iniBAC genes in EMB and 
INH-induced stress. Most importantly, the possibility that iniBAC plays a role in coping with toxic 
intermediates may very well lead to the identification of novel therapeutic targets that allow 
potentiation of current mycobacterial drug therapy. 
Material & methods 
Bacterial strains and culturing conditions 
  E. coli strain DH5α was used to for cloning and propagation of plasmid DNA. Cultures were 
grown at 37 °C in LB broth with the addition of antibiotics hygromycin B (50 µg/ml), kanamycin (25 
µg/ml), or streptomycin (30 µg/ml) where necessary. M. marinum wild type MUSA (36) was used as a 
basis for mycobacterial experiments, and mutants were derived from this parent strain. M. 
marinum MUSA and M. bovis BCG Copenhagen were used for transposon mutagenesis experiments. 
Cultures were grown in Middlebrook 7H9 liquid medium supplemented with Middlebrook ADC and 
0.05% Tween 80 with the addition of the aforementioned antibiotic concentrations when required. 
Additional antibiotics isoniazid (Sigma) and ethambutol (Sigma) were routinely added to log-phase 
cultures at the indicated final concentrations. Cyanocobalamin (Sigma) was added where indicated at a 
concentration of 10 µg/ml. Middlebrook 7H10 solid agar supplemented with Middlebrook OADC was 
used for bacterial plating. Both cultures and plates were grown at 30 °C. Sauton plates were prepared 
according to a protocol published by D. W. Allen (37). Human monocytic cell line THP-1 and carp 
leukocyte cell line CLC were cultured in RPMI 1640 supplemented with 10% fetal bovine serum 
(Gibco) and Glutamax (Gibco). THP-1 cells were grown in 37 °C with 5% CO2, whereas CLCs were 
grown at 30 °C with 5% CO2. 
Construction of plasmids 
  All plasmids used in this study are listed in Table 5, whereas all primers used in this study can 
be found in Table 6. Anchored primers containing either an XbaI site or BamHI site were used to 
amplify a 588-bp fragment that included the iniB promoter from M. marinum MUSA genomic DNA. 
The resulting product and a pAL5000 derivative containing pSMT3-hsp60-mCherry (38) were both 
digested with XbaI and BamHI, mixed, and ligated, resulting in pSMT3-piniB-mCherry. A 3′ 
promoter truncation was created as described by Alland et al. (12) by modeling the M. bovis BCG 
promoter sequence onto the M. marinum MUSA promoter sequence. Anchored primers containing an 
XbaI site for the 5′ primer and BamHI site for the 3′ primer were used to amplify a 211-bp fragment 
from M. marinum MUSA genomic DNA. The insert and pAL5000 derivative were digested with XbaI 
and BamHI, mixed, and ligated, creating pSMT3-piniB4-mCherry. Subsequently, a GFP variant 
encoded by the gene mEos3.1 (39) was amplified with anchored primers (BamHI for the 5′ primer and 
BsrGI for the 3′ primer) and subsequently digested together with pSMT3-piniB4-mCherry with 
BamHI and BsrGI creating pSMT3-piniB4-mEos3.1. Integrative plasmids were derived from 
pMV361, and all integrative constructs were created with In-Fusion (Clontech) cloning (40). The 
insert piniB4-mEos3.1 was amplified from pSMT3-piniB4-mEos3.1 and cloned via InFusion into a 
promoterless version of pMV361 that was digested with PmlI and NsiI creating pMV-piniB4-mEos3.1. 
A previously constructed variant pMV-hsp60-mEos3.1 (41) was digested with NheI and ClaI to serve 
as a backbone for complementation constructs pMV-hsp60-cobB and pMV-hsp60-mshD. 
Both cobB and mshD were amplified from M. marinum MUSA genomic DNA and cloned into the 
digested vector with InFusion to create pMV-hsp60-cobB and pMV-hsp60-mshD, respectively. The 
aforementioned promoterless version of pMV361 was digested with HindIII to introduce mutA and 
mutAB+MMAR_2304 to create pMV-mutA and pMV-mutAB-MMAR_2304 
 
Transposon mutagenesis 
  Transposon mutagenesis was performed in M. marinum MUSA and M. bovis BCG Copenhagen, 
both containing pSMT3-piniB4-mCherry. Both strains were infected with the mycobacterial phage 
phiMycoMarT7 that contains the Himar 1 transposon (42). Transposon mutants were assessed for 
increased mCherry expression, indicating induction of iniBAC by fluorescence microscopy. Colonies 
that showed a vast increase in fluorescence were isolated, and the transposon insertion site was 
determined by ligation-mediated PCR as described previously (36). 
 
Flow cytometry analysis 
  The induction of the iniBAC was assessed by flow cytometry. Bacteria were grown to 
an A600 of 0.3, and antibiotics were added at the indicated concentrations for a specified amount of 
time. For each time point, 1 ml was culture was collected by centrifugation and washed with PBS with 
0.05% Tween 80. The bacterial pellet was collected by centrifugation, and bacterial cells were 
resuspended in PBS containing 0.05% Tween 80 and subsequently analyzed on a BD Accuri C6 flow 
cytometer (BD Biosciences) equipped with a 488-nm laser and 585/40-nm filter for mEos3.1 and a 
640 laser and 675/25 filter to detect CrimsonE2. In total, 30,000 gated events were collected per 
sample per time point, and data were analyzed using BD CFlow software. 
 
M. marinum MUSA infection of THP-1 cells and CLCs 
  For infection of THP-1 and CLCs, 1 × 107 cells per well were seeded in 100-mm plates 
(Corning) and grown for 24 h. THP-1 monocytes were differentiated for 48 h by the addition of 25 
ng/ml phorbol 12-myristate 13-acetate (Sigma). M. marinum containing plasmid MSP-Crimson alone 
and a strain with both MSP-crimson and integrative construct pMV-piniB4-mEos3.1 were grown to 
an OD600 of 0.8 and washed in RPMI 1640 previous to infection. Bacterial cells were subsequently 
added at a multiplicity of infection of 5. THP-1 cells were incubated at 33 °C and CLCs at 30 °C. 
After 3 h, extracellular mycobacteria were removed by washing 3 times with RPMI 1640. Amikacin 
was added to a concentration of 200 µg/ml for 3 h to kill any remaining extracellular mycobacterial 
cells. This point was considered time point 0 h, and cells were subsequently harvested at 0, 24, 48, and 
72 hpi. THP-1 and CLC cells were both collected by the addition of 1× Accutase® (Sigma). Infected 
cells were spun down at 800 x g and washed with RPMI 1640 and resuspended in PBS for flow 
cytometry analysis. For confocal analysis, cells were fixed in 4% PFA in PBS, washed in PBS, and 
spun down on a coverslip using a cytospin. Vectashield (Vector Laboratories) with DAPI was added 
on the coverslip, and cells were subsequently analyzed with a Leica TCS SP8 confocal microscope. 
 
Sole carbon source experiments on HdB plates 
  HdB plates were prepared as previously described by Hartman and De Bont (44). Acetic acid, 
propionic acid, and valeric acid (Sigma) were dissolved by sonification in HdB medium containing 
0.02% tyloxapol to an end concentration of 0.1%. Glucose was added to a final concentration of 1%, 
and a plate with no carbon source was taken along as growth control. Bacterial cells were washed 3× 
in PBS containing 0.02% tyloxapol and subsequently 3 µl of 10-fold dilutions of WT M. marinum, and 
transposon mutants in cobB and mutA were added to the plates. Plates were incubated for 14 days and 
imaged to visualize bacterial growth. Flow cytometry was performed by resuspending the resulting 
bacterial colonies in PBS plus 0.05% Tween. 
 
Infection of zebrafish embryos 
  To visualize M. marinum in zebrafish embryos, pMV-hsp60-mEos3.1 was introduced in M. 
marinum MUSA strains that already contained the stress marker construct pSMT3-piniB4-mCherry. 
Zebrafish embryos were injected with 2000 CFUs by microinjection in the hindbrain ventricle as 
previously described (45, 46). Infection was monitored at specified times by means of fluorescence 
microscopy. For confocal analysis, zebrafish embryos were fixed in 4% paraformaldehyde dissolved 
in PBS for 24 h and subsequently stored in 0.5% paraformaldehyde. For confocal microscopy, 
zebrafish were immobilized in 1% low melting point agarose in PBS and imaged with a Leica TCS 
SP8 confocal microscope. 
 
Mycobacterial lipids extraction and TLC analysis 
  M. marinum transposon mutants mas::tn, cobB::tn, and mutA::tn were grown to an A600of 1.0. 
Then, 50 absorbance units were collected by centrifugation and washed three times with PBS. The 
extraction of the cell envelope lipids was performed in three steps to harvest the apolar, polar, and 
mycolic acid lipid fractions as previously described (47, 48). Both apolar and polar lipid fractions 
were analyzed with two-dimensional TLC for PDIM and the LOS lipid contents system A and system 
E, respectively, as earlier described by Besra (43). Briefly, equal amounts of lipid fractions were 
spotted on silica-60 TLC plates (Merck) and separated by a two-dimensional TLC system A (one-
dimensional, petroleum ether:ethyl acetate 98/2 (v/v); two-dimensional, petroleum ether:acetone 98/2 
(v/v)) and system E (one-dimensional, chloroform:methanol:H2O 60/30/6 (v/v/v) and two-
dimensional, chloroform:acetic acid:methanol:H2O 40/25/3/6 (v/v/v/v)). Subsequently, the lipids were 
visualized by addition of 5% molybdophosphoric acid in methanol (for PDIM analysis) or 0.2 g of 
orcinol in 100 ml of 20% H2SO4 coloring agents (for LOS analysis). Lipid contents were visualized by 
TLC-plate charring at 150 °C for 10 min. 
 
Antibiotic susceptibility assay 
  Both M. marinum and M. bovis BCG transposon mutants were grown in 7H9 supplemented 
with ADC to an OD600 of 0.6–1. Subsequently 104 cells were distributed per well in a 96-well plate, 
and serial 2-fold dilutions of ciprofloxacin, ethambutol, isoniazid, streptomycin, and rifampicin were 
added (Sigma). The MIC was determined as the concentration of antibiotics that inhibited visible 
growth. Wells without the addition of antibiotics were used as a growth control, and experiments were 
performed at least in triplicate. 
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 Figure 1. The iniBAC operon is induced upon treatment with EMB and INH both in culture and 
in vitro. Flow cytometry plots of untreated cultures (black line) compared to cultures treated with 
ethambutol (red line) and isoniazid (blue line) with the minimal inhibitory concentration (A). For each 
condition 30,000 events are plotted. The mean fluorescence intensity (MFI) is shown on the X-axis per 
amount of cells (Y-axis). Induction folds are indicated per day and calculated as treated sample MFI 
divided by untreated sample MFI. Plots of induction patterns in THP-1 and CLC cells on day 3 after 
infection (B). EMB and INH were added 3 hpi. Induction over time in THP-1 cells and CLC cells, 
plotted as the percentage of cells that fall into the ‘mEos3.1 positive’ gate (C). The graph shows the 
average percentage of induction of three independent experiments. The s.d. values were too small to 
be displayed. 
  
Figure 2.Induction of iniBAC in THP-1 macrophages reveals heterogeneity. THP-1 cells 1 day 
after infection without antibiotics (-), treated with 1µg/ml EMB or with 10µg/ml INH (A). Each panel, 
a representation of three images is shown, where the THP-1 nucleus is stained with DAPI (blue), M. 
marinum constitutively expresses CrimsonE2 (red) and conditionally expresses mEos3.1 as a measure 
for iniBAC induction (green). The same layout as in (A) but for day 2 after infection of THP-1 cells 
(B). 
 
 
 
 
 
 Figure 3. Mutants that show a strong up-regulation of iniBAC are in the vitamin B12-
biosynthesis pathway or mutAB-associated. A pie chart that depicts the distribution of mutants that 
were found in the transposon mutagenesis screen. In total 50 mutants were analyzed genetically (A). 
Schematic overview of the propionate degradation pathway adjusted from (20) (B). Enzyme 
abbreviations are: propionyl-CoA carboxylase (PCC), methylmalonyl-CoA epimerase (MMCE), 
succinate synthase (SCS), methylcitrate synthase (MCS), methylcitrate dehydratase (MCD), acotinase 
(ACN), 2-methylisocitrate lyase (MCL) and pyruvate dehydrogenase complex (PDHC). 
 
 Figure 4. M. marinum deficient in vitamin B12 production can be complemented by addition of 
exogenous vitamin B12 in vitro. Mutants mutA::tn, mshD::tn, and cobN::tn compared to a WT M. 
marinum containing the pSMT3-iniB4-mCherry and WT M. marinum without addition of vitamin B12 
on plate (A). The same mutations when exposed to 10µg/ml vitamin B12 (cyanocobalamin) (B). 
Genetic complementation (marked by C) was also performed by introduction of an integrative vector 
containing an intact copy of the mutated genes. Resulting strains were analyzed in triplicate by flow 
cytometry and compared in mean fluorescence induction (MFI) to their mutant counterparts (C). 
 Figure 5. Addition of acetic acid, propionic acid and valeric acid to M. marinum WT and 
cobB::tn and mutA::tn mutants shows no obvious effect on bacterial viability. The left row 
indicates the bacterial fold dilution and below each panels the corresponding carbon source and 
concentration is denoted (A). Flow cytometry was performed to quantify the induction on glucose, 
acetic acid and propionic acid (B). 
  
Figure 6. iniBAC induction of transposon mutants in mutA, cobN and mshD is transient and 
decreases over time. Confocal images of zebrafish embryos infected with WT M. marinum MUSA, 
mutA::tn, cobN::tn or mshD::tn containing a plasmid pmv-hsp60-mEos3.1 and piniB-mCherry. 
Zebrafish were injected in the hindbrain ventricle and fixed in PFA. The top panel shows a 
fluorescence induction overlay of mCherry (stress marker) and mEos3.1 (total infection) for 24 hpi, 
whereas the lower panel shows this for time point 120hpi. 
 
 
 
 Figure 7. Lipid analysis reveals differences in PDIM levels in mutA::tn and cobB::tn mutants. 
After isolation of apolar lipids, the presence of PDIMs was analyzed by 2D-TLC (A). For the first 
dimension PE:ethyl ether (98:2) was used and for 2D PE:acetone(98:2). MPA was used as a coloring 
agent. The presence of different PDIM types A, B and C is indicated with black arrows. The figure 
compares WT MUSA to transposon mutants in mas, cobB and mutA. The presence of PGL was analyzed 
by 1D TLC (B). As a solvent chloroform:methanol (90:10) was used. Oricinol was used as a colouring 
agent. 
 
 
 
 
 
 Figure 8. iniBAC induction is not caused by general stress. A flow cytometry plot analyzing the 
iniBAC expression of the transposon mutants in kasB (in blue), mshD (in green) and mutA (in red) 
versus a WT M. marinum (in black) harboring the stress marker construct with mCherry (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Features Source 
pSMT3-hsp60-mCherry hsp60 promoter, mCherry, hygR (38) 
pSMT3-piniB-mCherry iniB promoter, mCherry, hygR This study 
pSMT3-piniB4-mCherry truncated iniB promoter, mCherry, hygR This study 
pSMT3-piniB4-mEos3.1 truncated iniB promoter, mEos3.1, hygR This study 
pMV361 hsp60 promoter, L5 attP & aph, oriE, strR (40) 
pMV-piniB4-mEos3.1 truncated iniB promoter, mEos3.1, L5 attP  
& aph, oriE, strR 
This study 
pMV-hsp60-mEos3.1  hsp60 promoter, mEos3.1, L5 attP  
& aph, oriE, strR 
(41) 
pMV-hsp60-cobB hsp60 promoter, cobB, L5 attP & aph, oriE, 
strR 
This study 
pMV-hsp60-mshD hsp60 promoter, mshD, L5 attP & aph, oriE, 
strR 
This study 
pMV361-nohsp60 L5 attP & aph, oriE, strR This study 
pMV-mutA mutA, L5 attP & aph, oriE, strR This study 
pMV-mutAB-MMAR_2304 mutA, mutB, MMAR_2304, L5 attP &  
aph, oriE, strR 
This study 
pTEC19-MSP-crimsonE2 msp promoter, crimsonE2, hygR (Addgene) 
 
Table 1. List of plasmids used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 Name Sequence (5’  3’) 
iniB-FW TTCTAGAACTCGTTCTCGCCGCATGTT 
iniB-RV TTTGGATCCTTGTCCCTTCAATCGAATGT 
iniB4-FW TTTTTCTAGACGTCATTGGTGTTTGACGTGCAGA 
iniB4-RV TTTTGGATCCTTGTTCGCCGAAACGACCGGCGCTC 
iniB4mEos-FW TTTTGGATCCGAGGAATCACGCTAGCATGA 
iniB4mEos-RV TTTTTGTACACCTTATCGTCTGGCATTGTC 
pmv-hsp60mEos-FW GAACCACTTAATTAACTTGTTGTCGTTGGCGGTCA 
pmv-hsp60mEos-RV TTAATATTCCATCACTTATCGTCTGGCATTGTCAG 
pmv-B4-mEos-FW GAACCACTTAATTAACGTCATTGGTGTTTGACGTGC 
pmv-B4-mEos-RV TTAATATTCCATCACTTATCGTCTGGCATTGTCAG 
pmv-cobB-FW GAGGAATCACGCTAGCGGTGACGGCAAGGGCAAG 
pmv-cobB-RV ACTACGTCGACATCGATAGTGGTGACCGCCAGCG 
pmv-mutA-FW CGACATCGATAAGCTGCTGTCACAATCACCCAGAGT 
pmv-mutA-RV AGGTTAATTAAAGCTCTACGCTCCCAACCGCG 
pmv-mshD-FW  GAGGAATCACGCTAGCGTGACGGCGGTGCAATGG 
pmv-mshD-FW ACTACGTCGACATCGATCTAGGCCAACGCCGCG 
pmv-mutAB2304-FW CGACATCGATAAGCTCACGGTGCTGACCTTGCG 
pmv-mutAB2304-RV AGGTTAATTAAAGCTATTGACTCCGATGTCTACCGTCAC 
 
Table 2. List of primers used in this study 
 
 
 
 
 
 
 
 
 
Gene ID Gene product H37Rv 
orthologue 
Gene length Transposon 
position(s) within 
gene (bp from 5’ 
of gene) 
MMAR_0989 PE_PGRS - 3153 2149 
MMAR_1350 tetR repressor Rv3208 684 421 
MMAR_1768 mas Rv2940c 5616 1173 
MMAR_1885 cobB Rv2848 1377 
148, 194, 416, 
429, 597, 610, 
905, 1271, 1290, 
1293, 1324,  
MMAR_2302 mutA Rv1492 1878 
14, 225, 427, 
1836 
MMAR_2303 mutB Rv1493 2262 
6, 41, 521, 1095, 
1724, 2179  
MMAR_2304 meaB Rv1496 1011 204, 379 
MMAR_3037 cobN Rv2062c 3573 
76, 129, 311, 
1486, 3374, 3394 
MMAR_3045 cobH Rv2065 627 123 
MMAR_3046 cobI Rv2066 1470 256 
MMAR_3052 cobK Rv2070c 729 11 
MMAR_3053 cobM Rv2071c 740 715 
MMAR_3054 cobL Rv2072c 1173 1093 
MMAR_3251 cobU Rv0254c 561 75 
MMAR_3252 cobT Rv2207 1077 525 
MMAR_3307 cobC Rv2231c 1053 273 
MMAR_3311 cobD Rv2236c 942 792 
MMAR_4476 pks16 Rv1013 1635 652 
MMAR_4563 cobF - 744 
30, 134, 155, 232, 
610 
MMAR_4863 mshD Rv0819 963 469, 526 
 
Table 3. List of M. marinum mutants identified in transposon mutagenesis screen. This table 
contains an overview of the unique M. marinum mutants that were identified in this study. The H37Rv 
orthologue, if present, the gene length and the number of unique mutants per gene are indicated. 
 
 
 
 
 
 
 
 
 Strain Rifampicin 
(µg/ml) 
Ethambutol 
(µg/ml) 
Isoniazid 
(µg/ml) 
Streptomycin 
(µg/ml) 
Ciprofloxacin 
(µg/ml) 
WT 0.32 1.6 32 4 4 
mutA::tn 0.32 0.8 32 4 4 
mutB::tn 0.32 0.8 32 4 4 
cobB::tn 0.32 0.8 32 4 4 
mshD::tn 0.32 0.8 32 4 4 
 
Table 4. MIC determination on M. marinum mutants shows no change in antibiotic 
susceptibility. Measurements were performed in triplicate. The concentration at which no visible 
growth was seen is denoted as the MIC value in µg/ml. For the triplicate measurements, three identical 
values were found. As such, the standard deviation is zero and therefore not written behind the values 
in the table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Gene ID Gene product H37Rv 
orthologue 
Gene length Transposon 
position(s) within 
gene (bp from 5’ 
of gene) 
Mb0016c pbpA Rv0016c 1476 252, 652, 995 
Mb0673 carotenoid oxygenase Rv0654 1506 178 
Mb1041 pks16 Rv1013 1635 538 
Mb1069c PE protein Rv1040c 828 260 
Mb1445c MFS transporter Rv1410c 1557 661 
Mb1951c PPE34 Rv1917 4380 942 
Mb2370 lppQ Rv2341 420 8 
Mb2720c suhB Rv2701c 873 340 
Mb2953 tesA Rv2928 786 96 
Mb2956 ppsB Rv2932 4617 330, 1385, 3528 
Mb2958 ppsC Rv2933 6567 2764, 3227 
Mb2959 ppsD Rv2934 5484 
244, 903, 1370, 
5342 
Mb2960 ppsE  Rv2935 4467 1370, 4172 
Mb2964 papA5 Rv2939 1269 99, 361 
Mb2965c mas Rv2940c 6336 778, 1400, 3259 
Mb3024 lppY Rv2999 966 877 
 
Table 5. List of M. bovis BCG mutants identified in transposon mutagenesis screen. Table 
containing unique mutants that were found, with their H37Rv gene ID and gene length. Genes that are 
part of the PDIM biosynthesis cluster are shown in bold. 
 
 
 
 
 
 
 
 
 
 
 
Strain Rifampicin 
(µg/ml) 
Ethambutol 
(µg/ml) 
Isoniazid 
(µg/ml) 
Streptomycin 
(µg/ml) 
Ciprofloxacin 
(µg/ml) 
WT-B 0.0008 2 0.5 0.45 0.25 
papA5::tn 0.0016 2 0.5 0.27 0.25 
WT-B4 0.01 2 0.5 0.45 0.25 
mas::tn 0.005 2 0.5 0.45 0.25 
 
Table 6. MIC values for the M. bovis BCG mutants. MIC values for a papA5::tn mutant and the 
parent WT strain with pSMT3-piniB-mCherry (WT-B) and mas::tn mutant with its WT parent strain 
containing the stress marker pSMT3-piniB4-mCherry (WT-B4). Measurements were done in triplicate. 
For the triplicate measurements, three identical values were found. As such, the standard deviation is 
zero and therefore not written behind the values in the table. 
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Abstract 
The cell envelope of mycobacteria is a highly unique and complex structure that is functionally 
equivalent to that of Gram-negative bacteria to protect the bacterial cell. Defects in the integrity or 
assembly of this cell envelop must be sensed to allow the induction of stress response systems. The 
promoter that is most strongly induced upon exposure to antibiotics that affect cell envelope 
biogenesis is the iniBAC promoter. In this study, we set out to identify the regulatory cascade of the 
iniBAC operon in Mycobacterium marinum using transposon mutagenesis in a constitutively iniBAC-
expressing mutant. We obtained multiple mutants in the mce1 locus as well as mutants in an 
uncharacterized putative transcriptional regulator (MMAR_0612). This latter gene was shown to 
function as the iniBAC regulator, as overexpression resulted in constitutive iniBAC induction, whereas 
a knockout mutant was unable to respond to the presence of ethambutol and isoniazid. Experiments 
with the M. tuberculosis homologue (Rv0339c) showed identical results. RNAseq experiments showed 
that this regulatory gene was exclusively involved in the regulation of the iniBAC operon. We 
therefore propose to name this dedicated regulator iniBAC Regulator (IniR). IniR belongs to the 
family of signal transduction ATPases with numerous domains, including a putative sugar-binding 
domain. Upon testing different sugars, we identified trehalose as an activator and metabolic cue for 
iniBAC activation, which could also explain the effect of the mce1 mutations. In conclusion, cell 
envelope stress in mycobacteria is regulated by IniR in a cascade that includes trehalose.  
 
Author summary 
The mycobacterial cell wall is a complex and unique structure that protects extremely well against 
harmful compounds. Understanding the biogenesis and functioning of this cell envelope is essential to 
be able to effectively target mycobacteria. One way to uncover cell envelope functionality is to study 
stress mechanisms that are induced when the cell envelope is damaged. Here, we describe the 
identification of a major cell envelope stress regulator and the inducing signal. As stress inductors we 
used antibiotics that target the biogenesis of the mycobacterial cell envelope. We have identified a 
multi-domain regulator that is essential for the induction of cell envelope stress and named this IniR. 
Importantly, we were also able to show that cell envelope stress signaling was induced by free 
trehalose. Trehalose is a central unit in many mycobacterial lipids and mycobacteria have a dedicated 
trehalose salvage pathway that is used when lipids are degraded and recycled. We hypothesize that 
lipid degradation and concomitant release of free trehalose in the cell envelope is a signal for cell 
envelope stress in mycobacteria.  
 
 
 
Introduction 
  Mycobacterium tuberculosis, the causative agent of tuberculosis disease (TB), is currently the 
most deadly infectious agent, causing over 1.8 million deaths annually (1). Although TB can be cured 
with a six-month treatment regimen of different antibiotics and chemotherapeutics, this disease is still 
a huge public health burden in large parts of the world [1]. One of the major issues in combating TB is 
the emergence of multi-drug (MDR) and extensively-drug resistant (XDR) strains. To combat TB 
caused by these new strains novel anti-tubercular agents are urgently needed. A prominent drug target 
is the mycobacterial cell wall, a non-canonical and lipid-rich structure [2]. One of the unique elements 
of the mycobacterial cell wall is the so-called arabinogalactan layer that is covalently linked to the 
peptidoglycan. This layer is composed of a chain of galactofuranose residues and side chains of 
(branched) arabinofuranose units. The terminal arabinofuranose residues of these side chains can be 
substituted with long (C60-C90) carbon chain fatty acids, commonly known as mycolic acids. These 
mycolic acids form the inner layer of another unique element, the mycobacterial outer membrane. 
Mycolic acids can also be linked to trehalose, resulting in trehalose mono- (TMM) and trehalose 
dimycolates (TDM). These glycolipids are hypothesized to form the outer layer of the outer 
membrane. The mycobacterial outer membrane also contains a variety of other (glyco)lipids, many of 
which contain a trehalose unit [3].  
  The success of targeting mycobacterial cell envelope biogenesis with antitubercular drugs is 
best illustrated by first-line antibiotics ethambutol (EMB) and isoniazid (INH) and recently discovered 
antibiotics like benzothiazinone (BTZ). Both EMB and BTZ disrupt the formation of the 
arabinogalactan layer; EMB targets arabinosyltransferases EmbA, EmbB and possibly EmbC, which 
effectively abolishes the biosynthesis of arabinogalactan and lipoarabinomannan [4,5]. BTZ, in turn, 
inhibits arabinan biosynthesis by binding to the decaprenylphosphoryl-β-D-ribofuranose-2'-epimerase 
enzyme DprE1 [6,7]. INH enters the mycobacterial cell as a pro-drug and, after intracellular 
activation, binds and inhibits InhA, an essential NADH-dependent enyol-ACP reductase that is 
required for mycolic acid biosynthesis. Inhibition by INH causes severe cell wall deformations, 
ultimately leading to bacterial cell death [8,9]. 
  Mycobacterial cell wall composition and biosynthesis have been studied extensively. 
However, the induction and function of mycobacterial cell envelope stress responses are largely 
unexplored. Mapping bacterial stress pathways is important, because key components that are essential 
for dealing with stress caused by antibiotic treatment can be identified. This knowledge can 
subsequently shed light on possible resistance routes that subvert the current treatment regimen. 
Moreover, pinpointing these stress-associated networks may lead to new targets for anti-TB therapy or 
lead to the discovery of antimycobacterial agents that can synergize with currently used antibiotics. 
Also, identification of important antibiotic-associated regulatory networks can lead to the discovery of 
sensitizing agents, as shown previously by work from Peterson et al [10]. A recent example of a 
sensitizing agent is the recently identified ethR2-inactivating agent, which leads to reversion of 
ethionamide resistance [11]. Studying stress responses can also provide fundamental insights into the 
bacterial heterogeneity observed in patients receiving treatment.  
  To fill the gap in our knowledge on mycobacterial cell envelope stress responses, we study 
iniBAC operon induction. This operon is the most abundantly induced gene cluster upon incubation 
with sub-lethal concentrations of EMB and INH [12]. For our studies we used the causative agent of 
fish tuberculosis, Mycobacterium marinum, and confirmed our findings for M. tuberculosis. A 
previous transposon mutagenesis study performed by our group revealed that the iniBAC operon was 
strongly induced by mutations in vitamin B12 biosynthesis genes or in genes encoding the vitamin 
B12-dependent enzyme methylmalonyl-CoA mutase (MutAB) [13]. Because MutAB is a crucial 
component of the proprionate-degradation pathway, we hypothesized that iniBAC upregulation may be 
linked to coping with otherwise toxic levels of metabolic intermediates or that it may influence the 
production of (trehalose-containing) branched chain fatty acids [14]. However, the genes directly 
involved in regulation of the iniBAC operon remained unknown.  
Previous work by Colangeli et al. indicated that general regulator Lsr2 is involved in iniBAC 
expression [15], but this cannot explain the specific upregulation of only this operon during antibiotic 
stress conditions. Similar theoretical issues arise for other factors that have been suggested to play a 
role in the regulation of the iniBAC operon, such as MtrA and a factor called InbR [16,17]. In this 
study, we used a mutant screen to identify the activator that is essential and specific for iniBAC 
regulation.  
Results 
Identification of mutants unable to induce the iniBAC operon  
  Previously, we have shown that mutants affected in vitamin B12-biosynthesis already 
displayed high induction of the iniBAC operon in the absence of any antibiotic [13]. As an indicator 
for iniBAC induction we used a construct containing the iniBAC promoter cloned in front of a 
promoterless gene encoding the fluorescent protein mEos3.1. To identify the iniBAC regulator, we 
used one of these vitamin B12 biosynthesis mutants, cobC::tn, carrying an integrative variant of the 
iniBAC reporter plasmid and performed a second round of transposon mutagenesis. This time, mutants 
were selected for the absence of fluorescence on plates as assessed by fluorescence microscopy. We 
termed these non-fluorescent mutants ‘on/off mutants’. In total, 27 transposon mutants that repressed 
iniBAC induction were characterized, of which 2 could be retraced to mutations in the mEos3.1 gene 
of the reporter construct. The remaining 25 on/off mutants were all mapped to specific transposon 
insertion locations within the M. marinum genome (Table 1). With 5 independent Tn insertions, the 
mce1 operon was most prominently present in our mutant list. Although this operon is not directly 
involved in gene regulation, we decided to characterize these mutants in more detail because they 
could reveal clues on the signal transduction pathway.  
 
Selected mce1 operon mutants show altered levels of free and bound mycolic acids  
  It has been reported that disruption of the mce1 operon in M. tuberculosis results in the 
intracellular accumulation free mycolic acids (FMAs) [18], indicating that Mce1 is involved in the 
reuptake of FMAs from the cell envelope [18,19]. To identify whether M. marinum mce1 transposon 
mutants also show an aberrant lipid profile, thin layer chromatography (TLC) was performed to 
measure FMA levels. In line with these previous findings, disruption of both mce1D and yrb1EB of 
the mce1 operon resulted in a substantial increase in FMAs, as compared with WT M. marinum and 
the parent cobC::tn strain (Fig 1A) [18]. As a control, a double mutant affected in the 
cyclopropanation of mycolic acids, cmaA2::tn was included. This mutant seemed to be unaffected in 
the level of FMAs. In addition to FMAs also the amount of bound mycolic acids was analyzed. 
Interestingly, both mce1 mutants displayed a large decrease in the amount of bound mycolic acids, as 
compared with the parent strain (Fig 1B). We hypothesized that a decrease in bound mycolic acids 
might influence membrane integrity and thus cell envelope stress. To test this hypothesis, we 
performed a MIC assay with a selection of first and second-line antibiotics. In the experiment, a WT 
M. marinum MUSA, the cobC::tn parent strain and the double mutants affected in yrbE1B and mce1D 
were included. However, no major differences in the MICs between the mce1D, yrbE1B transposon 
mutants and the respective controls were observed (S1 Table), thereby disproving our initial 
hypothesis. In conclusion, mce1 mutants seem to be affected in the mycolic acid salvage pathway and 
this reduces the induction of the iniBAC operon, but this mutation does not affect cell envelope 
permeability significantly.  
iniBAC induction by EMB and INH is abrogated in iniR mutants 
  The second most abundant set of mutations in our transposon screen were three unique 
insertions in one gene, MMAR_0612. The gene product of MMAR_0612 has a predicted DNA-binding 
domain, suggestive of a role as transcriptional regulator (Phyre 2) and is located upstream of the 
iniBAC operon (Fig 2). Together, these characteristics make this gene a major candidate to code for 
the iniBAC regulator. To examine this, we tested whether the reporter construct present within the 
MMAR_0612 on/off mutants could still be induced by EMB (1µg/ml) or INH (10µg/ml) in culture. As 
a control, we included a selection of other on/off mutants. The on/off mutants were cultured with or 
without EMB or INH at concentrations previously established to cause a strong induction of our 
reporter plasmid [13]. The response was quantified by measuring fluorescence induction using a flow 
cytometer (a representative selection is shown in Fig 3). Out of the 25 mutants identified only three 
mutants were unresponsive and showed no induction of iniBAC upon antibiotic challenge. These 
mutants were all affected in MMAR_0612, indicating that this is indeed the iniBAC regulator. 
Consequently, we propose to name the MMAR_0612 gene product IniR for iniBAC Regulator. Next, a 
MIC assay was performed with first- and second-line antibiotics ciprofloxacin, ethambutol, isoniaizid 
and rifampicin on one of the iniR::tn mutants to address whether disruption of this gene altered 
antibiotic susceptibility. Comparing the MIC values of iniR::tn to the cobC::tn parent strain and an 
sdhA1::tn ‘on/off mutant’ revealed that there are no major differences in antibiotic sensitivity (S1 
Table). This finding is in line with previous evidence that constitutive upregulation of the iniBAC 
operon did not change antibiotic susceptibility [13].  
Complementation of iniR restores iniBAC induction  
  To confirm our previous results, as well as to exclude possible side-effects of the cobC::tn 
mutant background, we generated a targeted knockout of iniR in M. marinum. A complementation 
vector that contained the putative native iniR promoter and iniR (MMAR_0612) was also constructed 
and introduced into the ∆iniR strain. Subsequently, the iniBAC reporter plasmid was introduced into 
the ∆iniR and the complemented ∆iniR strain and cultures of the resulting strain were treated with 
either 1x MIC EMB or 1x MIC INH and compared with a control culture without antibiotic. On day 3, 
cultures were washed and bacterial cells were analyzed for fluorescence induction by flow cytometry. 
As shown in Fig 4, the ∆iniR mutant showed no induction upon treatment with EMB or INH, 
confirming previous findings with the iniR::tn mutants in the cobC::tn background. Upon 
complementation iniBAC induction levels were restored back to near wild-type levels. In addition, we 
also observed a mild (2-fold) repression of iniBAC in the knockout mutant grown without antibiotics, 
indicating that IniR is also required for basal production levels of the iniBAC operon. 
 
iniR is an unconventional regulatory element that is conserved among mycobacterial species 
  Bioinformatic analyses of the locus of iniR and iniBAC reveals that the synteny is conserved in 
several mycobacterial species, including M. tuberculosis, M. bovis and M. smegmatis (Fig 2). In all 
these species, the gene encoding the IniR regulator is separated from the iniBAC operon by a small 
gene designated iniB*, which shows a low percentage homology to iniB. This small gene is not 
regulated by ethambutol or isoniazid. The major differences in the iniBAC locus is caused by the 
presence and the size of the iniB gene; M. smegmatis lacks an iniB gene, whereas the iniB gene of M. 
marinum is, with 3000 bp, more than double the size of M. tuberculosis iniB. Moreover, M. smegmatis 
contains a dnaK-like gene directly downstream of iniR.  
  Bioinformatic analysis (BLAST and Phyre2) of the 818 amino acids long IniR of M. marinum 
revealed three distinct domains (Fig 5). The first domain is an AAA+ ATPase domain, located at the 
N-terminal side of the protein. This domain is predicted to be structurally highly similar to SSO_1545 
from Sulfolobus solfataricus, an archaeal ATPase [20]. A second domain (from AA 470 to AA 731), 
shows structural similarity (Phyre2) to domain III of MalT, a transcription factor found in E. coli. This 
domain is responsible for binding maltotriose, which subsequently triggers multimerization of the 
transcription factor MalT [21]. E. coli MalT is coupled to the maltose uptake system and, upon 
binding maltose, positively regulates transcription of the genes encoding the maltose transport (mal) 
[22]. Lastly, the C-terminal portion of IniR contains a putative DNA-binding domain, showing the 
highest similarity to E. coli SdiA, a LuxR-like regulator in E. coli. In conclusion, the bioinformatics 
analysis indicates that IniR is a multidomain regulator that is responsive to external effectors. 
 
IniR can induce transcription in a modified reporter assay 
  Based on our results and the bioinformatic analysis, we hypothesized that IniR is a direct 
activator of iniBAC. To test this, we created an anhydrotetracyclin-inducible (ATc) expression vector 
that encodes a FLAG-tagged M. marinum IniR (IniRMm) and introduced the construct in an M. 
smegmatis strain that also contained the iniBAC reporter plasmid. The resulting strain was grown in 
presence or absence of 10ng/ml ATc and fluorescence induction was assessed. At 2 days after 
induction a strong, ATc-dependent, mEos3.1-signal was observed as measured by flow cytometry, and 
this induction was specific for the presence of the vector containing iniRMm (Fig 6A). The induction of 
fluorescence by ATc compared very well to those of the known inductor EMB. Moreover, addition of 
EMB combined with ATc boosted induction to approximately 1.5 times the observed induction with 
ATc alone (Fig 6B). In order to investigate whether Rv0339c (iniRMtb) of M. tuberculosis is indeed the 
functional orthologue, the same experiment was repeated with a construct coding for a FLAG-tagged 
Rv0339c, designated IniRMtb. After addition of ATc, similar induction patterns were observed (Fig 
6C+ Fig 6D), indicating that IniRMtb is indeed the functional orthologue. These experiments show that 
expression of the IniR regulator is sufficient to induce the iniBAC operon, indicating that IniR is an 
activator protein.  
IniR only induces the iniBAC operon  
  To determine the IniR regulon we used a previously generated M. tuberculosis H37Rv iniR 
mutant. Using this strain, we performed mRNA sequencing using different growth conditions, 
comparing the RNA profiles of untreated, EMB- or INH-treated cultures of WT H37Rv to those of the 
iniR knockout strain. Consistent with prior observations, the iniBAC operon was highly induced in WT 
H37Rv M. tuberculosis after treatment with either ethambutol or isoniazid. Knocking out iniRMtb 
completely abrogated the induction with both antibiotics (Fig 7A+ Fig 7B), similar to our results for 
iniRMm. When comparing the expression in WT versus the iniR knockout mutant, iniBAC levels were 
reduced ~6 fold on average in untreated conditions, a similar repression as seen for iniRMm disruption 
(S2 Table). Treatment with EMB or INH does not increase transcription of the iniR activator itself, 
indicating that this element is not regulating its own expression. An important observation is that only 
the expression of the iniBAC operon was significantly altered when iniR was deleted, which implies 
that IniR is a highly specific and dedicated activator, only regulating this single operon.  
iniBAC can be directly activated by the addition of trehalose 
  Because IniR has structural homology to the MalT domain III that is responsible for 
maltotriose binding, we hypothesized that the presence or uptake of (di)saccharides may be triggering 
IniR multimerization and subsequent activation of iniBAC. To test this hypothesis, WT M. marinum 
containing an integrated iniBAC reporter plasmid was grown in the presence of maltose, sucrose or 
trehalose. The introduction of the iniBAC reporter on the chromosome was chosen to simulate a more 
natural expression level of iniBAC, even though an integrated variant reduces the dynamic range of the 
induction levels than can be observed. After exposure to maltose, sucrose and trehalose, fluorescence 
induction was measured by flow cytometry after one, two and three days of incubation. Both 1% 
maltose and 1% sucrose did not induce iniBAC. However, addition of 1% trehalose caused a small but 
reproducible 2.5 fold induction (Fig 8A), indicating that trehalose can slightly induce iniBAC 
expression. Trehalose plays an important role in mycobacterial cell envelope biogenesis. A well-
known example is the release of trehalose when TDMs are produced from two TMM molecules. To 
determine whether the levels of free mycolic acids were influencing iniBAC induction by trehalose, we 
assessed an cobC::tn + mce1D::tn mutant for induction. However, the mce1D::tn double mutant 
showed similar induction levels as the control transposon mutants (S1 Figure), indicating that the 
sensing and signaling of iniBAC induction is separate from the reimport of the trehalose-containing 
lipid TMM. 
iniBAC induction by trehalose is dependent on cell wall permeability  
  We hypothesized that outer membrane permeability could be a major factor in the limited 
induction levels observed upon addition of 1% trehalose. Therefore, a plasmid containing the gene 
coding for the M. smegmatis porin MspA, was introduced [23]. Introduction of MspA has previously 
been shown to increase the outer membrane permeability in slow-growing mycobacteria [23]. The 
resulting indicator strain with increased outer membrane permeability showed a significant increase in 
the ability to induce iniBAC in response to 1% trehalose (Fig 8B); a 12-fold induction was observed 
after three days. Importantly, the other disaccharides tested, sucrose and maltose, showed no response. 
These observations indicate that trehalose can serve as a trigger for iniBAC induction when it is taken 
up by the cell. To substantiate these results, we screened for transposon mutants that induced iniBAC 
induction at low trehalose levels. For this, we created another transposon mutant library in a WT M. 
marinum containing the integrated iniBAC reporter. Resulting mutants were plated on 2% trehalose, 
which only mildly induces a GFP signal in WT bacteria. Mutants that highly expressed iniBAC were 
identified by fluorescence microscopy, isolated and plated on 7H10 plates containing 2% trehalose and 
regular 7H10 plates to select for a trehalose-specific induction phenotype. In total, 25 mutants were 
found to be upregulated only on plates containing 2% trehalose. Strikingly, upon analysis of the 
transposon insertion sites by LM-PCR and sequencing, all mutations were mapped to the PDIM 
biosynthesis locus (Table 2). Our group has previously shown that PDIM mutations in M. marinum 
result in increased permeability of the mycobacterial outer membrane [23]. These results support our 
observation that the presence of trehalose in the periplasm triggers IniR activation and iniBAC 
induction.  
 
Crosslinking reveals that IniR forms multimers 
  Based on bioinformatics we found that IniR contains two domains (the ATPase domain and 
the MalT domain III) that suggested possible multimerization. To address this, a culture of M. 
smegmatis containing the plasmid encoding a FLAG-tagged IniRTb was grown in the presence of ATc. 
We hypothesized that trehalose could be required to allow multimerization, as maltose is required for 
MalT tetramerization in E. coli [21]. We therefore compared samples where either trehalose and ATP, 
trehalose alone or neither were added before crosslinking. Subsequently, formaldehyde was added to 
crosslink possible oligomers and samples were compared with untreated controls. As shown in Fig 9, 
clear higher order structures can be identified for ATc induced cultures. The extra bands are 
approximately at the expected heights of dimers (180kDa) and tetramers (360kDa) and these bands 
were specific for the presence of 1% formaldehyde. Oligomerization did not seem to be dependent on 
the exogenous addition of trehalose in this experimental setup. In summary, we see that IniR readily 
forms oligomeric structures similar to MalT in E. coli [19,21].  
Discussion 
  In this work, we describe the identification of the iniBAC regulator IniR, by performing 
transposon mutagenesis in a strain that highly expressed iniBAC by default. In our first publication on 
the regulation of the iniBAC operon we identified a strong link between upregulation of the iniBAC 
operon and the methylmalonyl-CoA pathway, a pathway that is involved in the degradation of fatty 
acids [13,14]. At the time, we attempted to identify a metabolic cue causing iniBAC activation. 
However, exogenously adding different kinds of fatty acids or small metabolites present in the 
pathway did not influence iniBAC expression. In this work, trehalose was identified as a strong 
metabolic signal that activates the iniBAC operon. Moreover, increasing the permeability by 
introducing mspA (Fig 8) or blocking PDIM production (Table 2) strongly increased the induction 
potency of trehalose. This finding also confirms our previous work that showed that PDIM mutations 
can allow for the essential uptake of nutrients when the ESX-5 system is deleted [23].  
   In mycobacteria, trehalose is used to synthesize a range of important outer membrane 
lipids, including trehalose monomycolates, trehalose dimycolates, penta-acyl trehaloses (PATs), diacyl 
trehaloses (DATs) and sulfolipids (only in members of the M. tuberculosis complex)[24,25]. Because 
of its importance, trehalose biosynthesis and metabolism has been extensively studied [26]. These 
studies showed that trehalose is recycled from TMMs, TDMs, PATs and DATs and import occurs via 
the LpqY-SugA-SugB-SugC system, identified and described Kalscheuer et al [27]. This system, upon 
knockout, causes attenuation of M. tuberculosis in vivo. Mycobacteria possess three separate 
biosynthesis routes for trehalose, a redundancy that also illustrates the importance of this disaccharide. 
The best studied route is the OtsA-OtsB pathway that synthesizes trehalose via glucose-6-phosphate 
and UDP-glucose intermediates [27]. Another pathway is the TreY-TreZ pathway that can synthesize 
trehalose from α(14)glucose polymers [28]. However, the glyoxylate shunt can also produce 
trehalose de novo from sucrose or maltose via the TreS pathway [26,29]. Interestingly, our transposon 
screen revealed that three mutants that are affiliated with an outflow to the TreS biosynthesis pathway 
no longer show iniBAC upregulation. These mutants are aceE::tn (two unique mutants) and shdA1::tn. 
As these enzymes play a role in the flux of the glyoxylate shunt, they might affect free trehalose 
production indirectly. This can possibly explain the observed relief of iniBAC induction in these 
transposon mutants.  
  The most intriguing evidence from our mutant analysis links iniBAC induction to trehalose is 
the fact that we identified multiple mce1 operon transposon mutants. These mutants show repression 
of iniBAC in the highly expressing cobC::tn strain. The mce1 operon, suggested to be involved in the 
reuptake of mycolic acids, was reported to show a high accumulation of FMAs in M. tuberculosis 
[18]. We not only confirmed this finding for M. marinum, but also identified a strong decrease in 
bound mycolic acids, suggesting that mce1 disruption has a pleiotropic effect in M. marinum. This 
multitude of effects of mce1 disruption on the mycobacterial lipidome has also been illustrated in M. 
tuberculosis by previous work by Queiroz et al. who found that disruption of mce1 significantly 
changes the abundance of over 400 lipid species [30]. One explanation for the decreased amounts of 
bound mycolic acids could be that the enzymatically reaction leading to increased amounts of FMAs is 
influenced by the amount of free mycolic acids. Similarly, the absence of FMA transport by mce1 
could also prevent the recycling of trehalose-containing lipids and the concomitant transport of free 
trehalose. In line with this theory, the mce1D::tn mutant is still inducible with trehalose.  
  More evidence for links between TMM recycling and iniBAC induction comes from a recent 
paper by Degiacomi et al., who examined the effect of a knockdown of the essential inner-membrane 
TMM-flipase MmpL3, [31]. This procedure resulted in the upregulated expression of the iniBAC 
operon. Whether the induction is caused because of a lack of TMMs or an overflow of trehalose by 
breakdown of TMMs that are not flipped over the inner-membrane is unknown. These combined 
observations could also explain why iniBAC induction is observed when EMB and INH are used, in 
both cases there is a strong disruption of outer membrane biogenesis and possibly a concomitant 
activation of the trehalose salvage pathway. Interestingly, analysis of the carbohydrate content of 
isoniazid-treated mycobacteria by Winder and Brennan established that there is a strong accumulation 
of free trehalose as a result of antibiotic treatment [32].  
  The IniR protein contains three domains that together make it a member of the small family of 
signal-transduction ATPases with numerous domains, with a domain composition similar to MalT of 
E. coli (61%). In E. coli MalT is bound to the maltose uptake system and released upon the binding of 
maltose. Binding maltotriose causes MalT to multimerize and leads to binding and transcription of the 
genes encoding the maltose transport system. For IniR the signaling molecule is probably trehalose. 
These findings reveal trehalose as a unique cell wall stress signaling molecule that has not previously 
been described as such in gram negative bacteria. Gram negatives are known to activate their cell wall 
stress signaling cascades through the detection of mistranslated proteins or aberrant folding of 
membrane proteins, but not through disaccharide metabolites [33].  
  Future experiments should address the question whether iniR can sense or bind trehalose. Our 
data on the oligomerization of IniR at least suggests that it occurs in dimers and/or tetramers and that 
trehalose is not required for oligomerization. Understanding the interaction of iniR with trehalose or 
other binding partners will shed light on the function of the iniBAC operon and will allow us to 
address why IniR is so specific, regulating only the iniBAC genes. The discovery of IniR also sparks 
further speculation on IniBAC function. Both IniA and IniC contain the same ATPase domain (P-
Loop NTPase domain) that is found also in the membrane-associated MalK, the ATP hydrolyzing unit 
of the maltose transporter that opens upon binding of maltotriose [34].  
  Studies on the localization of the IniBAC proteins and their association with IniR will allow us 
to address possible homology between the E. coli maltose uptake system and IniBAC. Our RNA 
sequencing data indicates that the stoichiometry of the system might favor a high amount of IniB 
molecules, as compared with the IniA and IniC counterparts of the operon. This high production of 
IniBAC proteins is also suggestive of a functional link between IniB, IniA and IniC, where all three 
are needed to mount an effective stress response. Another extrapolation of IniA and IniC protein 
function comes from the high similarity of the GTPase domain to dynamin family proteins. This may 
suggests that both proteins can function as vesiculating proteins, shielding the cell from possible toxic 
cell wall or lipid intermediates. Bacterial dynamins have already been shown to form tubulations in 
lipid bilayers in a GTP-dependent manner in Nostoc punctiforme [35]. The role of IniB in this is 
unclear, especially because the presence and size of this protein is varying extensively between 
species. Sequence analysis indicates that the N-terminal part of IniB is highly conserved and possibly 
contains a domain that is required for interaction or secretion. Studying these iniBAC genes, but also 
other genes that are strongly induced by antibiotics may very well lead to the discovery of essential 
stress coping routes in mycobacteria that can be targeted by novel anti-TB therapeutics. 
Materials & methods 
Bacterial strains, plasmids and culturing conditions  
  The E. coli strain ST08 (Clontech) was used to propagate plasmid DNA. Bacterial cultures 
were routinely grown at 37°C in LB broth with the addition of antibiotics kanamycin (25µg/ml), 
hygromycin B (50µg/ml) or streptomycin (30µg/ml), where indicated. M. marinum wild type MUSA , 
as described by Abdallah et al. [36], was used for the transposon mutagenesis experiments and 
generation of the iniR (MMAR_0612) knockout. Cultures were routinely grown in Middlebrook 7H9, 
supplemented with Middlebrook ADC and 0,05% Tween-80. M. smegmatis MC2155 was used for the 
modified reporter assay and cultured identically to M. marinum.  
M .tuberculosis H37Rv WT and an isogenic ∆rv0339c mutant, generated using specialized 
transduction with a phage kindly provided by Michelle Larsen and Bill Jacobs, were used for RNA 
sequencing experiments and cultured in 7H9, supplemented with ADC, 0,05% Tween-80 and glycerol 
[37,38]. Additional antibiotics isoniazid (Sigma) and ethambutol (Sigma) were added, where 
indicated, at mid-logarithmic phase . For isoniazid 10µg/mL was routinely added, whereas for 
ethambutol 1µg/mL was used. For the modified reporter assay anhydrotetracycline (Sigma) was added 
to indicated final concentrations. For mycobacterial experiments on solid medium, Middlebrook 7H10 
solid agar supplemented with Middlebrook OADC was used. Trehalose, maltose and sucrose were 
purchased from sigma and added to the final concentrations indicated in the figures. Both 
mycobacterial cultures and plates were grown at 30°C. Plasmids pSMT3-iniB4-mEos3.1 and pMV-
iniB4-mEos3.1 were previously described by Boot et al. [13]. Plasmid pEXCF-Rv0339c-FLAG has 
been previously described in [39]. 
Construction of plasmids 
  All the primers used in this study can be found in S3 Table. For complementation 
experiments, MMAR_0612 was amplified from M. marinum MUSA gDNA. A fragment of 2786 bp was 
generated with primers Comp0612pr_FW and Comp0612pr_RV containing the promoter and 
MMAR_0612 gene. Primers were designed to include 15-bp overlapping regions with the target vector, 
a pMV361 derivative described previously [13,40]. PCR was performed with iProof master mix (Bio-
Rad). The pMV vector was digested with HindIII. Subsequently, InFusion (Clontech) was used 
according to manufacturer’s protocol to generate the complementation construct pMV-prMMAR0612. 
pEXCF-Rv0339c-FLAG was digested with BsrGI and used for the introduction of MMAR0612. 
Primers FLAG0612_FW and FLAG0612_RV were used to amplify MMAR_0612 from M. marinum 
MUSA gDNA with 15bp overlapping regions with the pEXCF vector backbone. The resulting construct, 
pEXCF-MMAR0612-FLAG was generated with InFusion reagents.  
Mycobacterial lipids extraction and TLC analysis 
  The selected transposon mutants cobC::tn, cobC::tn+mce1D, cobC::tn+yrbE1B::tn and 
cobC::tn+cmaA2::tn and a WT M. marinum MUSA were pre-cultured, diluted and grown to an OD600 
of 1.0. Subsequently, 50 OD units were collected by centrifugation and the resulting pellets were 
washed three times with PBS. The pellets were weighed and adjusted accordingly to provide equal 
pellet masses. Subsequently, extraction of the cell envelope lipids was performed in three steps to 
harvest different lipid fractions: the apolar, polar and mycolic acids as previously described by 
Carrère-Kremer et al. and Minnikin et al. [41,42]. Both FMAs and bound mycolic acids were analyzed 
by 1D-TLC. For each sample, equal amounts of lipid fractions were loaded onto a silica-60 TLC plate 
(Merck) and separated by 1D-TLC. For MAMEs and FAMEs analysis running solvent 
hexane:ethylacetate 19/1 (v/v) was used. FMA analysis running solvent hexane:di-ethyl ether:HAc 
70/30/1 (v/v/v) was used (as previously described by Ritu Bansal-Mutalik and Hiroshi Nikaido [43]. 
Subsequently, the lipids were visualized with 5% molybdophosphoric acid (MPA) in methanol and 
TLC-plate charring at 160°C for 10 minutes. 
Determination of the minimal inhibitory concentration (MIC) for antibiotics 
  For MIC assays M. marinum MUSA WT and the indicated transposon mutants were grown in 
7H9 supplemented with ADC to an OD600 of 0.6-1, containing the appropriate antibiotics. Serial two-
fold dilutions of ciprofloxacin, ethambutol, isoniazid, streptomycin and rifampicin (all from Sigma) 
were added per well in a 96-well plate. Per well 104 bacterial cells were added. The 96-wells plate was 
inoculated for 7 days before the minimal inhibitory concentration (MIC) was determined. This 
concentration is described as the concentration of antibiotics that showed visible growth inhibition. 
Wells without the addition of antibiotics and 7H9 medium itself were used as a growth control and 
experiments. All the growth assays were performed at least in triplicate. 
 
Transposon mutagenesis 
  Transposon mutagenesis was performed in M. marinum MUSA containing pMV-iniB4-mEos3.1 
The strain was infected with the mycobacterial phage phiMycoMarT7 that contains the Himar1 
transposon with kanamycin resistance, as described previously by Sassetti et al. [44,45]. Transposon 
mutants were assessed for increased mEos3.1 expression, indicating induction of iniBAC, by 
fluorescence microscopy. For the permeability mutagenesis screen, resulting mutants were plated on 
7H10 plates containing 2% trehalose. Colonies that showed a vast increase in fluorescence were 
isolated and the transposon insertion site was determined by ligation-mediated PCR (LM-PCR) as 
described previously [35]. A cobC::tn mutant was used for a second round of mutagenesis, this time 
with a Himar transposon containing a hygromycin resistance cassette [44,45]. Colonies that showed no 
or severely decreased mEos3.1 expression were selected and isolated and LM-PCR was used to 
identify the transposon insertion site, utilizing the cobC::tn parent strain as a control.  
Flow cytometry analysis 
  The induction of the iniBAC was routinely assessed by flow cytometry on a BD Accuri C6 
flow cytometer (BD biosciences). For induction experiments bacteria were grown to a mid-log phase 
and diluted to an OD of 0.2. Subsequently, antibiotics or disaccharides were added at indicated 
concentrations for a specified amount of time. Time point analysis was performed by sampling 1 mL 
of culture. The sample was washed in PBS containing 0.05% Tween-80. The bacteria were then spun 
down and the resulting bacterial pellet was in PBS containing 0.05% Tween-80. Flow cytometry 
analysis was performed with a 488 nm laser and 530/30 nm filter for mEos3.1. Per sample, 30.000 
gated events were analyzed per sample per time point and data was analyzed and visualized using BD 
CFlow software and Graphpad Prism 6. For samples the mean fluorescence intensity (MFI) was used 
to quantify fluorescence intensity.  
Generation of an ∆iniR mutant in M. marinum  
  The MMAR_0612 knockout was created via allelic exchange with the phAE159 temperature-
sensitive phage method in M. marinum MUSA . Details on the origin of the phage system can be found 
in the manuscript by Jain et al. and further details on the method can be found in Phan et al. [38,46] . 
The knockout construct was generated by PCR by amplification of left (0612L_FW + 0612L_RV) and 
right flanking (0612R_FW + 0612R_RV) regions of MMAR_0612, covering a total of 82% of the gene 
(see S1 Table). The deletion was confirmed by PCR analysis and sequencing. Subsequently, the 
hygromycin resistance cassette was removed by γδ-resolvase (TnpR) and counter-selected with SacB 
for sucrose sensitivity. 
 
IniR multimerization assay and immunoblot analysis. 
  An M. smegmatis strain containing the plasmid with iniRTb was grown in 7H9 liquid medium 
supplemented with ADC, 0.05% Tween 80 until mid-logarithmic phase, after which the cells were 
washed and inoculated in 7H9 medium with or without 10 ng/ml ATc to an OD600 of 0.2 and grown 
for another 20 h. Subsequently, bacterial cultures were spun down for 10 min at 6,000 × g, washed 
with phosphate-buffered saline (PBS), and resuspended in PBS to a concentration of 20 OD units/ml. 
Cells were lysed by bead-beating with 0.1mm silica beads 3 times for 20 seconds each. Then 25mM 
MgSO4 was added, along with DNaseI (Thermo Fischer), to degrade chromosomal DNA and 
incubated for 1 hour at 37 degrees Celsius. Samples were spun down for 15 minutes at 16.000 x g to 
isolate soluble proteins. Subsequently, samples were split in equal volumes and trehalose (1%) and/or 
ATP (to 1 mM) were added to the appropriate samples. The resulting mixture was crosslinked with 
1% formaldehyde for 30 minutes, on ice and quenched with 100 mM cold glycine for 30 minutes. 
Protein fractions were separated on any kD SDS-PAGE gels (BioRad) and transferred to a 
nitrocellulose membrane. Membranes were stained with anti-FLAG M2 (Abcam) antibodies. The 
secondary antibody was a goat anti-mouse antibody coupled to a peroxidase (Abcam). Nitrocellulose 
blots were developed with ECL Western Blotting substrate (Pierce) and chemiluminescence was 
visualized with a Amersham 600 imager (GE healthcare).  
 
RNA sequencing on H37Rv and H37Rv-∆Rv0339c 
  Transcriptional RNA profiles between H37Rv wild type and a ∆Rv0339c were compared in 
triplicate. Cultures were grown until OD 0.2 and at that point INH or EMB was added to the cultures 
and allowed to respond to drug stress for 24 hours. Cultures without antibiotic treatment served as a 
control. Subsequently RNA was isolated using standard methods described previously [47] and rRNA 
was depleted using RiboZero Gold (Illumina) RNA sequencing was done using Illumina Nextseq with 
libraries generated using the NEBNext directional library kit (NEB). Alignment to the H37Rv genome 
was done using Bowtie 2.0 [48], read depth was determined using DuffyNGS tools (available at 
https://github.com/sturkarslan/DuffyNGS), and visualized using Arraystar (DNASTAR).  
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 Figure 1. Lipid profiles of selected mutants. TLC analysis of lipid extracts from M. marinum WT 
strain, the cobC::tn strain used for the transposon mutagenesis and three double mutants that showed 
decreased iniBAC induction, i.e. mce1D::tn, yrbE1B::tn and cmaA2::tn. (A) TLC of polar lipids, 
triacylglycerols (TAG), free mycolic acids (FMAs) and diacylglycerols (DAG) are distinguished. A 
clear increase in FMAs can be seen for both mce1 operon mutants. (B) TLC analysis of the different 
types of bound mycolic acids (MAMEs and FAMEs) where for MAMEs alpha (α), keto (k) and 
methoxy (m) species are indicated.  
 
 
 
 
 
 
 
 
 Figure 2. An overview of the iniR-containing regions in mycobacteria. The species containing iniR 
(blue) are M. marinum (top), M. tuberculosis (middle) and M. smegmatis (lower). Conserved genes are 
indicated by identical colors. Insertions of genes in the genome of M. smegmatis are indicated with the 
arrows. Distances are proportional to actual size. Red triangles indicate the approximate positions of 
the 3 independent transposon insertions that affect iniBAC induction. 
 
 
 
 
 
 
 
 
 
 Figure 3. The iniR::tn mutants are unable to induce iniBAC upon addition of EMB or INH. A 
selection of 5 out of the 25 mutants that were analyzed for induction by flow cytometry. The first 3 
columns show the cobC::tn parent strain, which is clearly induced by EMB (dark grey bar) or INH 
(light grey bar) as compared to untreated control (black bar). All the other mutants are derived from 
the cobC::tn parent strain and the second mutated gene is indicated below the bars. The mutant 
affected in MMAR_0612 (iniR) is the only one in the panel shown here that shows no upregulation of 
iniBAC. Measurements were performed in triplicate and the error bars show the standard deviation.  
 
 
 
 
 Figure 4. An ∆iniR mutant is unable to induce iniBAC upon addition of EMB or INH. Flow 
cytometry was used to quantify and compare the fluorescence induction of a WT M. marinum strain 
with an iniR knockout mutant and the complemented strain, all three containing the iniBAC reporter 
plasmid. Where indicated, EMB (1µg/ml) or INH (10µg/ml) was added to the cultures and 
fluorescence induction (in mean fluorescence intensity, MFI) was measured at day 3. Data in the plot 
are measurements that originate from a biological quadruplicate. Error bars represent s.d. values. 
 
 
 
 
 
 
 Figure 5. Overview of the three domains that can be found in iniR. Noted domains are the most 
significant hits using phyre2 structure prediction. The number between brackets indicates the 
confidence with which the phyre2 prediction was made. A combination of NCBI blast and the Phyre2 
server was used to obtain domain predictions. Domain I (amino acid 24 to 247) is an AAA+ ATPase 
domain sharing 15% amino acid identity with sso_1545 in S. solfataricus. Domain II (470-731) is 16% 
identical to domain III of MalT in E. coli and the C-terminal domain (745-812) contains a DNA 
binding domain sharing 20% identity to E. coli SdiA 
 
 Figure 6. overexpression of iniR induces iniBAC transcription. Overexpression of either M. 
marinum (MM) or M. tuberculosis (MT) iniR in M. smegmatis results in antibiotic-independent 
induction of the iniBAC promoter on the reporter plasmid (pREP). M. smegmatis containing the 
iniBAC reporter plasmid and the ATc inducible iniR of either M. marinum (MMAR_0612) (A) or M. 
tuberculosis (Rv0339c). The presence of these plasmids is indicated with piniR (C) were cultured with 
(in red) and without ATc (black), in the presence (blue) of EMB and in the presence of both ATc and 
EMB (green). M. smegmatis containing only the reporter plasmid and cultured with ATc was used as a 
control (grey). (B) and (D) are quantifications of (A) and (C), including day 1 data. The presence or 
absence of plasmids or EMB/ATc is indicated with either ‘+’, for presence and ‘-‘, for absence. The 
experiment was performed in triplicate. 
 Figure 7. RNAseq data of M. tuberculosis indicates that only the iniBAC operon is regulated 
through IniR. (A) The plots contain gene expression profiles in log2 fold change reads per kilobase 
million (RPKM) of ∆Rv0339c + INH compared to the control strain, i.e. M. tuberculosis H37Rv WT + 
INH. (B) Plotted gene expression profile in log2 fold change RPKM of ∆Rv0339c + EMB compared 
to H37Rv WT + EMB. The iniBAC genes are indicated with yellow arrows 
 
Figure 8. Addition of trehalose is sufficient to induce iniBAC induction in M. marinum. The 
effect of additional trehalose is especially prominent when the outer membrane is more permeabilized 
by the expression of the MspA pore of M. smegmatis. (A) Induction levels of a WT M. marinum 
containing the iniBAC reporter upon treatment with either 1% trehalose (green), 1% maltose (red), 1% 
sucrose (blue) or no disachharide (black line). In the graph plots are shown for day 1, 2 and 3 after 
addition. The graphs are representative images of an experiment performed in triplo. (B) Same as in 
(A) but this time the strains also contained a plasmid with the mspA gene.  
 Figure 9. Immunoblot analysis of IniR-TB with α-FLAG antibody. Cultures were exposed for 20 
hours to 10 ng/ml ATc and soluble proteins were isolated. Fractions were exposed to either trehalose 
(+) and/or ATP (+), and subsequently crosslinked with formaldehyde (+) or not (-). Indicated on the 
Western Blot are monomeric IniR (~90kDa), possible dimers and tetramers 
 
 
 
 
 
 
 
 
 
Gene ID Gene product H37Rv 
orthologue 
Gene 
length 
Unique mutants  
(TA position from 5’ of gene) 
MMAR_0076 DnaB Rv0058 1383 1196 
MMAR_0411 YrbE1B Rv0168 870 17 
MMAR_0413 Mce1B Rv0170 1041 791, 800 
MMAR_0414 Mce1C Rv0171 1566 11 
MMAR_0415 Mce1D Rv0172 1608 283 
MMAR_0511 SdhA_1 Rv0248c 1929 1885 
MMAR_0612 IniR Rv0339c 2454 290,392,1780 
MMAR_0831 CmaA2 Rv0503c 912 124 
MMAR_1706 LppZ Rv3006 1122 397 
MMAR_1803 LppW Rv2905 960 628 
MMAR_2219 MMAR_2219 Rv1410c 1554 1157 
MMAR_2286 MoxR1 Rv1479 1116 22 
MMAR_2628 MMAR_2628 - 999 223 
MMAR_3294 GlnA2 Rv2222c 1341 1093,1312 
MMAR_3334 AceE Rv2241 2790 187, 2569 
MMAR_4169 PknH_1 Rv1266c 1854 46 
MMAR_4184 Cyp130A4 Rv1256c 1242 1006 
MMAR_4717 Cyp188A3 - 1365 331 
MMAR_4806 CrtI - 1530 1332 
MMAR_5423 MMAR_5423 - 1206 143 
 
Table 1 List of M. marinum double mutants. List of mutants identified in a Tn mutagenesis screen, 
that showed repression of the high iniBAC induction of the parent cobC::tn mutant. The H37Rv 
orthologue, if present, the gene length and the number of unique mutants per gene are indicated. 
Unique mutants are annotated by the position of the transposon insertion from the 5’ of the gene. 
 
Gene ID Gene product H37Rv orthologue Gene length Unique mutants 
 (bp from 5’ of gene) 
MMAR_1765 FadD28 Rv2941 1743 223, 1009 
MMAR_1767 Mas Rv2940c 6300 154, 5071, 5266, 5654 
MMAR_1768 PapA5 Rv2939 1245 1111 
MMAR_1772 PpsE Rv2935 4446 
181, 1228, 1568, 1912, 
4279, 4288  
MMAR_1773 PpsD Rv2934 5421 225, 4288 
MMAR_1774 PpsC Rv2933 6606 33, 484, 808, 3283 
MMAR_1775 PpsB Rv2932 4574 848, 3261 
MMAR_1777 FadD26 Rv2930 1755 34, 254, 601 
MMAR_1777/
MMAR_1778 FadD26/TesA Rv2928/Rv2930 1755/750 443 bp before 5' of fadD26 
 
Table 2 List of M. marinum mutants identified that showed high induction of iniBAC on 2% 
trehalose plates. The H37Rv orthologue, if present, the gene length and the number of unique mutants 
per gene are indicated. Unique mutants are annotated by the position of the transposon insertion from 
the 5’ of the gene unless otherwise indicated 
 
 
 
 Figure S1. Induction by trehalose in mce1 mutants. Addition of trehalose induces iniBAC 
transcription in mce1 mutant background Induction with trehalose of the cobC::tn (black) parent strain 
was compared to cobC::tn+mce1D::tn (dark grey) and cobC::tn+cmaA2::tn (light grey) by exposing 
cultures to 1% trehalose and measuring mean fluorescence intensity over time. For day 1, 2 and 3 the 
MFI of 1% trehalose treated cultures was divided by the untreated controls, leading to fold induction 
values. Measurements were obtained from a biological triplicate and the error bars indicate s.d. values. 
 
 
 
 
 
 
 
 
 
 
 
Strain Rifampicin 
(µg/ml) 
Ethambutol 
(µg/ml) 
Isoniazid 
(µg/ml) 
Ciprofloxacin 
(µg/ml) 
WT 0.4 0.6 16.7 (7.2)  0.2 
cobC::tn 0.4 0.6 12.5  0.2 
cobC::tn+ 
mce1D::tn 
0.33 (0.11) 1.25 50  0.2 
cobC::tn+ 
yrbE1B::tn 
0.17 (0.06) 0.6 25  0.2 
cobC::tn+ 
sdhA1::tn 
0.8 0.65 25  0.4 
cobC::tn+ 
MMAR_0612 
0.8 0.65 25  0.4 
 
Table S1. MIC determination on MMAR_0612 mutant shows no change in antibiotic 
susceptibility. Measurements were performed in triplicate. The concentration at which no visible 
growth was seen is denoted as the MIC value in µg/ml. The standard deviation is shown between 
brackets behind the values in the table.  
 
 
 
 
 
 
 
 
 
 
 
Condition/  
Gene name  Untreated INH EMB 
iniR 4,6 3,2 3,6 
iniB 15,7 357,1 46,2 
iniA 1,9 32,7 5,6 
iniC 1,3 7,9 1,9 
 
Table S2. Fold changes in expression of iniBAC in M. tuberculosis. The fold changes in expression 
between H37Rv and the ∆iniR mutant were calculated for iniR, iniB, iniA and iniC for untreated, 
ethambutol treated and isoniazid treated samples. To do so the expression of the H37Rv wild-type 
samples were divided by the values of the ∆iniR mutant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer name Sequence 5’  3’ 
COMP0612pr_FW AGGTTAATTAAAGCTTCATCGGCGATAGCCTGCG 
COMP0612pr_RV CGACATCGATAAGCTTTCAGCCCGGTGCCG 
FLAG0612_FW ATGACAAGTTTGTACAAAAAAGCAGGCTCTGTGTCCGAGGGCCACGCTTC 
FLAG0612_RV TCTACGACTTTGTACAAGAAAGCTGAGTCGCCCGGTGCCGTCAACATCGC 
MMAR_0612_L-F GACTCACTCCAAAAACGACCGGCGCTCTGCCATAA 
MMAR_0612_L-R TACAGGACCTGCCAATACCCCATCTCGCTCTCCCCG 
MMAR_0612_R-F GACTCTAGCCAAAGACTGGCCGACCAGGTGGATGT 
MMAR_0612_R-R TGTCAAACCTGCCAACCGCTGTTGTGCGAGCCATA 
 
S3 Table Primers used in this study 
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Abstract 
Mycobacteria have a highly unusual cell envelope. Although the general outlay is similar to Gram-
negative bacteria, the composition and the biogenesis of this diderm layer is completely different. 
Understanding cell envelope functioning is one of the major goals in mycobacterial research, as it 
could reveal chinks in the protective armor of this group of pathogens. A set of genes that is highly 
induced upon treatment with cell-wall targeting antibiotics is the iniBAC operon. Although the 
induction and regulation of this operon has been extensively studied, the exact function of the encoded 
proteins in cell envelope functioning has largely remained unclear. In this study, we set out to 
elucidate the function of the IniBAC proteins in M. marinum, a close genetic relative of M. 
tuberculosis. We identified that the dynamin-like proteins IniA and IniC are (partially) located in the 
cell envelope or the cytoplasm, respectively. The mycobacterium-specific protein IniB is produced and 
partially secreted in response to antibiotic treatment. This localization could indicate a role in cell 
envelope functioning. Because IniB does not contain a signal sequence, we checked the involvement 
of alternative secretion systems for transport. We found that IniB secretion is independent of the 
alternative secretion systems ESX-1, ESX-5 or SecA2. In contrast, we could show that secretion of 
IniB is dependent on the presence of functional copies of IniA and IniC. Further analysis showed that 
this effect was on the regulatory level. By analyzing different mutants, we found that deletion of the 
iniBAC genes does not have an effect on growth in vitro or in vivo in a zebrafish embryo infection 
model. Finally, IniBAC does not seem to contribute to antibiotic resistance. Therefore, although we 
have uncovered the localization of these proteins, their exact functions remain to be elucidated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
    The non-canonical architecture of the mycobacterial cell envelope has been a subject 
of study since the discovery of the tubercle bacillus by Koch in 1882. Although the outline of the 
layers is similar to Gram-negative species, the biosynthesis routes of the cell wall and the 
macromolecules that form this barrier are mostly unique (Brennan & Nikaido 1995). Perhaps the most 
notable feature is the mycolic acid-containing outer membrane (MOM). The outer membrane mainly 
consists of these long-chain (C60-C90) fatty acids that are partially covalently attached to the terminal 
arabinofuranose residues of a structure that is known as the arabinogalactan layer (McNeil et al. 1990). 
This arabinogalactan layer consists of linked galactofuranose and arabinofuranose chains and is, in 
turn, covalently linked to the peptidoglycan layer (Jankute et al. 2015). Due to the hydrophobic nature 
of the mycolic acids in the MOM, mycobacteria are highly impermeable to hydrophilic (drug) 
molecules, which results in an intrinsic antibiotic resistance. Moreover, this impermeability also offers 
protection against many damaging host factors encountered during infection. In addition to the 
mycolic acids, many other unique (glyco)-lipids can be found in the MOM, including trehalose mono- 
and di-mycolates (TMMs and TDMs), phthiocerol dimycocerosate (PDIM) and sulfolipids (SL-1) 
(Jankute et al. 2015). Most of these lipids are considered important structural elements but are also 
involved in cellular homeostasis. In addition, because they are directly in contact with the host, most 
are crucial determinants of mycobacterial virulence (Jackson et al. 2007). Since studying the 
mycobacterial cell wall may reveal its weak spots, it is important to understand the biogenesis of this 
unique layer. Several currently used antibiotics already target the MOM. Moreover, a handful of newly 
discovered leads are also directed against essential enzymes that contribute to the biosynthesis of the 
outer membrane (Stanley et al. 2013; Kieser et al. 2015).  
  Two well-known antibiotics that target the mycobacterial cell wall are ethambutol (EMB) and 
isoniazid (INH). EMB targets the two indolylacetylinositol arabinosyltransferases EmbA and EmbB. 
Both enzymes are involved in the polymerization of the arabinan chain (Belanger et al. 1996). This 
action prevents the synthesis of the arabinogalactan layer that links the peptidoglycan to the outer 
membrane. As a result, major cell wall deformations occur and bacterial growth is inhibited. Isoniazid 
is a pro-drug that is activated by the catalase peroxidase KatG (Timmins & Deretic 2006). As a 
consequence, INH forms adducts with NAD+. These adducts can subsequently bind InhA, an enoyl-
ACP reductase. By inhibiting InhA, mycolic acid biosynthesis is inhibited which causes lethal cell 
wall deformations (Winder & Collins 1970). 
  Although the fundamental knowledge on the biosynthesis of the cell wall has increased 
drastically in the past decade, the dynamics of the cell wall during infection have proven difficult to 
study. Moreover, how bacteria respond to cell wall damage as a result of antibiotics and how this 
affects the efficacy of treatment has largely remained unaddressed. The gene cluster that is most 
induced upon treatment with anti-cell wall antibiotics EMB and INH is the iniBAC operon (Boot et al. 
2016). Previous work by our group has identified a novel type regulator, designated IniR, that was 
found to activate the transcription of iniBAC upon antibiotic-induced cell wall stress (Boot et al. 2017, 
under review). Strikingly, this regulator only regulates the iniBAC genes in both M. marinum and M. 
tuberculosis, hinting at the unique specificity of this response. In the same study, we identified 
trehalose as an inducing signal for cell wall stress and subsequent transcription of the iniBAC operon. 
  
  In this current work, we attempted to elucidate the role of the IniBAC proteins by generating 
knockout mutants in M. marinum. We found that operon induction is abrogated in single iniA, iniB or 
iniC mutants, indicating that signaling through IniR is dependent on the presence of all of the 
members of the operon. We also found that IniB is highly produced and secreted upon treatment with 
EMB or INH and that this secretion is independent of well-known alternative secretion systems.  
 
Results 
Deletion of the iniBAC operon does not affect growth or antibiotic susceptibility  
  To investigate the function of the iniBAC operon in M. marinum we generated four knockout 
mutants: ∆iniB, ∆iniA, ∆iniC and ∆iniBAC, utilizing a previously published phage knockout method 
(Tufariello et al. 2014; Jain et al. 2014). The knockout mutants were confirmed by PCR and 
sequencing. The resulting mutants showed no apparent growth defect in culture (supplemental figure 
1). Next, we assessed whether absence of the operon would cause a change in antibiotic susceptibility. 
As shown in table 1, the minimal inhibitory concentrations of all mutants for first-line antibiotics 
ciprofloxacin, ethambutol, isoniazid, streptomycin and rifampicin were unaltered as compared with 
wild-type M. marinum. In addition, we did not observe an altered susceptibility to ampicillin. This is 
in line with previous work, where we showed that high iniBAC-expressing mutants did not display 
altered antibiotic susceptibility (Boot et al. 2016) and with the observation that deletion of the 
regulator iniR did not change antibiotic sensitivity (Boot et al. 2017, under review). Therefore, we 
conclude that the IniBAC proteins are not directly involved in altering the antibiotic sensitivity of 
mycobacteria. Moreover, it is unlikely that the cell wall permeability is affected, as the mutants did not 
show increased sensitivity to ampicillin.  
 
Deletion of the iniBAC operon does not affect peptidoglycan biosynthesis 
Because iniBAC induced at a relatively late stage during specific cell envelope stresses (after 1 day), 
we hypothesized that cell envelope biogenesis could be affected. To address whether the deletion of 
iniBAC disrupts peptidoglycan biosynthesis, we compared the incorporation of a fluorescently labeled 
D-alanine: NBD-amino-D-alanine (NADA) between WT M. marinum and the iniBAC deletion strain. 
D-alanine analogues have been used successfully in Escherichia coli and Bacillus subtilis to visualize 
peptidoglycan biosynthesis in live bacteria before (Kuru et al. 2012; Hugonnet et al. 2016). After 
briefly exposing both WT and the operon deletion mutant to NADA-containing growth medium, 
fluorescence microscopy was used to assess incorporation of this label. We did not see alterations in 
the incorporation of fluorescent D-alanine into the PG-layer (supplemental figure 2). Quantification of 
this data confirmed that the iniBAC mutant did not show impaired incorporation of D-alanine, 
meaning that the D,D-carboxypeptidases and L,D-transpeptidases are functioning normally. The total 
NADA levels in the cell wall of analyzed mutant cells were comparable between the deletion mutant 
(5.25±1.53 RFI) and wild-type bacteria (3.93±1.89 RFI) (supplemental table 1). Also, the fluorescence 
at the cell poles was comparable in the ∆iniBAC strain (13.29±9.14 RFI) as compared with WT 
(7.41±5.06). In conclusion, the IniBAC proteins do not seem to play in PG biosynthesis during 
exponential growth in vitro. 
 
An ∆iniBAC mutant does not show attenuation in zebrafish embryo infection model 
  To address whether the IniBAC proteins play a role during infection in vivo, we decided to 
compare the infectivity of an ∆iniBAC deletion mutant to a WT M. marinum in our zebrafish embryo 
infection model (Stoop et al. 2011; Van Leeuwen et al. 2014). To do so, a vector encoding green 
fluorescent protein mEos3.1 was introduced in both strains (Zhang et al. 2012). Zebrafish embryo 
were systemically infected with 100 colony-forming units (CFUs) and infection was monitored over 
time with fluorescence microscopy. A representative selection of embryos was imaged 2, 3 and 4 days 
post infection for both WT and the mutant (Figure 1). In these experiments, we did not observe a 
significant growth defect or attenuation of the iniBAC mutant as compared infection with a WT M. 
marinum. Therefore, we conclude that IniBAC does not play a (major) role in the early stages of 
infection.  
 
IniA and IniC localize to the cytosol and (inner) membrane  
  The most peculiar protein encoded by the iniBAC operon is IniB. This protein does not show 
any similarity with known proteins as analyzed by computational tools such as BLAST or Phyre2. The 
protein is glycine-rich, contains several repeated motifs (QAG and GLG e.g.) and is highly variable in 
size in different mycobacterial species (Boot et al. 2017, under review). Both the IniA and IniC 
proteins contain a dynamin-like GTPase domain (confidence >99%) that is also present in the DNA 
replication fork binding protein CrfC of E. coli (Ozaki et al. 2013). Whether this domain has a similar 
function in the IniA or IniC proteins is not clear. Since the availability of nucleoside triphosphates is 
restricted to the cytosol, the localization of the GTPase domain of these proteins is likely cytosolic. 
Additional computational analyses performed on IniA and IniC reveal that IniA (618 AA) likely has 
one predicted transmembrane helix from amino acid 471 to 497, whereas the slightly smaller IniC 
protein (494 AA) does not (TM-Pred software). 
    To address the localization of the IniBAC proteins, the single genes iniB, iniA and 
iniC were modified to produce an extended protein with a C-terminal HA-tag and placed under the 
control of an hsp60 promoter. The resulting vectors were transformed into WT M. marinum. 
Interestingly, the vector containing the iniB-HA was toxic (n=2) and showed no colonies after 
transformation. This indicates that IniB by itself accumulates to toxic levels and that IniAC may 
mitigate this toxic effect. Both iniA-HA and iniC-HA transformants grew well on both solid and liquid 
medium. To analyze the localization of these two proteins, the transformants were grown, cultures 
normalized to OD and cytosolic, membrane and supernatant fractions were separated. As localization 
controls the cytosolic chaperone GroEL2 and membrane protein FtsH were used for Western Blotting. 
Figure 2A clearly shows that both IniA-HA and IniC-HA could be found in high quantities in the 
cytosol. In addition, a large portion of the IniA-HA protein localized to the membrane. IniC-HA is 
hardly present in the membrane fraction, probably due to the absence of a TM domain. Whether 
overexpression of IniA leads to a partly cytosolic localization is currently not known. 
  Because the iniBAC operon is strongly induced with antibiotics EMB and INH, we studied the 
localization of IniA-HA and IniC-HA after antibiotic treatment. After 72 hours of EMB or INH 
treatment, membrane fractions were isolated and untreated, EMB-treated and INH-treated samples 
were compared (Figure 2B). These experiments showed that IniA-HA and IniC-HA do not seem to 
change their subcellular localization upon exposure of the bacterial cells to antibiotics, as the changes 
in intensity in figure 2B between treatments is minimal. Remarkably, the membrane protein control 
FtsH is strongly affected by INH treatment, possibly as a result of an INH-induced bacterial stress 
response. In conclusion, IniA seems to be partially localized in the membrane, probably the IM, 
whereas IniC is cytosolic.  
  To analyze the localization of IniA and IniC in live cells, two fusion constructs were 
generated. Both iniA and iniC were fused with a gene coding for fluorescent protein mEos3.1 (Zhang 
et al. 2012). These chimeric genes were placed under control of an hsp60 promoter and the resulting 
plasmids were transformed to WT M. marinum. Because of the highly clumping nature of M. marinum 
we also transformed the constructs into a ppe10::tn mutant. This strain was previously shown to 
display reduced clumping due to an impaired formation of the capsular α-glucan layer (Ates et al. 
2015). Subsequently, fluorescence microscopy was used to analyze the localization of IniA-mEos3.1 
and IniC-mEos3.1 in live cells. The resulting images confirmed that the ppe10::tn mutant containing 
either IniA-mEos3.1 or IniC-mEos3.1 did not form clumps (Figure 3). The expression of IniA-
mEos3.1 seemed to be distributed diffusely throughout the cell with a few high-expression foci visible. 
In contrast, IniC-mEos3.1 was predominantly found in foci, scattered among the cell. To confirm these 
results, we repeated these experiments in a WT M. marinum background and utilized confocal 
microscopy to analyze the expression of the fusion proteins. In figure 4A, two representative z-slices 
are shown per strain. Confocal analysis confirmed the homogeneous distribution of IniA-mEos3.1 and 
the dotted appearance of the IniC-mEos3.1 fusion. To gain a better image of the foci that appear in the 
IniC-mEos3.1-expressing cells we used stimulated emission depletion (STED) microscopy, which 
resulted in an improved resolution. Multiple foci per bacterium can be distinguished in a z-stack 
showing multiple bacterial cells (Figure 4B). Blue color indicates bacteria that are more at the top of 
the stack, whereas warmer colors are more distantly localized. A 2x magnification on a single z-slice 
(Figure 4B, boxed area) reflects that the distribution of the foci seem to follow the outline of the 
bacterial cell wall. In summary, IniA-mEos3.1 seems to be spread among the cell more diffusely 
compared with distribution of IniC-mEos3.1 foci. Because IniC is a soluble protein, these foci are 
unlikely to be the result of inclusion bodies or lipid bodies.  
 
IniB is highly produced upon treatment with EMB and INH  
  Upon induction with EMB iniB mRNA levels increase 381 fold as compared with untreated 
samples (Boot et al. unpublished). To address whether this induction also translates to increased IniB 
protein levels, we analyzed supernatants of a WT M. marinum three days after incubation with 1x MIC 
of EMB or INH. Pellet and supernatant were isolated, proteins were separated on an SDS-PAGE gel 
and subsequently stained with Coomassie. Figure 5 shows that, after treatment with EMB or INH, a 
specific, intense band with an approximate molecular weight of 120 kDa could be observed. 
Moreover, a protein at the same height can be seen in supernatant fractions of treated samples after 
high speed ultra-centrifugation (EHS and IHS). To identify the protein in these samples, the 
corresponding bands of interest were excised from the gel together with a band at the corresponding 
height from the untreated control (excised lanes are labeled with * in figure 5). Unfortunately, standard 
tryptic digestion and subsequent proteomic analysis (LC-MS/MS) did not give any results. 
Bioinformatic analysis of IniB showed that there are only 5 trypsin sites in the IniB protein. We 
reasoned that the resulting tryptic fragments were too large to be detected with LC-MS/MS. Therefore, 
we changed digestion strategies and used chymotrypsin in the in-gel digestion steps leading up to mass 
spectrophotometry. As determined by in silico digestion with chymotrypsin, roughly 88.8% of the 
IniB protein should be detectable by mass spectrophotometry (ExPaSy). Indeed, after digestion with 
chymotrypsin and LC-MS/MS analysis, we confirmed that the intense protein band of approximately 
120 kDa was IniB. Multiple peptides were found, as illustrated by figure 6, where a plot containing the 
identified IniB peptides (green) and predicted peptide fragments (blue) are shown. In the untreated 
control, no peptide hits were found for IniB. The sequences of the identified peptides by LC-MS/MS 
can be found in supplemental table S2. Notably, a large region of the IniB protein was not identified, 
even though theoretical chymotrypsin sites were present. Moreover, almost all of the chymotryptic 
peptides contained a leucine residue at the cleavage site. Together this may indicate a post-
translational modification that shields the other cleavage sites (i.e. especially Phe), from digestion by 
chymotrypsin. Our analysis on SDS-PAGE gels revealed a marked difference in expected running size 
and actual migration of the IniB protein. The protein is calculated to be 86 kDa, whereas our analysis 
indicates a size of approximately 120 kDa, also indicative of possible modifications. We conclude that 
IniB is highly produced upon treatment with EMB and INH and that the protein is detectable in the 
cell envelope and the culture supernatant. 
 
 
IniA and IniC are both required for the production and secretion of the IniB protein 
  To address whether secretion of the IniB protein is dependent on the presence of functional 
copies of IniA and IniC we repeated the secretion analysis experiment with ∆iniA, ∆iniB and ∆iniC 
mutants and compared IniB induction levels after treatment with INH (which is indicated with a ‘+’ in 
supplemental figure 3) to a WT M. marinum by separating the samples on an SDS-PAGE gel. From 
supplemental figure 3, it is clear that IniB secretion is abolished in mutants that do not have a 
functional IniA or IniC. This effect can be complemented to near WT levels by introduction of 
constructs encoding IniA-HA or IniC-HA (Figure 7). This complementation shows that the effect is 
directly linked to the presence of IniA or IniC. In addition to secretion, we also noticed that IniB levels 
in the pellet fractions were severely reduced. This suggests that the regulation of induction or 
translation of IniB might be affected in these mutants.  
  To prove that the induction of IniB is affected by deletion of iniA or iniC, we utilized our 
iniBAC reporter construct (Boot et al. 2016) that allows fluorescent quantification of transcription of 
the operon. In previous work, we identified that the iniBAC operon is regulated by IniR and that that 
the addition of trehalose to the culture medium could directly induce transcription of the iniBAC 
operon (Boot et al. 2017, under review). We hypothesized that the gene products of the operon might 
serve as a cell wall stress sensing/signaling complex . To examine this, we performed flow cytometry 
experiments with the ∆iniB, ∆iniA, ∆iniC, and ∆iniBAC mutant and compared operon induction to WT 
M. marinum. The resulting analysis revealed that all the single mutants, as well as the complete operon 
mutant, were not able to induce the stress reporter in response to addition of EMB or INH on both day 
1 and day 3 (Figure 8A). Very mild induction phenotypes can be seen for EMB on day 3, up to a 3-
fold induction for the ∆iniB mutant. However, since these induction levels are very low, as compared 
with WT induction, we concluded that the individual members of the operon are required for (full) 
induction of the stress system that leads to induction of iniBAC. Moreover, the response to trehalose is 
lost in the single mutants and operon knockout mutant (Figure 8B). We conclude that the members of 
the iniBAC operon are all required for IniR-dependent activation of transcription of the iniBAC 
operon. 
 
IniB is not secreted by SecA2 or the ESX1 and ESX5 alternative secretion systems 
  Our results suggest that IniB is partially secreted during antibiotic stress, which means that a 
secretion mechanism is likely involved. Because IniB does not contain a traditional signal sequence as 
analyzed by SignalP software, and because the proteomic analysis showed that the N-terminal 
fragment of IniB was still present in the extracellular fraction, an alternative secretion pathway should 
be involved. To analyze whether well-known alternative secretion systems ESX-1 or ESX-5 play a 
role in IniB secretion we used available transposon mutants in eccCb1 and mycP5 that are deficient in 
ESX-1 and ESX-5 secretion, respectively to assess the amount of secreted IniB (Stoop et al. 2011; 
Van Winden et al. 2016). Moreover, we also included a secA2::tn mutant that was previously shown 
to be involved in the secretion of a subset of mycobacterial substrates, including proteins without a 
signal sequence (van der Woude et al. 2014). After three days of incubation with isoniazid, 
supernatant fractions were isolated and separated on an SDS-PAGE gel. The resulting gel was stained 
with Coomassie. The experimental analysis revealed that all mutants showed high levels of 
extracellular IniB (Figure 8). Remarkably, the mycP5::tn mutant even showed higher levels of 
extracellular IniB than WT and this effect was reproducible (n=3). In conclusion, mutants in ESX-1, 
ESX-5 and SecA2 secretion pathways do not hamper secretion of IniB and are therefore not directly 
involved in its secretion. 
 
Discussion 
  In this work we characterized the IniBAC proteins. In doing so, we identified that an ∆iniBAC 
deletion mutant does not cause differences in growth during exponential growth, nor antibiotic 
susceptibility. Additionally, loss of the operon does not affect the ability of M. marinum to infect 
zebrafish embryos in vivo. Previous work from our group already indicated that the overexpression of 
the iniBAC operon did not result in an altered antibiotic susceptibility. Moreover, deletion of the 
operon regulator IniR, which prevents iniBAC induction also did not result in altered MIC levels (Boot 
et al. 2016, Boot et al. 2017, under review). However, since the zebrafish embryo infection model 
only allows us to monitor short infection time periods (typically 5 days), we cannot rule out that the 
operon is required at a later stage of infection or perhaps during latent infection or states like hypoxia. 
In this respect, it is interesting to note that in a recent publication by Eoh et al. The authors showed 
that the levels of trehalose and TMM/TDMs are affected during hypoxic conditions in M. tuberculosis. 
Trehalose and trehalose-containing lipids are exactly the key players that also are pivotal for iniBAC 
induction (Eoh et al. 2017, Boot et al. 2017, under review). 
  The IniB protein that we identified by mass spectrophotometry runs with a significantly higher 
molecular weight than predicted. The protein weighs 86 kDa, whereas in our experiments it runs at 
around 120 kDa on SDS-PAGE gels. This may suggest the presence of post-translational 
modifications on the protein. Modifications of mycobacterial proteins are not an uncommon find. 
Examples of known modifications of secreted mycobacterial proteins include (di)methyl-lysines, but 
also O-glycosylation in which mannose residues are linked to serines or threonines (Dobos et al. 1995; 
Pethe et al. 2001; Pethe et al. 2002; van Els et al. 2014). In the case of IniB, the modification must be 
substantial (>30 kDa). Therefore, we can rule out methyl-lysines. Also pupylation, a more substantial 
mycobacterium-specific lysine modification, cannot account for the observed difference in weight, 
because IniB only has a single lysine residue. Peptide analysis obtained after chymotrypsin cleavage 
indicated that there was a paucity in peptides identified in the central region and the C-terminal region, 
which could indicate a blockade of some sort that prevents digestion. However, these two regions also 
barely contain leucine residues, which we found to be the predominant cleavage site for chymotrypsin 
in our experiment. Moreover, the chymotryptic fragments that are predicted are of considerable size, 
perhaps too big to be detected by LC-MS/MS. Together this could also explain the lack of detected 
chymotrypsin peptides in that region. A remarkable observation is that the chymotrypsin digest did not 
give a single peptide that was digested after a phenylalanine residue, whereas theoretically this should 
be main cleavage site. However, we also did not find such peptides for the control proteins, perhaps 
indicative of a technical issue in our digestion procedure. An alternative theory for the observed 
anomalous migration of IniB on SDS-PAGE gels could be that the protein contains domains of high 
rigidity resulting in elongated folding. An example of this is the polyproline domain of TonB, which 
also migrates slower through SDS-PAGE gels due to elongated folding (Bitter et al. 1993; Köhler et 
al. 2010). Indeed, the C-terminal domain of IniB contains a high proportion of proline residues 
supporting that IniB could adopt an elongated structure and cause altered migration patterns on an 
SDS-PAGE gel.  
  Deletion of iniA and iniC resulted in the disability of these strains to produce IniB (Figure 7). 
This finding suggests that the IniBAC components together with IniR form a stress sensing and 
signaling cascade, where all four proteins are required for the transduction of the signal. The role of 
IniA and IniC might be that of IM-associated factors that can form a complex to directly interact with 
IniR. IniA has been previously associated with the inner membrane as a homo-multimeric complex. 
Previous work by Colangeli et al. has hinted that IniA readily forms hexamers that assemble into a 
ring-like structure associated with the inner membrane (Colangeli et al. 2005). The fact that we see 
cytosolic localization of a fraction of IniA-HA might be due to overexpression of IniA in our assays. 
Moreover, we do not know for sure if the IniA-mEos3.1 can still correctly localize to or insert into the 
membrane. To examine this IniA-mEos3.1 could be placed under an inducible promoter. Why IniB 
itself is essential for induction of the stress reporter is not known. Possibly, the secreted IniB might be 
a periplasmic shuttle for the stress signal or even bound to the inner membrane stress complex that is 
formed by IniA/C/R. Conflicting with this theory is the fact that M. smegmatis has highly similar 
homologues of iniA, iniC and iniR, but not of iniB. How the deletion of iniB is compensated for in M. 
smegmatis and how the stress signaling exactly occurs remains in this species remains to be addressed. 
    In this work, we have shed some light on the secretion and production of IniBAC 
proteins. Although their exact role remains to be elucidated, studying these proteins will likely reveal 
important information on the functioning of the mycobacterial cell envelope.  
 
Material & methods 
Bacterial strains and culturing conditions  
  E. coli strain DH5α was used to propagate plasmid DNA. Cultures were grown at 37°C in LB 
broth with the addition of the appropriate antibiotics. Both wild-type M. marinum M-USA and E11 
were used as parents strain for our experiments (Abdallah et al. 2006). Mutants were derived from M. 
marinum M-USA unless otherwise indicated. The eccCb1::tn mutant, mycP5::tn, ppe10::tn and 
secA2::tn transposon mutants were described previously (van der Woude et al. 2014; Ates et al. 2015; 
van Winden et al. 2016). Mycobacterial cultures were grown in Middlebrook 7H9 supplemented with 
Middlebrook ADC and 0,05% Tween-80. Where indicated, antibiotics were added. All antibiotics 
used were purchased from Sigma and routinely added to log-phase cultures at the indicated final 
concentrations. For ethambutol and isoniazid induction experiments concentrations of 1µg/ml and 
10µg/ml were respectively used. Trehalose dihydrate (Sigma) was added to a final concentration 
indicated in the text.  
 
Generation of iniBAC operon knockout mutants 
  All primers used for cloning can be found in supplemental table 3. The iniBAC (MMAR_0614-
MMAR_0616), iniB (MMAR_0614), iniA (MMAR_0615) and iniC (MMAR_0616) knockouts were 
created via allelic exchange in M. marinum M-USA, with a substrate based upon the phAE159 
temperature-sensitive phage method (Jain et al. 2014; Tufariello et al. 2014). The knockout construct 
was generated by PCR amplification of left and right flanking regions of the genes, removing a total of 
100% of the gene (see table S1 in supplemental material). The deletion was confirmed by PCR 
analysis and sequencing. Subsequently, the hygR/sacB cassette was removed by transposon gamma-
delta resolvase (TnpR), followed by sucrose counter-selection of unmarked mutants. 
 
Construction of plasmids  
  For all PCRs iProof™ High-Fidelity DNA Polymerase was used according to manufacturer’s 
protocol. To create HA-tagged versions of IniA and IniC, both iniA and iniC were amplified by PCR 
from M. marinum M-USA genomic DNA with a 3’primer containing the DNA sequence for an HA-
tag. The primers also contained anchored NheI (5’) or XbaI (3’) sites. A previously published pSMT3-
hsp60-LipY vector was used as a backbone and digested with NheI and XbaI (Daleke et al. 2011). The 
vector and PCR product were ligated to create the resulting pSMT3-hsp60-iniA-HA and pSMT3-
hsp60-iniC-HA. The constructs encoding IniA-mEos3.1 and IniC-mEos3.1 were created by PCR with 
anchored primers containing NheI sites. A vector containing hsp60-mEos3.1 (van Leeuwen et al. 
submitted) was digested with NheI and dephosphorylated with shrimp alkaline phosphatase (SAP) 
purchased from Sigma. Correctly orientated colonies were identified in a colony PCR (and cPCR-
mEos3.1 primer). Constructs were transformed into M. marinum by electroporation.  
 
Antibiotic susceptibility assay 
  M. marinum WT and the iniBAC operon mutants were grown in 7H9 supplemented with ADC 
to an OD600 of 0.6–0.8. Subsequently 104 cells were distributed per well in a 96-well plate, and serial 
2-fold dilutions of ciprofloxacin, ethambutol, isoniazid, streptomycin, rifampicin and ampicillin were 
added. The MIC was determined as the concentration of antibiotics that inhibited visible growth. 
Wells without the addition of antibiotics were used as a growth control, and experiments were 
performed in triplicate. 
 NADA labeling of ∆iniBAC mutant 
  For labeling experiments with NBD-amino-D-alanine (NADA) (Kuru et al. 2012), both a WT 
M. marinum and the iniBAC operon deletion mutant were grown to a logarithmic growth phase. 
Subsequently, cells were labeled with 0.5 µM NADA for 2 minutes at 30°C. Afterwards, cells were 
washed three times with pre-warmed PBS and a cover slip with 1% agarose was used to immobilize 
M. marinum cells for imaging. Fluorescence imaging was performed on a Nikon Eclipse T1 (Nikon 
Plan Fluor × 100/1.30 Oil Ph3 DLL objective) coupled to an EMCCD camera.. The exposure time for 
imaging was 2 seconds and images were subsequently analyzed with ImageJ to obtain average 
fluorescence measurements (Vischer et al. 2015). 
 
Zebrafish embryo infection experiments  
  M. marinum M-USA wild type and the ∆iniBAC mutant containing a plasmid that encodes the 
fluorescent marker mEos3.1 under control of an hsp60 promoter, were grown to the logarithmic phase. 
In total, 100 colony forming units were microinjected into the caudal vein of Danio rerio zebrafish 
embryos (Benard et al. 2012). Subsequently, the bacterial infection was followed over time and 
zebrafish embryo infection was analyzed as described previously (van Leeuwen et al. 2014). Next, the 
bacterial infection was visualized 2, 3 and 4 days post infection (dpi) with a Leica MZ16FA 
fluorescence microscope. Bright-field and fluorescence images were generated with a Leica DC500 
(DFC420C) camera. All zebrafish embryo experiments were done according to the guidelines stated 
by the Dutch animal welfare laws. 
 
Localization experiments of IniA and IniC 
  For fractionation experiments pre-cultures of WT M. marinum and strains expressing IniA-HA 
and IniC-HA were washed thrice in 7H9 with 0.2% dextrose and glycerol and diluted to an OD of 1. 
Cultures were incubated at 30°C overnight and equal OD units were harvested by centrifugation. The 
culture supernatant was precipitated with TCA. The cell pellet was washed with PBS and cells were 
lysed with a One Shot cell disruptor (Constant Systems Ltd.). Intact cells were pelleted by 
centrifugation at 3.000 × g for 10 min. The cell envelope (CE) fraction was isolated by centrifugation 
at 200.000 × g for 45 minutes and resuspended in PBS and 250 mM sucrose. Supernatant, membrane 
fractions and cytosolic samples were equalized to contain equal OD values. Proteins were separated on 
SDS-PAGE gels and transferred to a nitrocellulose membrane, and membranes were stained with anti-
GroEL2 (Cs44; John Belisle, NIH, Bethesda, MD, USA), anti-HA (HA.11; Covance), or anti-FtsH 
antibodies (van Bloois et al. 2008). 
 
Imaging of IniA-mEos3.1 and IniC-mEos3.1 
  In preparation of experiments cultures were inoculated and diluted to OD600 of 0.1. 
Subsequently, cells were washed in PBS and subsequently pipetted on glass slides containing 1% 
agarose to immobilize the mycobacteria. Fluorescence imaging was performed on an Olympus BX60 
fluorescence microscope in a standard set-up. At least 20 representative fields were imaged per 
condition. Confocal microscopy was performed on a Leica TCS SP8 confocal microscope containing a 
white-light laser and HyD detectors. Subsequent deconvolution of indicated images was done in the 
Huygens Software environment. Images were processed using ImageJ software. 
 
IniB protein isolation and mass spectrophotometry 
  IniB protein was obtained by growing the strains described in the text with the required 
antibiotics. Pre-cultures of strains of interest were spun down and cell pellets washed 3x with 7H9 
containing 0.2% glycerol to get rid of BSA. Cultures were diluted to OD600 of 0.3 per ml. Cultures 
were subsequently inoculated in 7H9 + 0.2% glycerol containing either no antibiotics, EMB (1µg/ml) 
or (INH 10µg/ml). Cultures were grown for 72 hours. Bacterial cultures were normalized to OD600 
and an equal amount of OD units was spun down. The pellets were lysed by bead beating and 
resuspended in sample buffer before loading on SDS-PAGE. The supernatant was spun down three 
times at 3.000 x g to get rid of any remaining bacterial cells. Then, the supernatant was filtered with an 
0.2µM millipore filter. The supernatant was centrifuged in a Beckman Coultier (Optima XE-90) ultra-
centrifuge at either 25.000 x g (low-speed) for 1 hour and/or 200.000 x g for 1 hour (high-speed 
samples) at 4 ̊C. The resulting supernatant was discarded and the pellet was resuspended in PBS. 
Samples were loaded onto SDS-PAGE gels and stained Coomassie Blue G250 (Bio-rad). 
Subsequently, the bands indicated in the manuscript figures were excised from the gel and digested 
with chymotrypsin (V1061 sequencing grade, Promega) according to manufacturer’s protocol. 
Peptides were extracted in 1% formic acid and two times in 5% formic acid + 50% ACN. Extracts 
were pooled and dried in a vacuum centrifuge, and dissolved in 4% ACN in 0.5% TFA prior to 
injection. LC-MS/MS and protein identification and quantification was performed as described in 
(Piersma et al. 2013). Briefly, Peptides were separated with a 43 cm × 75 µm ID fused silica C18 
column (Dr Maisch GMBH, Ammerbuch-Entringen, Germany). Peptides were trapped on a 10 mm × 
100 µm ID trap column and separated at 300 nl/min in a 8–32% ACN in 0.5% HAc gradient in 60 min 
(90 min inject-to-inject) at 50°C. Eluting peptides were ionized at a potential of +2 kVa into a Q 
Exactive mass spectrometer (Thermo Fisher, Bremen, Germany). Intact masses were measured at 
resolution 70.000 (at m/z 200) in the orbitrap. MS/MS spectra (top-10 precursors) were acquired at 
resolution 17.500 (at m/z 200). MS/MS spectra were searched against the Uniprot M. marinum 
complete proteome (ATCC BAA-535M) (downloaded march 2013; 5418 entries) using MaxQuant 
1.5.2.8 (Cox & Mann 2008). Enzyme specificity was set to Chymotrypsin and up to two missed 
cleavages were allowed. Cysteine carboxamidomethylation was treated as fixed modification and 
methionine oxidation and N-terminal acetylation as variable modifications. Peptide precursor ions 
were searched with a maximum mass deviation of 6 ppm and fragment ions with a maximum mass 
deviation of 20 ppm. Peptide and protein identifications were filtered at an FDR of 1% using the decoy 
database strategy. 
 
Flow cytometry analysis 
  The induction of the iniBAC stress reporter was analyzed by flow cytometry on a BD Accuri 
C6 flow cytometer (BD biosciences) as previously described (Boot et al. 2016). For induction 
experiments bacteria were grown to a logarithmic growth phase and diluted to an OD of 0.1. 
Subsequently, antibiotics added at indicated concentrations. Per time point, 1 mL of culture was 
sampled. Bacterial cells were spun down and washed with PBS containing 0.05% Tween-80 and after 
one wash resuspended in PBS + 0,05% Tween-80. The flow cytometer set-up for mEos3.1 detection 
contained a 488 nm laser and 530/30 nm filter. Per sample, 30.000 gated events were analyzed per 
time point and data was analyzed and visualized using BD CFlow software and Graphpad Prism 6. For 
samples the mean fluorescence intensity (MFI) was used to quantify fluorescence intensity. 
Experiments were performed three times with independent biological replicates. 
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 Figure 1. The iniBAC genes do not play a role in early infection. Zebrafish embryo infection experiments were performed to compare the 
fluorescence intensities of an M. marinum M-USA WT and its isogenic ∆iniBAC deletion mutant. Both strains harbor a pSMT3-hsp60-mEos3.1 
plasmid to allow visualization of fluorescence by fluorescence microscopy. Representative images are shown for 2,3 and 4 days post infection 
(dpi). Background fluorescence in the non-infected group is due to auto-fluorescence in the yolk of zebrafish embryos. 
  
 
Figure 2. IniA and IniC associate with the inner membrane. The localization of IniA-HA and IniC-HA 
were determined after fractionation. Separation was performed on an SDS-PAGE gel and anti-HA 
immunoblotting was used to reveal proteins. A WT control (-) was taken along to visualize background 
signals. GroEL2 was used as a control for cytosolic proteins and FtsH served as a control for membrane 
protein fractions. A) Indicating the presence of IniA-HA and IniC-HA in cytosolic (c), membrane (m) or 
supernatant (s) fractions. The control shows no background signal at 55-100 kDa. B) Presence of IniA-HA 
and IniC-HA in the membrane fraction after treatment with ethambutol (E) or isoniazid (I). 
 Figure 3. IniA and IniC fusions both have a characteristic localization in live M. marinum cells. An 
M. marinum ppe10::tn mutant containing either no plasmid (control) or plasmids encoding an IniA-
mEos3.1 or IniC-mEos3.1 were immobilized on agarose (1%) slides and imaged using a fluorescence 
microscope. A representative image was selected from a total of 20 frames per sample. The bright field, 
fluorescence (GFP) and merged image are shown for sample. Merges were performed in ImageJ.
 Figure 4. IniC-mEos3.1 fusion proteins are expressed in foci in WT M. marinum. M. marinum containing plasmids encoding IniA-mEos3.1 or 
IniC-mEos3.1 were imaged with a confocal microscope. A) Two representative panels with z-slices of IniA-mEos3.1 and IniC-mEos3.1 are shown. 
B) A z-stack of IniC-mEos3.1 expressing bacteria is shown. The distal cells are colored red and proximal cells are blue. The box contains a 2x 
zoomed image of one single z-slice containing bacteria expressing IniC-mEos3.1. 
 Figure 5. A specific 120 kDa protein band is expressed after treatment with EMB and INH. 
Coomassie staining of an SDS-PAGE gel comparing the pellet and supernatant fractions of untreated (-), 
or EMB (E) or INH (I) treated cells. A distinction between low-speed centrifugation steps (LS) and high 
speed (HS) was made. Asterisks indicate the two excised gel fragments that were analyzed by LC-MS/MS
 Figure 6. LC-MS/MS analysis reveals that the 120 kDa protein is IniB. The peptide hits that were found by mass spectrophotometry with 
chymotrypsin digestion are plotted in green and their corresponding sequence and localization is plotted on the mapped IniB protein. The predicted 
chymotryptic peptides can be found in blue.
  
Figure 7. ∆iniA and ∆iniC mutants no longer produce IniB. An SDS-PAGE gel was Coomassie stained 
after separation of proteins. All samples shown are supernatant fractions that originate from isoniazid-
treated cultures, indicated with a +. A WT M. marinum, an ∆iniA or ∆iniC knockout mutant or their 
complemented versions (∆iniA +comp or ∆iniC+comp) were analyzed for IniB levels. 
 Figure 8. iniBAC induction is abolished in all single operon mutants. All strains contained the iniBAC 
reporter plasmid containing the iniBAC promoter transcriptionally fused to a gene that encodes mEos3.1 
A) Fold inductions on day 1 and day 3 were compared between WT M. marinum and mutants ∆iniA , 
∆iniB, ∆iniC, and ∆iniBAC after treatment with EMB (black) or INH (gray). Fold inductions were 
calculated by dividing the mean fluorescence intensity values of treated samples by the values of the 
untreated controls. B) Flow cytometry plots for WT M. marinum and an ∆iniBAC mutant on day 3, 
comparing iniBAC induction after treatment with EMB, INH, 1% trehalose or 5% trehalose. Events 
indicate single bacterial measurements for a certain mEos3.1 fluorescence value (MFI).  
  
Figure 9. Alternative secretion systems ESX-1, ESX-5 and SecA2 are not involved in IniB secretion. 
A Coomassie-stained SDS-PAGE gel after separation of proteins. All samples (except for the untreated 
sample called WT-) are supernatants that originate from isoniazid-treated cultures. Samples of an E11 
WT, ESX-1::tn affected in eccCb1, ∆iniBAC, secA2::tn and ESX-5::tn affected in mycP5 were analyzed 
for IniB production levels.  
 
 Figure S1. Deletion of iniBAC does not affect growth. Shown is a growth curve comparing the growth 
of the four iniBAC knockout mutants to WT M. marinum M-USA. The OD600 was measured over time. 
Measurements were performed with a biological triplicate. Error bars indicate the standard deviation 
values. 
 
 
 
 
 
 Figure S2. Peptidoglycan biosynthesis is not altered in an iniBAC mutant. Two representative images 
of NADA incorporation in WT M. marinum and the ∆iniBAC deletion strain are shown. Both phase 
contrast images and GFP channels are shown. The GFP channel visualizes NADA incorporation levels. 
The white scale bar indicates 5 µm. 
 
 Figure S3. ∆iniBAC knockout mutants are hampered in IniB production. Proteins were separated on 
an SDS-PAGE. The gel was stained with Coomassie. WT M. marinum M-USA and the three knockout 
mutants in iniA, iniB and iniC are shown. Treatment with isoniazid is indicated with a plus (+) and 
absence of antibiotics with a minus (-). Pellet (P) and supernatant (S) fractions were analyzed for levels of 
IniB.
 Strain Isoniazid 
(µg/ml) 
Ethambutol 
(µg/ml) 
Streptomycin 
(µg/ml) 
Ciprofloxacin 
(µg/ml) 
Rifampicin 
(µg/ml) 
Ampicillin 
(µg/ml) 
WT 18.8 0.8 3.10 0.65 (0.23) 1.56 200 
∆iniBAC 31.3 (10.8) 0.8 3.10 1.04 (0.45) 1.56 200 
∆iniB 18.8 0.8 3.10 0.80 1.56 200 
∆iniA 18.8 0.8 3.10 0.80 1.56 200 
∆iniC 18.8 0.8 3.10 1.04 (0.45) 1.56 200 
 
Table 1. iniBAC operon mutants do not show an altered antibiotic susceptibility. Results of the 
antibiotic susceptibility test comparing WT M. marinum M-USA to the four knockout mutants. 
Measurements were performed in triplicate. The concentration at which no visible growth was seen is 
denoted as the MIC value in µg/ml. The numbers in brackets indicate the s. d. values. 
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Abstract 
Due to the rise of drug resistant forms of tuberculosis there is an urgent need for novel antibiotics to 
effectively combat these cases and shorten treatment regimens. Recently, drug screens using whole cell 
analyses have been shown to be successful. However, current high-throughput screens focus mostly on 
stricto sensu life-death screening that give little qualitative information and often require the lengthy 
process of target and mode of action (MoA) identification. In doing so, promising compound scaffolds or 
non-optimized compounds that fail to reach inhibitory concentrations are missed. To accelerate early TB 
drug discovery, we performed RNA sequencing on Mycobacterium tuberculosis and Mycobacterium 
marinum to map the stress responses that follow upon exposure to sub-inhibitory concentrations of 
antibiotics with known targets: ciprofloxacin, ethambutol, isoniazid, streptomycin and rifampicin. The 
resulting dataset comprises the first overview of transcriptional stress responses of mycobacteria to 
different antibiotics. We show that antibiotics can be distinguished based on their specific transcriptional 
stress fingerprint i.e. DNA damage for ciprofloxacin and ribosomal stress for streptomycin. Notably, this 
fingerprint was more distinctive in M. marinum. We decided to use this to our advantage and continue 
with this model organism. A selection of diverse antibiotic stress genes was used to construct stress 
reporters. In total, three functional reporters were constructed to respond to DNA damage, cell wall 
damage and ribosomal inhibition. Subsequently, these reporter strains were used to screen a small anti-TB 
compound library to predict the mode of action. In doing so we could identify the putative mode of action 
for three novel compounds, which confirms our approach.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  Tuberculosis (TB) disease is caused by the human pathogen Mycobacterium tuberculosis. 
Annually, 10 million new TB cases are reported worldwide, according to the WHO (WHO 2016). In total, 
1.8 million people died of the consequences of TB infection in 2015, placing M. tuberculosis at the top of 
the list of most deadly bacterial pathogens known to mankind. Patients diagnosed with drug susceptible 
forms of TB can be cured with a six-month treatment regimen that includes four different drugs, i.e. 
pyrazinamide, isoniazid, ethambutol and rifampicin (WHO 2016). Treatment is complicated when M. 
tuberculosis is resistant to one or more first-line anti-TB agents. These cases are deemed multidrug- 
(MDR) or extensively drug-resistant (XDR) TB. As a result, the length of treatment is increased 
dramatically to 24-48 months (Coninx et al. 1999; Mitnick et al. 2008). Moreover, these forms of TB 
require second and/or third-line anti-TB drugs, which are generally more prone to cause side effects due to 
drug toxicity (Saukkonen et al. 2012). This toxicity leads to an increase in adverse events and a 
concomitant decrease in patient compliance. As a result, patients undergo intermittent treatment, which 
likely contributes to the increase in observed drug resistance and within patient evolution. Overall, this 
leads to an increase in the heterogeneity of (within patient) mycobacterial populations (Sun et al. 2012; 
Liu et al. 2015) .  
  The identification of new anti-TB drugs has proven to be a challenge. One of the reasons for this 
is the intrinsic resistance of M. tuberculosis to drug treatment. Mycobacteria possess a lipid-rich and thick 
cell wall containing very hydrophobic long-chained fatty acids known as mycolic acids (Jankute et al. 
2015). In addition, the presence of active efflux pumps and a chromosomally-encoded beta-lactamase also 
compromise the intracellular retention time of compounds, and thus, drug activity (Balganesh et al. 2012). 
Despite these difficulties, high-throughput screening (HTS) using a whole cell assay can be successful in 
the identification of compounds that inhibit growth or kill the bacterium (Ballell et al. 2013). Examples of 
these are diarylquinolines (bedaquiline) and the more recently discovered benzothiazinones (Andries et al. 
2005; Makarov et al. 2009). However, the overall hit rate of active compounds is low and specific 
chemical moieties are overrepresented, indicative of a scaffold exhaustion within current life/death 
screenings. Moreover, there is no direct insight into the mode of action (MoA) in HTS approaches, which 
requires the tedious process of finding resistant mutants in a target which might not always reflect the 
MoA accurately. Although it is the ultimate goal to find a strong and potent inhibitor of mycobacterial 
growth, in reality compounds or even compound scaffolds are likely far from their optimal forms. This is 
usually due to a suboptimal potency and/or affinity that requires optimization by directed chemical 
modification. Because chemical scaffolds rarely reach their minimal inhibitory concentrations (MIC), 
promising lead compounds might be missed in classical HTS screening. Moreover, compounds that 
synergize with current treatment or compounds that potentiate treatment to existing antibiotics, like the 
recently discovered SMARt-420 compound that reverses ethionamide resistance, could be missed 
(Blondiaux et al. 2017).  
  Whole-cell based screens with a different readout than life/death has already proven successful in 
identification of ESX-1 inhibitors which block the virulence of this bacterium (Rybniker et al. 2014). A 
different approach to increase the sensitivity of a HTS, and to acquire more qualitative information from 
screens, is by analyzing the induction of stress responses upon treatment with currently used antibiotics. 
So-called reporter strains with fluorescent or bioluminescent reporters will allow screening for new 
compounds which have a similar target or mode of action. An example of such a system is the iniBAC 
operon, which is highly induced when antibiotics targeting mycobacterial cell envelope biogenesis are 
applied. An iniBAC reporter has been used by our group and other groups as a tool to swiftly obtain 
information on the possible MoA of new potential drugs (Alland et al. 2000; Boot et al. 2016; Naran et al. 
2016). To identify more candidate stress reporters we decided to map the bacterial stress responses that 
follow upon treatment with currently used antibiotics, with a defined MoA and target. Although individual 
datasets have previously been reported, a complete overview is missing (Boshoff et al. 2004). To bridge 
this gap of knowledge we performed RNA sequencing on both M. marinum and M. tuberculosis treated 
with first and second-line antibiotics: ciprofloxacin inhibiting DNA unwinding, ethambutol and isoniazid, 
both targeting the mycobacterial cell wall, streptomycin, causing inhibition of ribosomes and rifampicin, 
which inhibits RNA polymerase. We show that M. marinum has a far more defined stress fingerprint upon 
exposure to these antibiotics as compared with M. tuberculosis and argue that this distinctive power of M. 
marinum allows more clear cut assays for quick MoA determination. We subsequently constructed stress 
reporters based on this data and confirmed the upregulation found in our RNA sequencing data. 
 
Results 
RNA sequencing of M. tuberculosis and M. marinum overlap in SOS-response activation 
  To map the bacterial stress responses upon antibiotic treatment we decided to utilize RNA 
sequencing, a powerful and unbiased tool to map the complete pool of mRNAs present at a certain time 
point. We chose to include M. marinum, which is a well-established model for tuberculosis virulence 
research due to its genetic similarity with M. tuberculosis ( >85% nucleotide identity), its relative ease of 
handling and relatively fast growth rate, as compared with M. tuberculosis (Stinear et al. 2008).We used 5 
different first-line antibiotics: ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin and one 
second-line drug, the fluoroquinolone ciprofloxacin. Pyrazinamide was excluded from the subsequent 
experiments as in vitro activity was difficult to reproduce. RNA was isolated from a biological triplicate, 
at two different time points, i.e. at 4h and 24h after exposure. As a control, RNA of untreated cultures was 
isolated to serve as a reference for differential gene expression. Before isolation of RNA we made sure 
that the antibiotic concentrations that we used to treat the mycobacteria were not bactericidal. We aimed at 
a concentration that caused a slight growth defect, as measured by OD600 (M. marinum, shown in 
supplemental Figure 1). After RNA isolation, RNA integrity numbers (RIN) were determined and all 
samples had a RIN value of >9. High reproducibility between replicates was observed, as indicated in 
supplemental figure 2. Analysis on the reproducibility between replicates was performed and is shown for 
M. tuberculosis (Figure S2A) and for M. marinum (Figure S2B). We also visualized the correlation for 
untreated and ciprofloxacin-treated cells for M. tuberculosis (Figure S3A) and M. marinum (Figure S3B). 
The highest overall correlation between untreated samples of M. tuberculosis was 0.98. For ciprofloxacin, 
the correlation between samples was 0.97. In M. marinum these respective values are: 0.95 and 0.96.  
  We decided to examine the reliability of our RNA sequencing data by comparing our 
ciprofloxacin stress profile with previously published data on ciprofloxacin induction and the SOS regulon 
members in M. tuberculosis (O’Sullivan et al. 2008; Smollett et al. 2012). In Figure 1A, M. marinum and 
M. tuberculosis expression profiles are compared with their respective untreated controls 4 hours after 
treatment. Only genes with an M. marinum orthologue were included in the analysis. Generally, the 
concordance between the expression levels of M. marinum and M. tuberculosis in response to 
ciprofloxacin and also the concordance with published members of the SOS response was high. The study 
from Smollet et al. predicts 23 genes that have LexA binding sites (Smollet a al. 2012). Although the 
presence of this binding site does not predict upregulation or downregulation, we found differential 
expression in our RNA sequencing for 21/22 of these genes in M. tuberculosis and for 17/18 of the 
predicted orthologues in M. marinum. Moreover, we confirmed 13/16 of the upregulated genes that were 
identified by the paper from O’Sullivan et al. for M. tuberculosis and upregulation of 12/15 of the alleged 
orthologues for M. marinum (O’Sullivan et al. 2008). Minor differences can be observed between M. 
marinum and M. tuberculosis at the 4 hour time point. However, the overlap between the two species 
further increased at the 24 hour time point (Figure 1B). Based on these data, it is likely that it takes M. 
tuberculosis a longer amount of time to mount a stress response to ciprofloxacin than it is for the faster 
growing M. marinum. The difference in growth speed would account for these differential early time point 
responses. In conclusion, we observe a strong correlation between previously identified SOS-response 
members and our RNA sequencing dataset for both M. marinum and M. tuberculosis, indicating that our 
analysis is reliable. 
 
M. marinum mounts an antibiotic stress response specific for antibiotic subclasses  
  One of the open questions was whether mycobacteria mount a more general stress response or if 
they activate specialized repair mechanisms to counteract a specific type of damage (i.e. mistranslation or 
cell wall damage) caused by the encountered antibiotic. The ciprofloxacin analysis indicated that known 
members of the SOS-response are induced, but also showed notable differences between M. marinum and 
M. tuberculosis. Possibly, these two strains respond differently to antibiotic stress. To visualize this, we 
looked at the overlap of the induced genes at 4 hours and 24 hours for both M. marinum and M. 
tuberculosis (All of the RNA sequencing data can be found in Supplemental file 1). Surprisingly, M. 
tuberculosis induced a large number of identical genes in response to antibiotics with very different 
cellular targets, leading to a significant overlap in the observed transcriptional response (Figure 2A). 
These genes include non-specific, and more general stress genes, like hspX, acr and hrp1. In contrast, M. 
marinum seems to mount a stress response that is highly specific for the type of antibiotic used and thus 
for the type of damage, showing virtually no overlap between the different antibiotics (Figure 2B). This is 
also visible when the data is sorted based on gene ontology (GO) groups. Both 4 hours after treatment and 
24 hours after treatment provide a very specific stress fingerprint (Figure 3). For M. tuberculosis, the gene 
ontology groups overlap more between antibiotics (Figure S4). An explanation for this might be, as 
observed with the ciprofloxacin induction kinetics as well, the difference in growth speed between the two 
species. M. marinum has a relatively short generation time of 4 to 6 hours, as compared to approximately 
20-24 hours for M. tuberculosis. From these combined data, we conclude that M. marinum is better suited 
to examine specific stress response in order to evaluate the mode of action of new antibiotics.  
 
Constructing reporter strains based on the M. marinum antibiotic stress responses 
  Because M. marinum seems to mount a more rapid and specific stress response to a specific type 
of antibiotic, we decided to construct stress reporters based on the generated dataset of M. marinum in 
response to antibiotics. Subsequently, we assessed their functionality in this model organism. Genes were 
selected based on the induction levels for a specific antibiotic, exclusively responding to that antibiotic 
and also on the total RNA levels upon induction, to ensure that the promoter strength is strong enough to 
produce ample levels of reporter molecules. For the response to the two antibiotics that target cell 
envelope biogenesis, i.e. EMB and INH, there was an extensive overlap in response. Therefore, we 
decided to allow an overlap in induction for only these two antibiotics. A literature search was performed 
to exclude that the selected genes were also expressed upon exposure to environmental stresses or host 
signals like hypoxia, starvation or during macrophage infection (Karakousis et al. 2004; Bacon et al. 
2004; Voskuil et al. 2004; Betts et al. 2002; Schnappinger et al. 2003). In total, we selected 10 genes and 
cloned the promoters in front of a reporter gene encoding fluorescent GFP variant mEos3.2. The genes 
selected included responders to rifampicin (2), ciprofloxacin (2), streptomycin (3) and isoniazid (3). The 
selected genes can be found in table 1. Of these genes, only three produce proteins that have been 
previously described in literature: hflX, found to be upregulated by streptomycin, is a GTPase that 
functions as a ribosome-binding protein in E. coli (Ghosh et al. 2016); eis, an acetyltransferase was 
induced by streptomycin and secreted during macrophage infection (Shin et al. 2010); and lastly, the gene 
mmpR5, that encodes a regulator of the efflux components MmpL5 and MmpS5, was found to be induced 
by INH (Hartkoorn et al. 2014).We included the previously published iniBAC reporter for EMB/INH, 
which served as a positive control in the subsequent experimental procedures (Boot et al. 2016).  
 
Flow cytometry confirms the functionality of MMAR_2946, MMAR_1007 and MMAR_4645 stress 
reporters 
  To confirm that the stress reporters were functional, flow cytometry experiments were performed. 
In these assays, a triplicate of cultures was followed over time and fluorescence induction was measured 
after the addition of antibiotics. Of the 10 stress reporters, three were found to have a reproducible 
upregulation upon antibiotic exposure that could be measured by flow cytometry (Figure S5). A modest 
upregulation was seen for MMAR_1007, which responds to isoniazid (Figure 4A). When corrected for the 
control, MMAR_1007 was upregulated 1.7 fold (Figure 4B). Flow cytometry analysis of the MMAR_2946 
reporter revealed that the reporter has a high background fluorescence. However, upon addition of 1x MIC 
streptomycin, there was a reproducible 3-fold induction three days after treatment (Figure 4B). 
MMAR_4645 was the highest induced stress reporter, with an upregulation of 34-fold after one day of 
ciprofloxacin treatment. The reporter further induced to a maximum of 46-fold after 2 days (Figure 4B). 
The strain showed a low background signal and a clear fluorescence induction after addition of antibiotics. 
In conclusion, we managed to construct functional stress reporters for ciprofloxacin, isoniazid and 
streptomycin-induced stresses in M. marinum.  
 
MMAR_4645 is a functional stress reporter in RAW macrophages  
  The next step in the characterization of the stress reporters was to monitor induction in vitro in a 
cell infection assay. For this analysis RAW macrophages were used to test the three newly generated 
reporter strains. As a control, we included the iniBAC reporter (Boot et al. 2016). RAW cells were 
infected with the four different reporter strains and treated with the corresponding inducing antibiotic. 
Subsequently, cells were analyzed by flow cytometry 1 day post infection (dpi), as well as 2 dpi. The 
reporter MMAR_4645 was clearly induced after 48 hours, showing a more than two-fold increase in the 
median fluorescence intensity (Figure 5A). The streptomycin reporter, MMAR_2946, also showed minor 
upregulation upon antibiotic treatment (Figure 5B). The reporter for MMAR_1007 was tested with both 
EMB and INH and showed a minor upregulation upon treatment after 1 or 2 days (Figure 5C). However, 
both MMAR_1007 and MMAR_2946 also showed increased fluorescence over time in untreated cells, 
indicating a non-specific induction response in presence of host cells. The iniBAC reporter showed a 
steady increase in fluorescence for both EMB and INH (Figure 5D). This is in line with our previously 
published results (Boot et al. 2016). In conclusion, our ciprofloxacin (MMAR_4645) reporter works in cell 
infection studies, albeit at significantly reduced levels as compared to induction in culture.  
 
Screening a compound library with 190 anti-mycobacterial compounds 
  To provide proof of concept that these stress reporters can be used to accelerate drug discovery, 
we tested a compound library of potential anti-TB drugs against two of our reporter strains in a 96-wells 
format. The library we used was a selection of compounds that showed activity against M. bovis BCG and 
were identified in two separate high-throughput screens from a library of over 2 million compounds 
(Ballell et al. 2013;Rebollo-Lopez et al. 2015). Because the MIC values obtained from the paper were for 
M. bovis BCG instead of M. marinum, we first tested the 190 compounds in three concentrations 10 µM, 1 
µM and 0.1 µM. After 5 days incubation, resazurin was added and M. marinum cell viability was 
measured on day 6. At a concentration of 10 µM 46% (87/190) of the compounds reached their MIC90. As 
a reference, we performed the same experiment with M. tuberculosis H37Rv. We found that 39% (75/190) 
reached MIC90 after 7 days of incubation in our setup. Although these numbers are significantly lower as 
compared with the original analysis, they are comparable to the results obtained for M. marinum, again 
confirming the suitability of M. marinum as a model for M. tuberculosis.. Next, we tested the complete set 
of compounds on our reporter strains, including the compounds that did not show antimicrobial activity in 
our first assay. In the initial screening, we found one compound that induced the stress reporter for 
MMAR_4645 in one out of two experiments, and six compounds that induced iniBAC in both experiments 
(data not shown). Upon retesting the compounds that induced the iniBAC reporter, we found two 
reproducible hits: YML-G12 induced iniBAC at 1µM and 2 µM and YMM-C1 at 5 µM and 10 µM. 
(Figure 6A). Interestingly, when we compared stress induction with MIC levels, we noticed that 
compound YMM-C1 does induce the iniBAC reporter, but did not affect growth of M. marinum at these 
concentrations. Apparently, this compound is already inducing the iniBAC stress system at levels of 
compound that are significantly below the MIC value. Compound YML-G12 behaved more as expected, it 
induced the iniBAC reporter at lower concentration (1.25 and 2.5 µM) and showed growth inhibition at the 
at a concentration of 5 µM (Figure 6B).  
  In our first analysis, compound YMM-G4 induced the MMAR_4645 reporter close the limit of 
detection of our 96-wells reporter assay. Therefore, we decided to retest this compound in a small culture 
and measure the induction with flow cytomtery. We confirmed that the compound induced the stress 
reporter to about 6-fold on day 3 at 10 µM. (Figure 7A). We subsequently tested three different 
concentrations (0.1µM, 1 µM and 10 µM ) and observed a dose-dependent induction of the MMAR_4645 
reporter over time, to a maximum induction of 2-fold at 1 µM and 6-fold at 10 µM . In conclusion, we 
found 2 compounds that induce the iniBAC reporter as well as 1 compound that induced our ciprofloxacin 
reporter, MMAR_4645. This confirms that our stress reporters are functional in discovering compounds 
with unknown MoA.  
 
Discussion 
  In this study, the first comprehensive transcriptional dataset is presented for both M. marinum and 
M. tuberculosis in response to clinically relevant antibiotics. The datasets suggest that M. marinum 
displays a clear stress fingerprint in response to treatment. This fingerprint is unique for each type of 
damage caused by the antibiotic that was used.  
 The SOS response is activated in response to DNA damage, and specifically double strand DNA 
breaks (Witkin 1976; Sassanfar & Roberts 1990). The SOS regulon is the collective name for a group of 
around 40 genes that is induced to repair double strand breaks that follow upon UV damage or treatment 
with DNA damaging agents or gyrase inhibitors such as mitomycin C or fluoroquinolones (Movahedzadeh 
et al. 1997; Dos Vultos et al. 2009). Key components of the response are RecA, the SOS activator protein 
that binds the damaged DNA. After binding damaged DNA, RecA cleaves the SOS-response repressor 
LexA to activate transcription of the LexA-dependent SOS regulon members (O’Sullivan et al. 2008; Dos 
Vultos et al. 2009). However, contrary to model organism E. coli there are also several examples of genes that 
seem to be activated in a RecA-independent manner in M. tuberculosis (Rand et al. 2003). In this study, 
we found a major transcriptional overlap in the response of M. marinum and M. tuberculosis to 
ciprofloxacin (Figure 2). However, some genes that were already upregulated at 4 hours for M. marinum 
showed a delayed induction in M. tuberculosis. Examples of these are SOS-response genes ruvC and 
dnaE2, both upregulated at 24 hours upon ciprofloxacin treatment for M. tuberculosis, but already clearly 
upregulated for M. marinum starting at 4 hours (see supplemental file 1). These temporal differences could 
be explained by the differences in division time for the two species, i.e. the slow-growing M. marinum has 
a relatively short generation time of 4 to 6 hours, compared to approximately 20-24 hours for M. 
tuberculosis. This growth difference perhaps also explains a more general stress response that is observed 
in M. tuberculosis as opposed to a more specific stress fingerprint in M. marinum.  
  Remarkably, we do not see any specific genes up-regulated for the EMB samples in M. marinum. 
Only three genes (the iniBAC genes) are significantly upregulated, but these are also found for INH. For 
M. tuberculosis, we do see differential expression of EMB-specific genes (23 genes upregulated). The 
orthologous genes (20/23) of these in M. marinum do not show this upregulation (supplemental file 1). 
The lack of EMB-induced genes in M. marinum may be explained by the fact that EMB causes an early 
onset of the bacteriostatic effect that rapidly halts transcription and possibly degrades mRNA pools. 
However, another explanation might be that the concentration of EMB that we used was too low. As a 
result, the stress levels might have been insufficient to cause significant transcriptional changes, even 
though the iniBAC system was induced.  
   In our study, we describe three newly identified functional stress reporters that respond to 
DNA damage (ciprofloxacin), inhibition of protein translation (streptomycin) and cell wall damage 
(isoniazid). The promoters are those of genes MMAR_4645, MMAR_2946 and MMAR_1007, respectively. 
MMAR_4645 is annotated as a conserved cytosolic protein. Its homologue in M. tuberculosis, Rv0887c is 
regulated by the gene product of Rv3249c. The gene is not predicted to be regulated by the SOS regulon 
and seems to be a novel and unidentified player in the stress response to DNA damage. Phyre2 predictions 
show that the gene likely encodes a glyoxylase. The H37Rv homologue of MMAR_1007, Rv0678, encodes 
the transcriptional regulator MmpR5. This regulator has been found to regulate both Mmps5 and MmpL5, 
a complex that is likely involved in the transport of large molecules. It has been shown that mutations in 
the mmpR5 promoter lead to overexpression of the pump counterparts, which subsequently leads to 
increased clofazimine and bedaquiline resistance in mycobacteria (Radhakrishnan et al. 2014; Hartkoorn 
et al. 2014). However, a role in isoniazid resistance has not been reported previously. Lastly MMAR_2946 
encodes a short protein of unknown function that is not conserved in M. tuberculosis, but can be found in 
M. kansasii, M. abscessus, Nocardia spp and Streptomyces spp (NCBI protein blast). Phyre2 predictions 
show that the protein structure is highly similar conserved protein found in Corynebacterium diptheriae 
(41% amino acid identity), which unfortunately, has no known function. In M. marinum, this gene is 
highly and specifically expressed upon addition of STR, making it a promising tool to study ribosomal 
inhibition in M. marinum.   
  We found that the reporters work well in bacterial culture, but in our micro-titer plate assays only 
MMAR_4645 and iniBAC could be used as a functional reporters to identify the MoA of new 
antimycobacterial compounds. Upon screening a small compound anti-TB drug library of 190 compounds, 
we identified two compound hits with our iniBAC reporter: YML-G12 (GSK3011724A) and YMM-C1 
(GW623128X). Both compounds have been described previously. GSK3011724A is targeting KasA, an 
enzyme required for the synthesis of long-chain fatty acids (Abrahams et al. 2016), whereas GW623128X 
is a compound that was shown to be effective in both cultured M. tuberculosis as well as in macrophage 
infection. Upon retesting of one alleged compound hit for the MMAR_4645 reporter with flow cytometry, 
we identified that YMM-G4 (GSK1519001B) induces the reporter in a dose-dependent manner. This 
compound has not been described previously and predict that this compound will (indirectly) induce DNA 
damage in mycobacteria.  
 Only a subset of selected stress reporters were functional (3 out of 10). One explanation for this 
relatively low success rate is that we did not include, both activating and repressing, regulatory elements 
in our cloning strategy. Therefore it is possible that there is no transcription of the fluorescent reporter due 
to repression or lack of transcriptional activation. Finally, we also produced reporters that were designed 
to respond to rifampicin and streptomycin, antibiotics that inhibit the transcriptional inhibition and 
ribosomal inhibition, respectively. Therefore, the production of stress reporter for these antibiotics is 
probably highly precarious, as gene transcription and translation is required for reporter synthesis.  
  In summary, we present a large RNA sequencing dataset that includes the responses to sub-lethal 
amounts of the currently used anti-TB drugs. With this, we hope to provide the TB community insights 
into the bacterial stress responses that follow on treatment as well as tools to aid MoA identification to 
speed up TB drug discovery. 
 
Material & methods 
Bacterial strains, plasmids and culturing conditions 
  Constructed plasmids were propagated in E. coli ST08 (Clontech). E. coli cultures were inoculated 
in standard LB and incubated at 37°C with the addition of hygromycin (50µg/ml). M. marinum wild type 
MUSA , as described by Abdallah et al.(Abdallah et al. 2006), was used for all the M. marinum 
experiments. Mycobacterial cultures were grown in Middlebrook 7H9, supplemented with Middlebrook 
ADC and 0,05% Tween-80. Both mycobacterial cultures and plates were grown at 30°C. Antibiotics were 
added where indicated. 1x MIC concentrations used for RNA isolation experiments and flow cytometry 
experiments were: 1 µg/ml for ciprofloxacin, 1 µg/ml for ethambutol, 10 µg/ml for isoniazid, 2 µg/ml for 
streptomycin, and 1 µg/ml rifampicin for M. marinum (all purchased from sigma). For M. tuberculosis 
these values were: 0.5 µg/ml for ciprofloxacin, 1 µg/ml for ethambutol, 0.05 µg/ml for isoniazid, 0.5 
µg/ml for streptomycin, 0.25 µg/ml for rifampicin and 50 µg/ml for pyrazinamide. RAW264.7 mouse 
macrophages were cultured in DMEM with 10% fetal bovine serum (Gibco) and Glutamax (Gibco). RAW 
cells were grown in 37 °C with 5% CO2.  
 
RNA preparation for Illumina Sequencing 
  RNA isolation was performed with a NucleoSpin® RNA kit (Machery Nagel). In total 25 OD 
units were spun down and used for isolation per sample. RNA was isolated from a biological triplicate of 
cultures. There was one deviation to the first step of the protocol with regards to lysis of the mycobacterial 
cells. Cells were disrupted by 0.1 mm zirconium beads in 500 µL Buffer RA1 and 5 µL ß-mercaptoethanol 
for 1 minute. Subsequent steps were performed according to the protocol provided by the manufacturer. 
After RNA isolation, RNA concentrations were measured. RNA integrity numbers (RIN) were determined 
with a bioanalyzer 2100 expert (Agilent). The RIN value was measured for one sample per triplicate. All 
RIN values were >9. As ribosomal RNA comprises the vast majority of the extracted RNA population, 
depletion of these molecules through RiboMinus-based rRNA depletion was used in efforts to increase the 
coverage of mRNA and to reduce rRNA reads. For this mRNA enrichment, the Invitrogen's 
RiboMinusTM Prokaryotic kit was used according to manufacturer's instructions. Briefly, 2 µg of total 
RNA samples was hybridized with prokaryotic rRNA sequence-specific 5′-biotin labeled oligonucleotide 
probes to selectively deplete large rRNA molecules from total RNA. Then, these rRNA-hybridized, 
biotinylated probes were removed from the sample with streptavidin-coated magnetic beads. The resulting 
RNA sample was concentrated using the RiboMinusTM concentrate module according to the 
manufacturer's protocol. The final RiboMinusTM RNA sample was subjected to thermal mRNA 
fragmentation using Elute, Prime, and fragment Mix from the Illumina TruSeqTM RNA sample 
preparation kit v2 (Low-Throughput protocol). The fragmented mRNA samples were subjected to cDNA 
synthesis using the Illumina TruSeqTM RNA sample preparation kit (Low-Throughput protocol) 
according to manufacturer's protocol. Briefly, cDNA was synthesized from enriched and fragmented RNA 
using SuperScript III Reverse Transcriptase (Invitrogen) and SRA RT primer (Illumina). The cDNA was 
further converted into double stranded DNA using the reagents supplied in the kit, and the resulting 
dsDNA was used for library preparation. To this end, cDNA fragments were end-repaired and 
phosphorylated, followed by adenylation of 3′ends and adapter ligation. Twelve cycles of PCR 
amplification were then performed, and the library was finally purified with AMPure beads (Beckman 
Coulter) as per the manufacturer’s instructions. A small aliquot (1 µl) was analyzed on Invitrogen Qubit 
and Agilent Bioanalyzer. The bar-coded cDNA libraries were pooled together in equal concentrations in 
one pool before sequencing on Illumina HiSeq2000 using the TruSeq SR Cluster Generation Kit v3 and 
TruSeq SBS Kit v3. Data were processed with the Illumina Pipeline Software v1.82. 
 
Analysis of RNA sequencing data 
  Sequencing read quality was assessed using FASTQC tool. Trimming of Illumina adaptor 
sequences and low quality reads were done using Trimmomatic (v 0.33) and quality assessed again 
(Bolger et al. 2014). Quality trimmed read sequences were mapped to M. tuberculosis H37Rv and M. 
marinum MUSA reference genomes using BWA (Cole et al. 1998; Stinear et al. 2008; Li et al. 2009). Gene 
expression estimates were made as raw read counts using the Pyhton script ‘HTSeq- count’ (model type – 
union). Counts data were converted to counts per million (cpm) and genes were filtered if they failed to 
achieve a cpm value of 1 in at least 30% of libraries per conditions. Normalization of raw read counts and 
differential expression analysis was performed using DeSeq2 (Love et al. 2014). Genes with fold change ≥ 
2 and FDR value ≤ 0.05 were considered as differentially expressed. M. tuberculosis and M. marinum 
gene ontology terms were downloaded from UniProt gene ontology annotation database 
(https://www.ebi.ac.uk/GOA). Gene ontology enrichment analysis was performed on differentially 
expressed genes using GOstats R package (Huber et al. 2007). Comparison of differentially expressed 
genes in different conditions and visualization was carried out using online tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/).  
 
Construction of reporter plasmids 
  The primers that were used to amplify the promoter regions from M. marinum MUSA gDNA can be 
found in supplementary table 1. For all 10 created stress reporters the promoter region was amplified with 
primers that contained a 15-bp overlap with the target vector. iProof 2x master mix (Bio-Rad) was for 
PCR. The PCR products were loaded on gel and purified. The target vector, a pSMT3-iniB4-mEos3.2 
(Boot et al. 2016), was digested with XbaI and BamHI, loaded on gel, excised and gel purified as well. 
InFusion (Clontech) was used according to manufacturer’s protocol to ligate the obtained promoter 
regions into the target vector. Plasmids were transformed by heat shock to E. coli and plasmids were 
isolated and digested to control for the correct insert. All obtained stress reporter sequences were 
confirmed by sequencing of the appropriate region (Macrogen).  
 
Flow cytometry analysis  
  Fluorescence induction of the reporter strains was assessed on a BD Accuri C6 flow cytometer 
from BD biosciences. For these experiments the reporter strains were grown in 7H9 to a logarithmic 
growth phase and diluted to an OD of 0.2. Antibiotics were added where indicated at 1x MIC. At the 
indicated time intervals or time points 1ml of culture was spun down, washed and resuspended in PBS 
+0.05% Tween-80. Flow cytometry analysis was performed with a 488 nm laser and 530/30 nm filter for 
mEos3.2. Per sample, 30.000 gated events were analyzed per time point and data was analyzed and 
visualized using BD CFlow software and Graphpad Prism 6. Fold inductions were calculated routinely by 
dividing the mean fluorescence intensities (MFI) of the treated samples by the MFI of untreated controls. 
 
RAW cell infection assay 
  For RAW cell infection, 2 × 104 cells per well were seeded in 12-wells (Corning) and grown for 4 
days to a confluency of 70%. The M. marinum reporter strains were grown to an OD600 of 0.8-1 and 
washed in DMEM + 10% FBS prior to infection. Bacterial cells were subsequently added at a multiplicity 
of infection of 2. RAW cells were incubated at 33 °C After three hours, extracellular mycobacteria were 
removed by washing 3 times with DMEM. Amikacin was added to a concentration of 200 µg/ml for 3 
hours to kill any remaining extracellular mycobacterial cells. Cell were then washed and the indicated 
antibiotics were added at their appropriate concentration. This point was considered time point 0h, and 
cells were subsequently harvested at 0, 24, 48, and 72 hpi. RAW cells were harvested by addition of 
trypsin (Sigma). Infected cells were spun down at 1000 x g washed with DMEM and resuspended in PBS 
for flow cytometry analysis.  
 
Micro-titer plate reporter assays and resazurin micro-titer plate Assay 
  The reporter strains of M. marinum as well as M. tuberculosis H37Rv (table 1) were grown in 
Middlebrook 7H9 medium (Difco) supplemented with 10% ADS (0.5% albumin, 0.2% glucose, 0.085% 
NaCl), 0.2% glycerol and 0.05% tween-80 to mid-logarithmic phase and harvested by centrifugation. The 
cells were washed with 120 mM NaCl, tyloxapol 0.02% and filtered (pore size 5 µm) to remove cell 
aggregates. The OD600 was adjusted to 0.002 and 100 µL of the cell suspension was added to wells of a 
96-well plate containing 100 µL of medium with screening compound at two-fold of the final screening 
concentration. The lids of the plates were sealed with tape and the plates were incubated static for five 
days at 30°C for M. marinum and 7 days at 37°C for M. tuberculosis. The fluorescence of the stress 
reporters was determined using a plate reader (Biotek, excitation: 485 nm, emission: 528 nm, bottom-
reading mode). Afterwards, the bacterial viability was determined using the Resazurin Microtiter Assay 
(REMA). To each well 25 µL of development solution (200 µM resazurin, 10% tween-80) was added and 
the plates were incubated overnight at 30°C for M. marinum or 37°C for M. tuberculosis. The 
fluorescence was determined with using a plate reader (Biotek, excitation: 560 nm, emission: 590 nm, 
bottom-reading mode). Percent viability was defined as (test well FU/mean FU of triplicate drug-free 
wells) x 100 %. The lowest drug concentration inhibiting viability by ≥ 90% was considered the MIC. 
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 Figure 1. RNA sequencing results for ciprofloxacin match with previously published data. The 
correlation between M. tuberculosis and M. marinum is shown for known members of the SOS regulon. 
A) The 4 hour responses of M. marinum to ciprofloxacin and the untreated control and the ciprofloxacin-
treated M. tuberculosis with its corresponding control were compared with previously published results of 
Smollet et al. and O’Sullivan et al. B) same but for the 24 hour time point. A red colour indicates 
upregulation, whereas green indicates downregulation.. Only genes that have an orthologue in both 
species were selected based on the publication of Smollet et al. and O’Sullivan et al.  
 
 Figure 2. The overlap in up- and downregulated genes for both M. tuberculosis and M. marinum. 
Combined Venn diagrams were made based on combined (4 and 24 hours after treatment) transcriptional 
responses. A) Number of genes for M. tuberculosis that are upregulated (left panel) or downregulated 
(right panel). B) Number of genes for M. marinum that are upregulated (left panel) or downregulated 
(right panel). Colors indicate the antibiotic with CIP (blue), EMB (brown), INH (red), RIF (green and 
STR (yellow)  
 Figure 3. M. marinum shows a specific stress fingerprint for each type of antibiotic. The stress 
fingerprint of M. marinum visualized per antibiotic for selected GO terms. The type of gene product that a 
gene encodes determines the GO-term. The size of the dot indicates the P-value. The color of the dot 
indicates the Log2 value odds ratio.The X-axis indicates the antibiotic that was used as well as the time 
point. 
 Figure 4. Three separate reporters for DNA damage, inhibition of cell wall damage or ribosomal stress are functional. A) A representative 
plot of the responses of MMAR_4645 (CIP, black), MMAR_2946 (STR, orange) and MMAR_1007 (INH, red) over time. The mean fluorescence 
intensity (MFI) of the treated stress reporters was corrected for by deduction of the corresponding untreated stress reporter MFIs. MFIs, 
representing mEos3.2 levels, are indicated on the Y-axis. B) The fold inductions were calculated relative to the to the corresponding untreated 
parent reporter strain culture (MFI treated divided by MFI untreated). Experiments were performed in triplicate. Standard deviations are indicated 
with the error bars.  
 Figure 5. MMAR_4645 is a functional stress reporter in RAW macrophages Mean fluorescence 
intensities of stress reporters were analyzed in a RAW macrophage cell infection assay, over two days of 
infection. Bars represent 1 representative measurement of 30.000 cells per time point. A) The 
MMAR_4645 reporter was tested with 1x MIC ciprofloxacin (CIP). B) The MMAR_2946 reporter was 
tested with 1x MIC streptomycin (STR) C) The MMAR_1007 reporter was tested for induction with 1x 
MIC ethambutol (EMB) and isoniazid (INH) and D) the previously published iniBAC reporter was used as 
a positive control for induction (with both 1x MIC EMB and INH) 
 
 Figure 6. Two compounds show induction of the iniBAC reporter. In total, six compounds were 
selected for additional induction experiments in a concentration range from 0.1 – 10 uM. The names of the 
compounds can be found in the legend. A) the fold induction of the iniBAC reporter for the six tested 
compounds. Fold induction was calculated by dividing the mean fluorescence intensity (MFI) of the 
treated sample by the MFI of untreated controls B) The bacterial viability for the range of concentrations 
that were used. The viability was determined with a REMA assay (see material & methods). The 
percentages indicate the fraction of fluorescence compared to growth controls.
 Figure 7. Compound YMM-G4 (GSK1519001B) induces the ciprofloxacin reporter in a dose-
dependent manner. Cultures were treated with 0.1 µM, 1 µM or 10 µM of compound YMM-G4 and 
compared to an untreated culture of MMAR_4645 to compare relative fluorescence intensities of mEos3.2. 
A) A flow cytometry histogram of 30.000 gated cells per condition comparing untreated (black) to a 
culture treated with 1 µM or 10 µM of compound. There is a concentration-dependent shift of the peak. B) 
Fold induction over time for the three different concentrations. Fold induction was calculated by dividing 
the mean fluorescence intensity (MFI) of the treated sample by the MFI of untreated controls. Error bars 
indicate standard deviations. The experiments were performed in triplicate. 
 
 
 
 
 
 
 
 
 
Gene H37Rv 
orthologue 
Induced by 
(antibiotic): 
Fold induction 
compared to NT 
Gene 
product 
name 
MMAR_0614* Rv0341 EMB/INH 100/381 IniB 
MMAR_1007 Rv0678 INH 2 MmpR5 
MMAR_1988 Rv2725c STR 11 HflX 
MMAR_2308 - RIF 70 MMAR_2308 
MMAR_2352 Rv1517 RIF 10 MMAR_2352 
MMAR_2389 Rv1592c INH 7 MMAR_2389 
MMAR_2946 - STR 24 MMAR_2946 
MMAR_3740 Rv2416c STR 50 Eis 
MMAR_4413 Rv1057 INH 5 MMAR_4413 
MMAR_4645 Rv0887c CIP 51 MMAR_4645 
MMAR_4658 - CIP 112 MMAR_4658 
 
Table 1. Selected genes for stress reporter construction. Indicated are the MMAR gene numbers, the 
H37Rv orthologues (if present), the antibiotic that was found to induce the gene in M. marinum. The fold 
inductions were calculated by dividing the transcript levels of the antibiotic induced sample to the 
untreated samples. The gene product name is indicated in the last column. * indicates a previously 
constructed reporter (Boot et al. 2016).  
 Figure S1. Cultures stressed with antibiotics show a slight growth defect. OD600 values over time of 
the triplicate of M. marinum cultures that were used as basis for RNA isolation. The standard deviation is 
indicated by the error bars. The control without antibiotic is marked - (black). 
 Figure S2. The RNA sequencing results are highly reproducible. The reproducibility of the data for the triplicate of RNA samples is indicated 
for both A) M. tuberculosis and B) M. marinum. Correlation between the samples is indicated by the colored scale bar. A positive correlation is 
visualized by a dark blue color. 
  
Figure S3. The transcriptional responses for ciprofloxacin are highly reproducible. The reproducibility of the data for the triplicate samples 
for ciprofloxacin for both A) M. tuberculosis and B) M. marinum. A positive correlation is visualized by a blue color. A scale bar indicating the 
correlation values is placed next to the figure. Both control (ctrl) as well as ciprofloxacin (cip) samples are included. 
  
Figure S4. M. tuberculosis shows a less defined stress fingerprint for each type of antibiotic. The 
stress fingerprint of M. tuberculosis visualized per antibiotic for selected GO terms. The type of gene 
product that a gene encodes determines the GO-term. The size of the dot indicates the P-value. 
  
 
Figure S5. Fluorescence responses of the ten stress reporter strains in M. marinum. Ten stress 
reporters were monitored over the course of three days. The mean fluorescence intensity (MFI) of the 
treated stress reporters was corrected by deducting the corresponding untreated stress reporter induction 
levels. MFIs (mEos3.2 levels) are indicated on the Y-axis. The colors indicate the type of antibiotic: 
ciprofloxacin (red), ethambutol (blue), isoniazid (orange), streptomycin (green) and rifampicin (purple). 
 
 
 
 
 
 
Primer name Sequence 5' > 3' 
Mmar_2352FW  TGGCGGCCGCTCTAGAGGCGCCGAGAACTCGAAC 
Mmar_2352RV GTGATTCCTCGGATCCACCGCCGAACCAGAATGC 
Mmar_2308FW TGGCGGCCGCTCTAGAAGCACCAGCGCCAGC 
Mmar_2308RV GTGATTCCTCGGATCCGGTCAGCCAAGTTACCTGCAAC 
Mmar_4645FW TGGCGGCCGCTCTAGACCGAGGGGAACAAAAGGCA 
Mmar_4645RV GTGATTCCTCGGATCCGAAAGTCTCCTTGCTGTTGGTTTCC 
Mmar_4658FW TGGCGGCCGCTCTAGAGGCTGTCACCATCCCCAC 
Mmar_4658RV GTGATTCCTCGGATCCGCCGACACGGTGCCT 
Mmar_2389FW TGGCGGCCGCTCTAGAGCGCTGCGCCCTCCA 
Mmar_2389RV GTGATTCCTCGGATCCTCTCGCGCACGATCCATCC 
Mmar_1988FW TGGCGGCCGCTCTAGAGTGACCGCCGCGCGTG 
Mmar_1988RV GTGATTCCTCGGATCCCAGATCAGGTTACGTGCCGC  
Mmar_3740FW TGGCGGCCGCTCTAGAGGCCGTGTGCGTACACAC 
Mmar_3740RV GTGATTCCTCGGATCCGGGCTCCGACTCTGGCAC 
Mmar_2946FW TGGCGGCCGCTCTAGAGTCAGCTGCTGCAGCCT 
Mmar_2946RV GTGATTCCTCGGATCCAATCCCTGCTCCTCAGTTCG 
Mmar_1178FW TGGCGGCCGCTCTAGAGCCGTCGCTGCGGCGG 
Mmar_1178RV GTGATTCCTCGGATCCGCTTGCTCCCATCGGATTTGG 
Mmar_5163FW TGGCGGCCGCTCTAGAACCGCCAACTCCAGCG 
Mmar_5163RV GTGATTCCTCGGATCCGGCTTCGAATCAACACCAGGTC 
Mmar_1007FW TGGCGGCCGCTCTAGAAACCGGCGATCGCGAC 
Mmar_1007RV GTGATTCCTCGGATCCAAGTTTCACTGTACTCTGAAACCTTAGTAGATTT 
Mmar_4413FW TGGCGGCCGCTCTAGAGCCCGCCGTTGCCTCA 
Mmar_4413RV GTGATTCCTCGGATCCGCTGGCACCGCCTTTG 
 
Table S1. All primers used in this study 
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Abstract 
Cytochrome bd is a component of the oxidative phosphorylation pathway in many Gram-positive and 
Gram-negative bacteria. Next to its role as a terminal oxidase in the respiratory chain this enzyme plays an 
important role as a survival factor in the bacterial stress response. In Mycobacterium tuberculosis and 
related mycobacterial strains, cytochrome bd is an important component of the defense system against 
antibacterial drugs. In this report we describe and evaluate an mCherry-based fluorescent reporter for 
detection of cytochrome bd expression in Mycobacterium marinum. Cytochrome bd was induced by 
mycolic acid biosynthesis inhibitors such as isoniazid and most prominently by drugs targeting oxidative 
phosphorylation. We observed no induction by inhibitors of protein-, DNA- or RNA-synthesis. The 
constructed expression reporter was suitable for monitoring mycobacterial cytochrome bd expression 
during mouse macrophage infection and in a zebrafish embryo infection model when using 
Mycobacterium marinum. Interestingly, in both these infection models cytochrome bd levels were 
considerably higher than during in vitro culturing of M. marinum. The expression reporter described here 
can be a valuable tool for elucidating the role of cytochrome bd as a survival factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
In the oxidative phosphorylation pathway the respiratory chain transfers electrons derived from NADH or 
other reduced shuttle molecules onto oxygen. Coupling redox reactions to proton transport, the respiratory 
chain complexes establish a proton motive force across a biomembrane, which is subsequently utilized by 
ATP synthase for synthesis of ATP. The terminal oxidases catalyze the final step in the respiratory chain, 
the reduction of molecular oxygen. Cytochrome bd is such a terminal oxidase and is found in many 
prokaryotes1. Although cytochrome bd can contribute to the proton motive force, it is energetically less 
efficient than other terminal oxidases, such as cytochrome bo or cytochrome aa3-type oxidases1. 
Therefore, cytochrome bd typically becomes important under conditions that limit the function of these 
other terminal oxidases. For instance, cytochrome bd is required for respiration under low oxygen tension2 
and in the presence of nitric oxide3-5 peroxynitrite6, and hydrogen sulfide7 in Escherichia coli. Moreover, 
E. coli cytochrome bd plays a central role in the defense against hydrogen peroxide8 and is strongly 
induced upon genetic knock-out of ATP synthase9. As such, cytochrome bd can be regarded as an 
important component of the bacterial stress response8. 
In mycobacteria, cytochrome bd is found among both fast-growing as well as slow-growing 
strains. Mycobacterium tuberculosis employs a branched respiratory chain, one branch comprises the 
cytochrome bc1 complex together with a cytochrome aa3-type terminal oxidase, while the other branch 
employs cytochrome bd as terminal oxidase10. In M. tuberculosis and related mycobacterial strains a 
knock-out of cytochrome bd does not influence growth under standard growth conditions11-13. However, 
mycobacterial cytochrome bd is upregulated under hypoxia9, in the presence of nitric oxide14 and during 
the transition from replicating state to non-replicating persistence14. Mycobacterial cytochrome bd is also 
important when the parallel cytochrome bc1 respiratory chain branch is inactivated15-18. In recent years, it 
has become clear that mycobacterial cytochrome bd also plays an important role in survival in the 
presence of antibiotics. Transcriptional and proteomic studies have revealed that cytochrome bd was 
strongly induced by the ATP synthase inhibitor bedaquiline in M. tuberculosis19, and in Mycobacterium 
smegmatis20. Interestingly, M. tuberculosis strains lacking cytochrome bd displayed enhanced sensitivity 
for bedaquiline12 and cytochrome bc1 inhibitors17,21,22. A cytochrome bd knock-out in M. smegmatis was 
found hypersensitive for bedaquiline13,20 and for the type-II NADH dehydrogenase effector clofazimine13. 
Clofazimine also induced cytochrome bd transcription in M. tuberculosis23. These results identified 
cytochrome bd as an important survival factor in the presence of antibiotics and indicate that this enzyme 
can be an efficient drug target.  
To gain insight into the role of cytochrome bd as a survival factor it is important to assess which 
antibacterial drugs and other stressors trigger induction of cytochrome bd. To this end, reliable molecular 
markers are required that are easy to handle and provide information on cytochrome bd expression in real-
time. Previously, genetic reporters to monitor the expression of the iniBAC operon have been constructed 
and used for characterization of the mycobacterial cell wall stress response upon treatment with 
ethambutol and isoniazid24. These transcriptional fusions of a promoter and a gene encoding a fluorescent 
reporter proved to be successful in following operon induction kinetics as well as assessment of the mode 
of action of new drugs (M. Boot et al., in preparation). In this study we employ this approach and 
construct a molecular reporter as a tool for monitoring mycobacterial cytochrome bd gene expression in 
response to antibacterial compounds and during infection. 
 
Results 
Construction of the cytochrome bd expression reporter  
  The cytochrome bd terminal oxidase consists of two main subunits, CydA (subunit I) and CydB 
(subunit II)25,26. Although the presence of a third, minor subunit has been demonstrated for cytochrome bd 
in various bacterial strains such as E. coli27,28 and Geobacillus thermodenitrificans29 our database search 
indicated no homologues of these minor subunits in the mycobacterial genome. In mycobacteria, the cydA 
and cydB genes are located in one operon under control of the cyclic AMP receptor protein30. To construct 
the cytochrome bd expression reporter we amplified the region containing the cydA promoter 
(MMAR_2426) from Mycobacterium marinum MUSA. To visualize operon induction, we placed the gene 
encoding the fluorescent protein mCherry under the control of this promoter (Figure 1A).  
  For our study we used M. marinum, a slow-growing, pathogenic mycobacterium that is genetically 
closely related to strains of the M. tuberculosis complex31. Moreover, M. marinum can be used in 
combination with the zebrafish embryo infection model, a powerful in vivo tool that has been shown to 
mimic the infection processes of M. tuberculosis accurately32,33, and can be used for anti-mycobacterial 
drug discovery34. 
 
Construction and basic characterization of the cydA expression reporter 
  M. marinum carrying the plasmid encoding mCherry under control of the cydA promoter, referred 
to as the cydA reporter strain, displayed similar growth characteristics as the parent strain (‘wild-type’) 
(Figure 1B). We confirmed that the cydA reporter strain emitted substantially higher fluorescence than the 
wild-type control during three days of culture and subsequently deducted the auto-fluorescence of the WT 
control from induction levels observed in flow cytometry experiments. Next, we assessed the induction of 
the reporter under normoxia and hypoxia (Figure 1C). The observed fluorescence was stable and did not 
increase over the course of the experiment. When cultured under low oxygen tension, we observed a small 
cydA induction over time (Figure 1C). In the presence of the nitric oxide donor DETA-NO, previously 
found to enhance cydA transcripts in M. tuberculosis14, we observed cydA induction at concentrations of 
1x MIC (125 uM) and 10x MIC (Figure 1D). These results indicate that the cydA reporter is functional.  
 
Selected antibacterials in the M. marinum/zebrafish embryo infection model  
  In order to evaluate which type of drugs trigger expression of cytochrome bd we first confirmed 
that selected antibacterials were active against M. marinum. Both front-line drugs as well as experimental 
drugs with various mechanisms of action were tested, including three drugs targeting oxidative 
phosphorylation (Table 1). The latter included the ATP synthase inhibitor bedaquiline (BDQ)35-37, the 
cytochrome bc1 inhibitor Q20338 and the type-II NADH dehydrogenase effector clofazimine (CFZ)39. 
BDQ has been approved for treatment of multi-drug resistant tuberculosis, Q203 presently is evaluated in 
phase I clinical trials, and clofazimine is already in clinical use for treatment of leprosy and presently is 
being re-purposed as anti-TB drug.  
We determined the minimal inhibitory concentrations (Table 1) and also characterized BDQ, 
Q203 and CFZ activity against M. marinum in a zebrafish embryo infection model. The zebrafish embryo 
infection model allows for real-time visualization of fluorescently labeled pathogens40,41. The colonization 
of zebrafish embryos by M. marinum is visualized by a constitutively expressed mEos3.1 variant and can 
be quantified by fluorescence microscopy40,42 (Figure 2A). BDQ prevented bacterial colonization in a 
dose-dependent manner (Figure 2B). Q203 also suppressed bacterial growth at 1x MIC, however, at 5x 
MIC and 10x MIC the compound seemed to precipitate, apparently limiting its activity (Figure 2C). At 1x 
MIC, CFZ cleared bacterial loads, whereas concentration of 5x MIC and higher were toxic for the 
zebrafish embryo host under these conditions (Figure 2D). These results show that BDQ, Q203 and CFZ 
are active against M. marinum. 
 
Cytochrome bd induction by antibacterial compounds  
  Ethambutol and isoniazid, both inhibitors of mycobacterial cell envelope biosynthesis 43,44, 
showed slight cydA induction when high concentrations were applied (10x MIC) (Figure 3). In contrast, 
the RNA polymerase inhibitor rifampicin decreased cydA expression at 10x MIC as compared with 
control samples (Figure 3). Among the second-line drugs used for tuberculosis treatment, pronounced 
cydA downregulation was observed for the protein synthesis inhibitor streptomycin at 10x MIC (Figure 3), 
and for the DNA gyrase inhibitor ciprofloxacin at 10x MIC (Figure 3). Next, we tested drugs active on 
three distinct targets in the oxidative phosphorylation pathway. As depicted in Figure 4, all three drugs, 
BDQ, CFZ and Q203, significantly induced cytochrome bd expression at 1x MIC and 10x MIC (Figure 3). 
These data reveal that inhibitors with different mechanisms of action can induce cydA expression, but 
induction was most prominent in response to inhibitors of oxidative phosphorylation. We confirmed the 
validity of the cydA reporter by quantitative reverse-transcription PCR, which clearly showed increased 
levels of cydA transcripts in the presence of inhibitors of oxidative phosphorylation (Supplementary 
Figure 1). As these three drugs are slow-acting and display only minimal kill of M. tuberculosis in the first 
2-3 days of treatment 19,38,45, we subsequently investigated time- and concentration dependency of cydA 
expression in more detail for these drugs. 
 
Time- and concentration dependency of cydA induction 
  For the ATP synthase inhibitor BDQ, cytochrome bd induction increased from 2.3 fold at day 1 to 
4.5-fold at day 2 of treatment, with only marginal changes between day 2 and day 3 time points (Figure 
4A). For this drug, maximal induction was achieved at 1x MIC and induction dropped at elevated 
concentrations (10x MIC and 100x MIC) at all three time points investigated (Figure 4A). For the 
cytochrome bc1 inhibitor Q203 cydA induction levels at 1x MIC induction steadily increased to 8.3-fold at 
day 3 (Figure 4B). Similar to BDQ, induction by Q203 at 1x MIC was stronger as compared with higher 
drug concentrations at all three time points (Figure 4B). The NDH-2 effector CFZ at 1x MIC triggered 
slowly increasing cydA levels until day 3 (Figure 4C). CFZ displayed only marginal concentration-
dependency of induction at day 1 and day 2, whereas at day 3 induction was clearly higher at 10x MIC 
(6.6-fold) and 60x MIC (6.9-fold (Figure 4C). For comparison, the time- and concentration dependency of 
cydA regulation by the front-line drugs are shown in Supplementary Figure 2. 
In line with the delayed bactericidal activity of the three oxidative phosphorylation inhibitors 
induction of cytochrome bd was time-dependent and maximal induction was not reached before two days 
of treatment. Both BDQ and Q203 showed maximal cytochrome bd expression at concentrations of 1x 
MIC, whereas the higher, bactericidal concentrations were less effective in cytochrome bd induction. 
These two inhibitors strongly decrease bacterial ATP levels19,36,38. It can be speculated that pronounced 
ATP depletion at elevated drug concentrations renders the bacteria less capable of mobilizing an effective 
metabolic response. 
 
The cydA reporter induced in macrophages 
  To evaluate if cytochrome bd expression can be monitored under conditions as encountered within 
a mammalian host we examined the cydA reporter in a mouse macrophage infection model. To 
differentiate between infected and non-infected macrophages and to assess which proportion of the 
infected cells expressed the cydA reporter, we introduced an integrative plasmid with a gene encoding 
fluorescent protein mEos3.1 under control of the hsp60 promoter in our M. marinum cydA reporter strain. 
Expression levels of mCherry (cydA) and mEos3.1 were assessed by flow cytometry using a gating 
strategy depicted in Supplementary Figure 3. The analysis showed that the percentage of untreated 
mEos3.1-positive RAW macrophage cells steadily increased within a 3-day period after start of infection 
(Figure 5A). Treatment with BDQ suppressed infection (Figure 5A). To assess cydA expression relative to 
bacterial cell number, we normalized the mCherry signal relative to the mEos3.1 signal. Whereas for M. 
marinum in culture the mCherry signal was ~70fold lower than the mEos3.1 signal, during RAW cell 
infection the ratio mCherry/mEos3.1 ratio increased to ~1:3 within one day. Prolonged incubation resulted 
in a marginal further increase between day 1 and day 3 of infection (Figure 5B). Upon treatment with 
BDQ an additional increase of the normalized cydA expression in the RAW cell infection model was 
observed (Figure 5C). These results suggest that the cydA reporter is working in a mouse cell line 
infection model and that cytochrome bd is induced during intracellular growth. 
 
The cydA reporter is functional in a vertebrate host system 
  Next, we explored if the constructed cydA reporter can also be used to study cytochrome bd 
expression in a zebrafish embryo infection model. M. marinum carrying the cydA reporter and the 
constitutive mEos3.1 marker were injected into in the hindbrain ventricle of zebrafish embryos. Both 
mCherry and mEos3.1 fluorescence signals were readily detectable by confocal microcopy. The mEos3.1 
signal allowed for monitoring the spread of the infection within the hindbrain (Figure 6, upper row). 
Treatment with BDQ decreased bacterial growth (Supplementary Figure 4), supporting the usage of a 
hindbrain ventricle infection model to address drug efficacy. Although quantification of in vivo 
fluorescent signals is difficult, a similar trend was observed for the mCherry signal as in the macrophage 
infection model. Even without antibiotic treatment high induction of the mCherry reporter was visible in 
vivo, exceptionally pronounced at day 4 post infection (Figure 6, middle and lower row). Due to the high 
cydA expression levels in the non-treated control we were not able to quantify if treatment with BDQ 
additionally induced cydA (Supplementary Figure 4). Interestingly, in certain infected areas of the central 
nervous system mCherry induction appeared exceptionally strong (Figure 6, lower row), which may be 
due to varying levels of cytochrome bd inducing factors in specific micro-environments. These results 
show that the cydA reporter allows for monitoring cytochrome bd expression in vivo and indicates that 
cytochrome bd is produced at elevated levels during infection in a vertebrate host. 
 
Discussion 
Previously, alkaline phosphatase fusions to subunit I or subunit II have been applied to investigate 
cytochrome bd topology46 and a galactosidase-based marker was used to assess cytochrome bd expression 
under hypoxia11. Green Fluorescent Protein (GFP)-fusions to subunit II facilitated investigation of 
cytochrome bd dynamics in the E. coli cytoplasmic membrane47 and in Corynebacterium glutamicum GFP 
under the control of the cytochrome bd promoter was used to study expressional control of the branched 
respiratory chain48. In our study, we describe an expression reporter for cytochrome bd in a pathogenic 
(myco)bacterium. M. marinum, and we applied this reporter to evaluate differential regulation of 
cytochrome bd in response to antibiotics and during infection. The marker revealed cytochrome bd 
induction in response to antibacterials of different classes, but in particular to inhibitors of oxidative 
phosphorylation. Drugs targeting this pathway are under consideration as components for next-generation 
anti-tuberculosis chemotherapy regimen49-52. The reporter constructed here may assist in characterizing 
new candidate antibacterials and may provide input for the rational combination of antibacterials in drug 
regimen. It would be interesting to test if induction of cytochrome bd in response to inhibition of oxidative 
phosphorylation is also found in non-mycobacterial pathogens, such as Staphylococcus aureus, 
Streptococcus pneumoniae or Acinetobacter baumanii, for which small molecules targeting ATP synthase 
and components of the respiratory chain have been reported previously53-55. 
Induction of cytochrome bd in response to clofazimine, a ROS-producing drug39, is most likely 
due to this enzyme’s ability to metabolize and/or prevent the formation of peroxides. Cytochrome bd as a 
high-affinity oxygen scavenger2 may decrease the intracellular oxygen tension, thereby preventing the 
formation of reactive oxygen species. Moreover, for cytochrome bd from E. coli both catalase activity56 
and peroxidase activity57 has been reported. This enzyme may thus directly metabolize peroxides. Activity 
of BDQ and Q203 was not found linked to ROS production13,18. Induction of cytochrome bd may facilitate 
respiratory electron flow when the cytochrome bc1 complex is inhibited by Q203. Enhanced levels of 
cytochrome bd in response to the ATP synthase inhibitor BDQ may prevent membrane hyperpolarization 
and/or maintain respiratory electron flow. Alternatively, cytochrome bd induction may be associated with 
the enhanced respiratory flux and the uncoupling effect reported for bactericidal concentrations of 
BDQ20,58. 
The cydA reporter revealed high cytochrome bd levels for M. marinum in two relevant infection 
models, illustrating the importance of this respiratory protein for survival in the host. In a recent report no 
clear attenuation phenotype was found for a ∆cydAB strain in mice22, however, consistent with our 
findings, earlier results indicated that genetic inactivation of cytochrome bd in M. tuberculosis decreased 
bacterial counts in a mouse infection model14. In addition, numerous studies suggest that lack of a 
functional cytochrome bd severely compromises bacterial viability during infection for a broad spectrum 
of Gram-positive and Gram-negative bacterial strains, such as Group B Streptococcus59, Staphylococcus 
aureus
60
, Shigella flexneri61, Brucella abortus62, Salmonella enterica63,64 and uropathogenic E. coli 
strains65. It needs to be clarified to which extent elevated cytochrome bd levels represent a general feature 
of pathogens residing in a vertebrate host. Fluorescent expression reporters, such as constructed and 
characterized here, may be important tools for elucidating the role of cytochrome bd in pathogenic 
bacteria.  
 Materials & methods 
Construction of the cydA reporter plasmid 
   A list of primers can be found in supplemental table 1. Anchored primers containing either an 
XbaI site or BamHI site were used to amplify a 290-bp fragment that included the cydA promoter from M. 
marinum MUSA genomic DNA. Subsequently, both the pAL5000 plasmid derivative pSMT3-iniB-
mCherry24 and the amplified PCR product were digested with XbaI and BamHI, mixed, and ligated, 
resulting in pSMT3-pCydA-mCherry.  
Strains and culturing conditions 
   M. marinum wild type MUSA 66 was used as a basis for mycobacterial experiments. Cultures were 
grown in Middlebrook 7H9 liquid medium supplemented with Middlebrook ADC (Difco) and 0.05% 
Tween 80. Antibiotics (Sigma) were added to cultures where indicated. Antibiotics for the induction 
experiments were routinely added to log-phase cultures at the indicated final concentrations. Middlebrook 
7H10 solid agar supplemented with Middlebrook OADC was used for bacterial culturing on agar plates. 
Both cultures and plates were grown at 30 °C. For hypoxic conditions, M. marinum cultures were grown 
to log phase in a culture flask in Middlebrook 7H9 medium at 30°C and diluted to an OD600 of 0.3 per 
mL. A total of 1.5 mL was incubated per screwcap tube to acquire a headspace ratio (HSR) of ~0.5 64. The 
tubes were incubated at 30°C on a shaker. Per time point one tube was opened and the hypoxic culture 
was tested for growth, as measured by OD600, and expression of cydA by flow cytometry. Experiments 
were performed three independent times 
 
Flow cytometry analysis 
  The induction of cydA was measured by flow cytometry. M. marinum containing the reporter 
plasmid was grown to an OD600 of 0.2-0.3, and antibiotics were added to the indicated concentrations for 
a specified amount of time. For each time point, 1 mL culture was collected, spun down by centrifugation, 
washed once with PBS containing 0.05% Tween 80 and resuspended in 100µl 0.05% Tween 80. Cell 
infections were also analyzed by flow cytometry. Cell infection samples were resuspended in PBS. 
Samples were acquired on a BD Accuri C6 flow cytometer (BD Biosciences) equipped with a 488-nm 
laser and 610/20-nm filter to detect mCherry and 533/15 to detect mEos3.1. The exact gating strategy 
varied between experiments. Per sample, 30,000 gated events were collected per time point, and data were 
analyzed using BD CFlow software and GraphPad prism 6. 
 
 
RNA isolation and qRT-PCR 
   RNA isolation was performed with a NucleoSpin® RNA kit (Machery Nagel). In total 25 OD 
units were spun down and used for isolation per sample. Isolation was performed with three biological 
replicates. There was one deviation as compared to the first step of the manufacturer’s protocol to lyse the 
mycobacterial cells. Cells were beadbeated in 500 µL Buffer RA1 and 5 µL ß-mercaptoethanol for 1 
minute. Subsequent steps were according to the protocol provided by the manufacturer. RNA samples 
were subsequently treated with DNAseI (Thermo Scientific) according to manufacturer’s protocol. Equal 
amounts of RNA were analyzed in an ABI7500 thermocycler using a EXPRESS One-Step Superscript® 
qRT-PCR Kit. Instructions supplied with the kit were followed. sigA was used as a reference gene for 
qRT-PCR. The sequences for the primers and probes can be found in Supplementary Table 1. The 
resulting data of triplicates were analyzed using the ABI7500 software. 
 
Cell infection assay with RAW macrophages 
   For RAW cell infection, 2 × 104 cells per well were seeded in 12 wells plates (Corning) and 
grown for 4 days until ~70% confluence. The cydA reporter strain that also contained the integrated pMV-
hsp60-mEos3.1 was grown to an OD600 of 0.8-1.5 and washed with DMEM + FBS (10%) prior to 
infection. Bacterial cells were subsequently added to a multiplicity of infection of 2. RAW cells were 
incubated at 33 °C After three hours, extracellular mycobacteria were removed by washing 2 times with 
PBS. Amikacin was added to a final concentration of 200 µg/ml for 3 hours to kill any remaining 
extracellular mycobacterial cells. Cell were then washed and BDQ was added at the indicated 
concentrations. At time points 24 hpi, 48 hpi, and 72 hpi RAW cells were harvested by addition of 
trypsine (Sigma). The trypsin was neutralized by addition of DMEM + FBS (10%) and cells were pelleted 
at 1400 rpm. Cells were subsequently fixed with 4% PFA for 30 minutes at room temperature, washed 
with PBS and analyzed by flow cytometry. 
 
Infection of zebrafish embryos 
   To assess the anti-mycobacterial effect of Q203, clofazimine and BDQ, zebrafish embryos were 
infected with 100 colony forming units (CFUs) in the caudal vein by microinjection with M. marinum 
MUSA containing the plasmid pSMT3-hsp60-mEos3.1. (Stoop et al./van Leeuwen et al. unpublished). The 
embryos were treated 1 day post infection with the aforementioned antibiotics at the indicated 
concentrations. Fluorescence was monitored at specific time-points with a Leica MZ16FA fluorescence 
microscope and a Leica DFC420C camera. All experiments were performed at least three times. For 
expression analysis in zebrafish embryos pMV-hsp60-mEos3.168 was introduced in M. 
marinum MUSA already containing the cydA reporter plasmid. Zebrafish embryos were injected with 2000 
CFUs by microinjection in the hindbrain ventricle, as previously described24,41. Subsequently, zebrafish 
embryos were fixed O/N at 0, 2 and 4 days post infection in 4% paraformaldehyde dissolved in PBS, 
washed with PBS and subsequently stored in PBS at 4°C. For confocal microscopy, zebrafish were 
mounted in 1% low-melting-point agarose in PBS and imaged with a Leica TCS SP8 confocal 
microscope. 
Animal experiments 
  All methods were carried out in accordance with relevant guidelines and regulations. Danio 
rerio (zebrafish) were handled in compliance with the local animal welfare regulations and maintained 
according to standard protocols (zfin.org). The breeding of adult fish was approved by the local animal 
welfare committee (Animal Experimental licensing Committee, DEC) of the VU University medical 
center. All protocols adhered to the international guidelines specified by the EU Animal Protection 
Directive 86/609/EEC, which allows zebrafish embryos to be used up to the moment of free-living 
(approximately 5–7 days after fertilization). Because embryos used in this study met these criteria, this 
specific study was therefore approved by the Animal Experimental Licensing Committee of the VU 
University medical center (Amsterdam, the Netherlands). 
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 Figure 1. Construction and basic characterization of the cytochrome bd expression reporter. 
A: Genetic construction of the reporter plasmid with the mCherry gene under control of the cydA 
promoter. B: Growth of Mycobacterium marinum carrying the cydA reporter in 7H9 medium. Three 
independent biological replicates were monitored for growth. Error bars indicate the standard deviation 
(s.d.) value. C: mCherry fluorescence emitted by the cydA reporter during in vitro culture under aerated 
(normoxia) conditions and hypoxic conditions. Three independent biological replicates were monitored 
for growth. The fluorescence signal was corrected for autofluorescence of WT bacteria without a plasmid. 
Error bars indicate the s.d. . D: cydA induction in response to the nitric oxide donor DETA-NO (1x MIC 
and 10x MIC) on day 3 after induction. Three independent biological replicates were monitored for 
growth. Error bars indicate the s.d. value.  
  
Figure 2. Selected drugs are active in a zebrafish infection model. A: Infected fish, untreated (top) brightfield and fluorescence image as 
compared to a control, uninfected fish. B: BDQ treated fish 3 days post treatment. C: Treatment with Q203. D: treatment with CFZ. Zebrafish 
infection experiments were performed with at least three biological replicates.
 Figure 3. Differential regulation of cydA in response to antibacterials. A histogram plot showing the number of events (y-axis). Peak height 
indicates mCherry fluorescence intensity (x-axis) for: Untreated samples (red line), 1x MIC of the shown antibiotic (blue line) and 10x MIC (green 
line). WT without cydA reporter served as a background control (black line). The histograms represent data from one representative experiment 
with 30,000 cells. The experiment was performed three independent times.
 Figure 4. Time- and concentration dependency of cydA induction by inhibitors of oxidative phosphorylation. A: response to BDQ for 1x, 
10x and 100x MIC over time. B: response to Q203 for 1x, 10x and 100x MIC. C: response to CFZ for 1x, 10x and 100x MIC. The fold inductions 
were calculated by dividing the mean fluorescence intensities of the treated samples by the corresponding untreated controls. The data of three 
independent biological replicates were used. Error bars represent the s.d. values.
Figure 5. The cydA reporter in a mouse macrophage infection model. A: The percentage of 
infected RAW cells over time for NT (non-treated) as compared to cells that were treated with 1x or 
10x MIC BDQ. The experiment was performed in triplicate and error bars represent s.d. values B: 
Flow cytometry experiment determining the ratio of mCherry signal (MFI) relative to the mEos3.1 
signal (MFI) for bacteria in culture compared to values obtained from mouse macrophage cell 
infection. Data represents triplicate measurements and error bars represent s.d. values C: Normalized 
mCherry MFI over time, during cell infection, comparing non-treated (NT) to BDQ-treated infected 
macrophages. The experiment was performed in triplicate and s.d. values are indicated by the error 
bars. 
 
 Figure 6. The cydA reporter in a zebrafish embryo model. Confocal microscopy images of casper 
zebrafish embryos at maximum projection. Time course of mEos3.1 and mCherry signals during 
infection (dpi = days post infection). Upper row: mEos3.1 signal indicates infection. Middle row; 
mCherry fluorescence indicates cydA transcription. Lower row: overlay of upper and middle row. 
Scale bars, 100 µm. Three independent experiment were performed, the images were selected from as 
representative experiment. 
 
 
Antibiotic Target pathway MIC (M. marinum) 
Isoniazide (INH) Cell wall biosynthesis 10µg/ml (24) 
Ethambutol (ETH) Cell wall biosynthesis 1µg/ml (24) 
Rifampicin (RIF) RNA synthesis 0.32 µg/ml (24) 
Streptomycin (STR) Protein synthesis 4 µg/ml (24) 
Ciprofloxacin (CIP) DNA synthesis 4 µg/ml (24) 
Bedaquiline (BDQ) Oxidative phosphorylation 0.062µM (this study) 
Q203 Oxidative phosphorylation 3.5 µM (38) 
Clofazimine (CFZ) Oxidative phosphorylation 0.8µg/ml (this study) 
 
Table 1. List of antibiotics and minimal inhibitory concentrations (MICs) used in this study.  
 
 
 
 
 
 
 
 
 Supplementary Figure 1. qRT-PCR to confirm upregulation of cydA in M. marinum. 
qRT-PCR was utilized to measure induction the cydA reporter after three days of treatment with BDQ, 
Q203, CFZ and INH (1x MIC each), as compared to a not treated control. Values are from three 
biological replicates, error bars indicate the standard deviation (s.d.) values.
 Supplementary Figure 2. Time- and concentration dependency of cydA induction by other first and second-line antibiotic for 1x, 10x and 100x MIC 
over time A: Response to isoniazid. B: Response to ethambutol. C: Response to rifampicin. D: Response to streptomycin E: ciprofloxacin. Three independent 
experiments were performed. Error bars indicate s.d. values.
 Supplementary Figure 3. The gating strategy for RAW cell infection A: Gating of the intact 
RAW cell population after infection (P1). B: A non-infected control was used to set gate R2 in P1 
and defined as positive for mEos3.1. C: Cells that fall in gate R2 were used for analysis of mCherry 
signal. 
 
 
  
Supplementary Figure 4. BDQ decreases bacterial growth in the zebrafish hindbrain infection. 
Treatment of zebrafish embryos was started directly after infection. After 2dpi and 4dpi a significant 
reduction in bacterial load can be seen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Name Sequence (5’ > 3’) 
cydA_FW TTTTCTAGAtcatcggtgtcatcagcctg 
cydA_RV TTTTGGATCCgtgccatctcccgggcctgc 
qsigA_FW AAGCCAACCTGCGTCTG 
qsigA_RV CTTGTAGCCCTTGGTGTAGTC 
qsigA-probe JOE-TCTGATCCGTGCGGTCGAAAAGTT-BHQ1 
qcydA_FW GTGCCCCTACGTATTACCGATC 
qcydA_RV CAGTAGGTGACGAAGAGAATTGG 
qcydA_probe 6-FAM-TGTTTGGTAGTCCCGTTGCAGGTC-BHQ1 
 
Supplementary Table 1. Primers and probes used in this study 
  
 8. 
 
Summarizing discussion 
 
 
 
 
 
 
 
 
 
 
 Drug resistance is a large problem in the treatment of tuberculosis. Understanding the dynamics of the 
complex stress responses that mycobacteria deploy upon antibiotic treatment will possibly allow us to 
discover drug-induced salvage or repair pathways that can serve as novel drug targets. Traditional 
high-throughput screening has proven to be suboptimal over the past decade, which emphasizes that 
alternative approaches are required to find new anti-TB therapeutics to combat MDR- or XDR-TB 
infection. In this thesis, we present our contribution to the understanding of mycobacterial stress 
responses that follow upon treatment with currently used antibiotics or conditions (e.g. low phosphate) 
that are relevant in vivo.  
 
Exploiting M. marinum as a model to study stress responses in pathogenic mycobacteria 
  In chapter 6 of this thesis, we describe an RNA sequencing approach for both M. tuberculosis 
and M. marinum to study the stress responses that follow upon treatment with currently used 
antibiotics. These antibiotics are ciprofloxacin, ethambutol, isoniazid, streptomycin and rifampicin. 
We chose to include M. marinum in our experiments because of the high (>85%) nucleotide similarity 
with M. tuberculosis (Stinear et al. 2008). Moreover, M. marinum can be used in the well-established 
M. marinum-zebrafish embryo infection model that our group and others have developed over the past 
decade (van der Sar et al. 2004; Stoop et al. 2011). Finally, M. marinum is relatively easy to handle 
(BSL-2 level instead of BSL-3) and has a doubling time of around 6 hours, much shorter than the 24 
hours of doubling time of M. tuberculosis (Stinear et al. 2008). We examined the reliability of our 
RNA sequencing data by comparing our ciprofloxacin stress profiles with previously published data 
on ciprofloxacin induction of SOS regulon members (O’Sullivan et al. 2008; Smollett et al. 2012). 
The overlap in response between these studies and our RNA sequencing was high. Upregulation of 
major genes of the SOS-regulon was identified in both species, albeit at an earlier time point for M. 
marinum as compared with M. tuberculosis. In general, M. marinum showed a very clear 
transcriptional stress ‘fingerprint’ that was specific to the type of antibiotic that was used. Although 
this distinction was not as clear-cut in M. tuberculosis, large parallels could be drawn between the two 
species. Notably, we did observe some differences between M. marinum and M. tuberculosis. For 
instance, we found that M. tuberculosis upregulated more general heat shock responses (e.g. hsp, acr 
and hrp1), a feature we did not observe in M. marinum. This might be explained by the fact that initial 
stress levels caused by antibiotics are perceived by more general stress sensors, such as heat shock 
proteins in M. tuberculosis. Even minute, far below-MIC concentrations of antibiotics have been 
shown to induce transcriptional changes in bacteria to respond and cope with the perceived stress. 
Therefore, it could be that these general responses are deployed at low concentrations at early time 
points (Andersson & Hughes 2014). During treatment, the intracellular concentration of an antibiotic 
likely has to build up to reach a certain threshold. Only after reaching this threshold concentration, 
specific stress responses are activated to deal with the perceived stress accordingly. These 
concentrations and temporal differences possibly vary, depending on the specific type of damage, e.g. 
cell wall damage (EMB/INH) or ribosomal stress (STR) that is sensed. Another possible explanation 
for the more general stress response that we observed in M. tuberculosis comes from comparison with 
other Gram-negative bacteria. In Gram-negatives, many chaperones, heat shock proteins and genes 
encoding proteins that are required for cell homeostasis are known to be induced by antibiotics. 
Moreover these proteins are often induced in parallel to antibiotic stress responses (Guest & Raivio 
2016). An example is the Psp response that is induced by certain antimicrobial compounds, but also by 
osmotic shock, heat shock or changes in PMF (Jovanovic et al. 2006). The suitability of M. marinum 
as a model for studying M. tuberculosis is underscored by the large overlap in major antibiotic stress 
operons that were induced in our RNA sequencing experiment. These include mycolic acid 
biosynthesis (INH), the SOS response (CIP) and ribosomal stress (STR). Moreover, the major 
antibiotic stress operon iniBAC is highly induced in both species upon treatment with ethambutol and 
isoniazid (Alland et al. 2000; Boot et al. 2016). In this thesis, we further explored the function of this 
operon in pathogenic mycobacteria. 
 
The induction signals that activate transcription of iniBAC 
  Originally, the iniBAC operon was found to be highly transcribed after the addition of cell-
wall targeting antibiotics ethambutol, ethionamide and isoniazid (Alland et al. 2000). As both 
antibiotics target the mycobacterial cell wall it was assumed that the induction resulted from general 
cell wall stress. In chapter 3, we probed the genetic stress network of the iniBAC operon in an 
unbiased screen by performing transposon mutagenesis in a wild-type M. marinum containing the 
iniBAC stress reporter. We found that transposon mutants, defective in the vitamin B12 biosynthesis 
pathway or the vitamin-B12-dependent methylmalonyl-CoA mutase MutAB, express the iniBAC 
operon at high levels. MutAB is an enzyme that plays a role in the degradation of fatty acids and 
cholesterol. It is responsible for the conversion of methylmalonyl-CoA to allow further processing of 
these molecules in the TCA cycle and glyoxylate shunt (Muñoz-Elías et al. 2006). In the transposon 
mutants deficient in functional MutAB or its cofactor vitamin B12, the production of phthiocerol 
dimycocerosates was altered, reflecting a clear link with outer membrane lipid biosynthesis and cell 
wall homeostasis. In a transposon screen in M. bovis BCG, we discovered PDIM-defective mutants 
that also induced the iniBAC operon. However, no transposon mutants were identified in mutAB or in 
the vitamin-B12 biosynthesis pathway. This may be explained by the observation that M. tuberculosis 
and M. bovis BCG seem to lack one gene (cobF) required for a functional vitamin B12 biosynthesis 
pathway (Gopinath et al. 2013). Therefore, MutAB is probably dependent on the acquisition of 
external vitamin B12. Although M. tuberculosis is a natural vitamin B12 null mutant, unable to 
produce vitamin B12 under standard culture conditions, M. tuberculosis (and M. bovis BCG) does not 
constitutively express iniBAC. This is in stark contrast with M. marinum vitamin B12 mutants. This 
may indicate differences in the genetic stress network of M. marinum and M. tuberculosis.  
 A common denominator of iniBAC induction in both the M. marinum and M. bovis BCG 
transposon screens is the apparent inability to produce WT levels of PDIMs, perhaps indicating that 
cell wall permeability is affected. This lack of PDIMs is either the result of a MutAB deficiency (as 
determined by TLC) in M. marinum, or directly by mutations in the PDIM locus in M. bovis BCG. 
Remarkably, because M .tuberculosis does not seem to produce vitamin B12 itself, it must take up the, 
rather large, cyanocobalamin molecules. Previous work by Savvi et al. has indicated that vitamin B12 
plays a role in the growth on propionate as a carbon source (Savvi et al. 2008) . Upon addition of 
exogenous vitamin B12 to M. tuberculosis H37Rv, the authors saw an increase in growth speed (as 
determined by OD600), due to the functional activation of the vitamin B12-dependent MutAB. In an 
attempt to speed up the diagnosis of possible TB cases we performed a pilot experiment with vitamin 
B12 mycobacterial growth indicator tubes (MGIT). This assay is routinely used to detect M. 
tuberculosis-positive patient material. Unfortunately, we did not find a clear difference between time 
to positivity when we compared MGIT tubes that either did or did not contain vitamin B12. The 
combination of a lipid carbon source (oleic acid) and vitamin B12 did seem to assert some positive 
effect, but more research is needed to confirm these preliminary findings. 
  In work summarized in chapter 4, we tried to further define iniBAC induction triggers by 
performing a second round of transposon mutagenesis in a constitutively iniBAC-expressing cobC::tn 
mutant strain. In doing so, we identified mutants that switched from constitutive iniBAC stress to a 
state that repressed this induction. We called these mutants ‘on/off mutants’. We found that five on/off 
mutants had transposon insertions in the mce1 locus. The Mce1 complex is thought to be responsible 
for the (re)import of free mycolic acids (FMA), cholesterol and fatty acids over the inner membrane 
(Nazarova et al. 2017). As a result of a dysfunctional Mce1 complex, free mycolic acids readily 
accumulate in the periplasm (Forrellad et al. 2014; Cantrell et al. 2013). Impaired uptake and halted 
recycling of FMAs or fatty acids may cause altered pools of lipid precursors in the cytoplasm (Figure 
1). As a result, concentrations of the two main building blocks of mycobacterial lipids, acetyl-CoA and 
propionyl-CoA, may be altered. Since we hypothesized that iniBAC induction could be the result of a 
misbalance in lipid precursors in the cobC::tn mutant background (Figure 1, middle panel), it is not 
unlikely that a secondary transposon insertion, disrupting Mce1 functionality, restores the levels of 
these lipid precursors to such an extent that the operon is no longer induced (Figure 1, right panel). 
Previous studies have shown, that the balance between acetyl-CoA and propionyl-CoA is delicate and 
that metabolic stress can occur as a result of minor changes in the intrabacterial fatty acid pools (Lee et 
al. 2013). The lowered iniBAC induction may be caused by rebalancing of lipid precursors in the 
cobC::tn + mce1::tn double mutant (Figure 1, right panel). However, in these mutants both EMB and 
INH still induce iniBAC, which indicates that stress signalling is still intact Other evidence that hints at 
the importance of metabolic pathways in the induction of the operon is the identification of three other 
on/off mutants in pathways associated with fatty acid degradation. These on/off mutants have a second 
transposon in either sdhA1, encoding the succinate dehydrogenase, or in aceE (two unique transposon 
mutants), encoding an enzyme that is part of the pyruvate dehydrogenase complex. Both of these 
enzymes are part of the TCA cycle. 
 
Figure 1. Different metabolic cues lead to iniBAC induction. Left panel: In a WT bacterium there is a balance 
between internal lipids and lipid precursors. Therefore, there is no upregulation of the iniBAC operon (red 
arrow). Middle panel: Induction of the iniBAC operon in a cobC::tn mutant, as a result of MutAB deficiency, 
may alter the pools of lipid precursors that are produced in the β-oxidation pathway. The pathway is used to 
degrade fatty acids and cholesterol. Right panel: The Mce1complex can take up cholesterol, fatty acids and free 
mycolic acids to provide lipid precursors. This uptake can play a role in the misbalance that occurs in a cobC::tn 
background. A secondary mutation in the mce1 locus disrupts Mce1 functionality and may rebalance the lipid 
intermediates, resulting in a repression of the original iniBAC induction observed in the parent strain. Green 
arrows indicate induction signals, whereas red arrows represent inhibitory signals. 
  
Trehalose as an iniBAC inducer  
  In chapter 4, we found that trehalose can directly induce the iniBAC operon in M. marinum. 
We also found that this induction is amplified when cell wall permeability is increased by either 
introducing the M. smegmatis porin MspA, or by mutations in the PDIM locus. Although we found 
that PDIM mutants in M. bovis BCG also show upregulation of iniBAC, not all permeabilization 
events seem to result in induction of the operon by default. Evidence for this comes from a study 
where compounds were tested for their ability to permeabilize mycobacteria (Jeon et al. 2017). In their 
search, the authors found AI-2, an agent that reduces the amount of sulfolipids (SL-1), thus causing 
partial permeabilization of the M. tuberculosis outer membrane. The authors also an RNA sequencing 
approach to examine the transcriptional consequences of AI-2-treatment and did not find induction of 
iniBAC genes (Jeon et al. 2017).  
  That trehalose directly induces iniBAC is a completely new finding. However, in hindsight, it 
is not surprising, as trehalose is crucial for the biogenesis of the mycobacterial cell wall. Specifically, 
this disaccharide is an essential building block for the biosynthesis of several outer membrane lipids, 
including trehalose monomycolates (TMM), trehalose dimycolates (TDM), penta-acyl trehaloses 
(PAT), diacyl trehaloses (DATs), triacyl trehaloses (TATs), lipooligosaccahrides and sulfolipids (SL-
1, only found in members of the M. tuberculosis complex)(Angala et al. 2014).  
Because trehalose cannot be acquired from the human host during infection, mycobacteria synthesize 
trehalose de novo, to ensure its bioavailability for lipid production. The importance of this availability 
is underscored by the fact that mycobacteria possess three different pathways that are able to 
synthesize trehalose. Two of these, the OtsA-OtsB pathway and the TreY-TreZ pathway, use glucose 
intermediates as a source for the production of trehalose. The third route is via the bidirectional TreS 
that can utilize sucrose or maltose to produce trehalose (De Smet et al. 2000). According to studies 
performed in M. smegmatis, nutrient-deprived bacteria mainly rely on OtsA-OtsB and TreY-TreZ to 
synthesize trehalose (Shleeva et al. 2017).  
  The origin of the trehalose required for iniBAC induction is speculative. However, it is 
tempting to think that the source of trehalose are trehalose monomycolates (TMM) or trehalose 
dimycolates. (TDM). During cell wall biosynthesis the antigen 85 complex (Ag85A, Ag85B and 
Ag85C) can produce TDMs from TMMs (Belisle et al. 1997). In this process, a trehalose molecule is 
released from TMM. The Ag85 complex is bidirectional, meaning that it can also use trehalose and 
TDM to form TMMs. These TMMs can subsequently be reimported through Mce1. This indicates that 
a functional knockout of Mce1 may not solely change the balance of lipid precursors (as depicted in 
Figure 1), but may also influence the amount of free trehalose that is reimported into the cell. This 
speculative decrease in intracellular trehalose could then lower iniBAC induction, as observed in the 
mce1::tn on/off mutants. More evidence that the flux of trehalose from trehalose-containing lipids 
plays a role in the induction can be found in literature. For example, Degiacomi et al. showed that 
silencing the protein that is responsible for flipping TMMs from the cytoplasmic side to the 
periplasmic side of the inner membrane results in iniBAC induction (Degiacomi et al. 2017; Xu et al. 
2017). Inhibition of this process may result in an increase of trehalose concentrations, high enough to 
induce the operon. Interestingly, Brennan and Winder showed, as early as in 1964, that isoniazid 
treatment caused an accumulation of free trehalose in mycobacteria (Brennan & Winder 1964). These 
observations indirectly link trehalose accumulation to concomitant iniBAC induction due to INH 
treatment.  
  Whether the induction of the iniBAC operon is caused by trehalose that originates from the 
extracellular milieu, the periplasm, or that it is the result of cytoplasmic accumulation, remains to be 
addressed. Moreover, whether the induction is due to a lack of degradation of trehalose (via TreS or 
the trehalase encoded by Rv2402) or an overproduction (OtsA-OtsB or TreY-TreZ) is hard to pinpoint 
based on current data. The blocking of the only known importer LpqY-SugA-SugB-SugC of trehalose 
could perhaps help to answer this question (Kalscheuer et al. 2010). Interestingly, preliminary 
experiments in an M. marinum sugA::tn mutant background showed that there is still iniBAC induction 
in such a mutant, both in response to antibiotics and in response to exogenous trehalose. Moreover, the 
question whether accumulation of existing trehalose or production of de novo trehalose is the trigger 
could perhaps also be addressed with mutants in biosynthetic, salvage or degradation pathways. It has 
for instance been shown that knocking out treS in M. tuberculosis causes a significant build-up of free 
trehalose over time (Eoh et al. 2017). Alternatively, we could use compounds to block specific routes. 
An example of such a compound is ebselen, a potent Ag85 inhibitor (Favrot et al. 2013). If Ag85 
inhibition in a cobC::tn mutant background causes a difference in iniBAC induction, it would further 
establish the link between operon induction and the turnover of TMMs and TDMs, in addition to the 
results already obtained in the mce1::tn on/off mutants.  
  Trehalose itself has been widely described as a protective agent during oxidative stress in 
many organisms including yeast, bacteria and plants (Benaroudj et al. 2001; Fernandez et al. 2010). In 
yeast, trehalose can contribute to up to ~30% of the fungal cell’s dry weight during oxidative stress 
conditions (Feofilova et al. 2014). Under these conditions, trehalose functions as an osmoprotectant 
and buffers oxidizing reagents to protect the cell. E. coli has also been shown to use trehalose as an 
osmoprotectant (Strøm & Kaasen 1993). Trehalose, but not other protectants like glycine or betaine, 
specifically increased the capacity of E. coli to deal with dehydration (Welsh & Herbert 1999). 
Whether mycobacteria also utilize trehalose as a buffer for oxidative stress is unknown. Experiments 
with M. smegmatis revealed that trehalose can account for a staggering 64% of the total organic 
material of the bacterial cell during nutrient deprived conditions (Shleeva et al. 2017). This indicates 
that trehalose can accumulate into high abundance in mycobacteria. The reason for the accumulation 
according to Shleeva et al. is likely due to the inactivation of a conserved trehalase (encoded by 
MSMEG_4535). 
  Possibly, the accumulation of trehalose in mycobacteria serves a dual function: it may not only 
be used as a cell wall stress signal, but also as a functional unit to prevent oxidative stress resulting 
from cell wall disruption by EMB or INH. A study by Deretic et al. in M. tuberculosis showed that 
relevant oxidative stress levels are present as a result of INH treatment (Deretic et al. 1995). The 
authors showed that wild type M. tuberculosis does not produce high amounts of AphC, an alkyl 
hydroperoxide reductase that plays a role in protecting cells from oxidative stress. Upon 
transformation of M .tuberculosis with aphC from M. leprae, the sensitivity of the mutants to INH 
shifted an order of magnitude. In addition, Bulatovic et al. showed that an increase in oxidative stress 
potentiates INH’s bacteriostatic activity, further providing evidence that oxidative stress may be 
present during antibiotic exposure (Bulatovic et al. 2002).  
The role of IniR in iniBAC induction 
  In chapter 4, we describe the identification of the iniBAC activator IniR. We show that this 
protein interacts with the promoter region of the iniBAC operon to activate transcription of the iniBAC 
genes. Crosslinking experiments further revealed that IniR can multimerize into a dimer or tetramer. 
Computational analysis showed that the iniR gene is well-conserved among mycobacterial species like 
M. tuberculosis, M. marinum and M. smegmatis. Moreover, iniR seems to be conserved among 
actinobacteria and can be found in Rhodococcus spp. and Nocardia spp. Both of these species also 
have an outer membrane that contains long carbon chain mycolic acids and trehalose-lipids.  
  A striking observation is that IniR only seems to regulate the iniBAC genes. When we 
compared the transcriptome of EMB or INH-treated cultures of an M. tuberculosis ∆iniR mutant to 
that of a WT H37Rv control, the only differentially expressed genes were the three operon members. It 
is currently not known how expression of iniR itself is regulated. We identified potential candidates 
from chromatin immunoprecipitation (ChIP) sequencing data of transcriptional regulators in M. 
tuberculosis: iniR (by auto-regulation), Rv1423 (whiA), Rv1776c (AcrR-type family regulator) and 
Rv3488 (a PadR-type family regulator) (Minch et al. 2015). Because iniR induction leads to a high 
increase in iniBAC transcription, it is likely that one of these members could also be involved in a 
feedback loop or degradation cascade. IniR itself is a large protein that belongs to the family of signal-
transduction ATPases. It has three separate protein domains, one of which is similar to the MalT 
maltose-binding domain of E. coli (61% amino acid identity). In E. coli, MalT is part of the maltose 
uptake system as activator of transcription upon binding of maltotriose. The full system includes the 
maltose binding protein (MBP) which transfers maltose to the IM-spanning MalFGK2 complex (Boos 
& Shuman 1998) (Figure 2). Upon binding maltotriose and ATP, MalT multimerizes and activates 
transcription of malFGK and mbp. If IniR has a similar function as MalT, it is likely that the signalling 
molecule is trehalose (Chapter 4).  
  Whether trehalose itself is required for multimerization of IniR remains to be addressed. Our 
initial crosslinking experiments, with heterologously expressed of IniRMtb in M. smegmatis, did not 
provide direct support for a trehalose-dependent multimerization. However, these results might be 
explained by the sheer overexpression of IniR or the presence of crude M. smegmatis cell lysate. 
Furthermore, additional signals that are dependent on the presence of EMB and/or INH, may be 
required to facilitate IniR multimerization. Such a signal could for instance be the accumulation of 
trehalose as a result of exposure to EMB or INH. Attempts to purify the protein from E. coli and M. 
smegmatis proved to be difficult, as a minority of the protein ended up in the soluble fraction and 
protein degradation readily occured. This suggests that monomeric IniR is either not stable or correctly 
folded and that a conformational change, binding of a substrate, or multimerization is required for 
proper folding. If trehalose is the substrate for IniR, we could learn more about the origin of the 
trehalose by looking at MalT from E. coli. In E. coli, the substrate (maltotriose) is imported from the 
periplasmic space into the cytoplasm. Similarly, once imported over the inner membrane, trehalose 
could bind IniR, multimerize and allow IniR to activate transcription of iniBAC. Techniques such as 
isothermal titration calorimetry (ITC) or saturation-transfer difference (STD)-NMR could prove to be 
useful to address whether trehalose is the substrate for IniR and whether this influences its oligomeric 
state. The analogy with the E. coli maltose uptake system makes it tempting to extrapolate the function 
of the IniBAC proteins as well. Perhaps these are the MalFGK counterparts, mediating the import of 
free trehalose or trehalose-containing lipids, even though these proteins do not show a strong 
resemblance to solute transporters.  
 
Figure 2. The maltose uptake system in E. coli. As maltose enters through a porin, the maltose binding protein 
(MBP) binds it and shuttles it through the periplasm. MBP subsequently binds the MalGFK2 complex which 
causes a conformational change in the transporter complex. This causes ATP to bind both MalK subunits. The 
ATP is subsequently hydrolysed and maltose is released into the cytoplasm. There, maltose binds MalT, causing 
a multimerization of MalT. This, in turn, leads to binding of MalT to the promoter of the mal operon genes 
causing upregulation of the maltose uptake system. Green arrows indicate induction signals, whereas red arrows 
represent inhibitory signals. 
 
The function of IniA and IniC with the Mal-system as a blueprint 
  In chapter 5 we present our research efforts to elucidate the role of the IniBAC proteins by 
making targeted single and triple knockout mutants. We show that IniB is in fact the major cell 
envelope protein that is produced and secreted in very large amounts in response to EMB and INH 
treatment. In addition, the production of this protein is dependent on the presence of functional copies 
of IniA and IniC; induction of the operon seems to be dependent on the presence of all the operon 
members. In light of these observations, we hypothesize that the IniBAC proteins transduce the stress 
signal to IniR to activate transcription of the operon.  
  IniA and IniC both have an ATPase domain (P-Loop NTPase domain). Both iniA and iniC are 
conserved among mycobacterial species, such as M. smegmatis, M. tuberculosis and M. bovis BCG. In 
chapter 5, we describe that IniA is partially associated with the (inner) membrane, which in 
concordance with the presence of a single transmembrane (TM-) helix (as predicted with TM-pred 
software). IniC does not have a predicted TM-helix and localization analysis also shows that the 
protein is predominantly found in the cytosol. Because IniA and IniC are co-expressed as a result of 
antibiotic stress, it is tempting to speculate that the proteins interact to form a functional unit that 
interacts with IniR. This would explain our observation that both an iniA and iniC knockout mutant are 
unable to activate iniBAC transcription. When we draw a parallel between the maltose uptake system 
from E. coli and the iniBAC operon members, it is noteworthy that the membrane-associated MalK 
also has an ATPase domain, similar to those of IniA and IniC. In E. coli, MalK is the subunit that 
forms the channel during the transfer of maltotriose to MalT (Boos & Shuman 1998). Interestingly, 
previous work on the structure of IniA has suggested that IniA can form a homo-hexameric ring-like 
structure that is associated with the membrane (Colangeli et al. 2005). 
  Work from Sawant et al. sheds another interesting light on the possible function of IniA and 
perhaps IniC (Sawant et al. 2016). The authors investigated the function of the IniA-homologue DynA 
in Bacillus subtilis. They found that under normal growth conditions DynA was associated with the 
membrane. However, when B. subtilis was transfected with phages or treated with nisin, a pore-
forming antimicrobial agent, DynA was redirected to the site of damage. There, DynA assembled into 
large polymers/aggregates to close the pores (Sawant et al. 2016). Even though the sequence 
homology between DynA and IniA (24%) and DynA and IniC (22%) is low, all three are considered 
dynamin-like-proteins (DLPs). Like DynA, IniA contains one TM domain. Although fascinating, it is 
unlikely that IniA closes inner membrane pores, like DynA. This is mainly because this activity would 
not explain why we see iniBAC induction upon treatment with antibiotics that specifically target the 
outer membrane. Although perhaps counterintuitive, it would be interesting to analyze whether 
bacteriophages or pore-forming agents can induce iniBAC by damaging the inner membrane. 
  The stoichiometry of three operon members is not known. However, RNA sequencing data 
from chapter 6 (and also data from chapter 4) suggest that the RNA levels for iniA and iniC are 
comparable after antibiotic induction: 32 fold and 23 fold for EMB, and 8 fold and 10 fold for INH, 
respectively. In stark contrast, iniB levels rise a staggering 381 fold after exposure to EMB and 99 fold 
in response to INH, an order of magnitude difference with iniA and iniC. In the case of iniB, these high 
transcript levels also reflect the tremendous overproduction that we observed at the protein level in our 
induction experiments and subsequent SDS-PAGE analysis. These experiments led to the 
identification of IniB by mass spectrophotometry.  
 
Speculating on the role of the IniB protein 
  One of our frustrations is that the exact role of the IniB protein has not been unveiled as a 
result of the work presented in this thesis. However, we can reflect on our findings regarding this 
unique protein. We first detected that IniB was produced in high amounts upon treatment of 
mycobacterial cells with EMB or INH. Subsequently, we identified IniB in multiple cell fractions and 
showed that it is (at least partially) secreted over the inner membrane. Because IniB does not have a 
traditional signal sequence (as determined by SignalP software), we attempted to identify whether 
alternative secretion systems are involved in secretion of this protein. To do so, we compared ESX-1, 
ESX-5 and secA2 transposon mutants with a WT M. marinum strain in their ability to produce and 
secrete IniB, in response to treatment with INH. Because all three mutants generated near-WT-levels 
of IniB, we concluded that these alternative secretion machineries are not involved in the secretion of 
IniB. Although we found that deletion of iniA or iniC abrogates production of IniB, we cannot rule out 
that these molecules also play a role in the secretion of this unusual protein.  
 The IniB protein contains highly repetitive and G-residue rich sequences (QAG, GLG e.g.) 
similar to those found in PGRS-like proteins. This could indicate a structural role for the IniB protein. 
M. tuberculosis also contains a copy of the iniB gene. However, the size of iniB in M. tuberculosis is 
only half (1440 bp) of that of the homologue found in M. marinum (3000 bp). A small part of the N-
terminal domain of IniB is conserved between species, indicating that this domain might be required 
for secretion, folding, function or membrane anchoring. Again, looking at the Mal-system as a 
blueprint for the stress transduction system that the iniBAC operon may encode, it is striking to note 
that all of the mal genes are essential for transducing the MalT-dependent transcriptional activation. 
This is also true for the iniBAC operon, as deletion of iniB results in the same inability to induce the 
iniBAC operon as observed in iniA and iniC knockout mutants.  
  In the analogy of the Mal system, IniB could fulfil the role of the substrate-binding protein: a 
periplasmic shuttle that can capture and transfer an incoming signal molecule, like maltose does for 
the Mal system. However, there is no structural evidence and no computational indication that IniB 
contains a substrate-binding domain that can facilitate this shuttle function. Even more so, there is no 
conserved sequence (and thus possible binding pocket) between M. marinum and M. tuberculosis. An 
explanation for the latter could be that M. tuberculosis IniB dimerizes to form roughly the same unit as 
the monomeric M. marinum IniB. Support for the hypothesis that IniB may bind an essential substrate 
(like TMMs or trehalose) comes from the observation that overexpression of iniB was lethal in a WT 
M. marinum strain. An overview of some of the speculated functions of the IniB protein can be found 
in figure 3. 
 
  
Figure 3. Left panel: The maltose uptake system of E. coli serves as a blueprint for the function of the IniBAC 
proteins. Right panel: Hypothesis of how the situation in mycobacteria could be. Trehalose or trehalose-
containing lipids can enter through an unknown porin-like protein or complex or can perhaps directly be taken 
up by IniB. IniB binds the trehalose-containing molecule and shuttles it through the periplasm. Then IniB 
interacts with the IniAC complex which causes a conformational change. Likely, IniA and IniC hydrolyse ATP 
(orange ‘P’) to induce this conformational change to translocate the trehalose-containing molecule to the 
cytoplasm. There, IniR binds trehalose and multimerizes into a dimer or tetramer to activate transcription (Boot 
et al. 2017, under review). Green arrows indicate experimentally proven interactions, whereas orange arrows 
indicate speculative steps in the system.  
 
 To IniB or not to IniB? 
  The IniB protein that we identified by mass spectrophotometry runs with a higher molecular 
weight than predicted. The protein size is around 86 kDa, whereas in our experiments it runs at around 
~120 kDa on SDS-PAGE gels. This size shift is suggestive of either a substrate that binds the protein 
(that can resist reducing conditions) or of post-translational modifications of IniB. Since our SDS-
PAGE gels display one clear IniB band and not a ladder of differently sized forms, the modification, if 
present, is likely uniformly present on all IniB molecules. There are some known examples of post-
translational modifications in mycobacteria, including mannosyl-serines and mannosyl-threonines 
(Pethe et al. 2002). Other modifications include the anchoring of sugars or lipids (van Els et al. 2014). 
However, in the case of IniB, it seems unlikely that these relatively small modifications could result in 
a shift of 35 kDa. A more plausible theory is that IniB binds a partner molecule that can withstand 
reducing conditions. Although we did not see such a molecule in our mass spectrophotometry data, 
this molecule might have been lost during processing of the sample or could be of non-protein nature 
(e.g. lipid). Alternatively, the 35 kDa size shift could be explained by a high intrinsic rigidity caused 
by the many prolines in the C-terminal domain of the IniB protein. This rigidity could lead to an 
elongated folding of regions in the protein and cause anomalous migration on SDS-PAGE gels. An 
example of such a rigid protein is the prokaryotic TonB, which contains a poly-proline domain 
responsible for the altered mobility on gel (Köhler et al. 2010). The IniB molecule of M. tuberculosis 
possesses a similar poly-proline C-terminal region, hinting at a rigid structure. It would be interesting 
to delete the C-terminal region to see whether it is responsible for the size shift in SDS-PAGE gel 
analyses. Notably, it is hypothesized that these elongated, poly-proline regions can span the periplasm. 
This could indicate that IniB can form a bridging structure or link between the cytoplasmic membrane 
and the outer membrane, in line with the theory that the protein has a more structural role in cell wall 
stress.  
 How the peculiar IniB protein is partially secreted in mycobacteria also remains speculative. 
Possibly, it is secreted in a similar to that of the maltose binding protein (MBP) of E. coli, which is 
predominantly secreted via the co-translational route. During the secretion process MBP interacts with 
SecB. SecB prevents premature folding and allows effective secretion. Interestingly, mycobacteria 
only have one specialised SecB-like chaperone, which is encoded by Rv1957. This SecB-like molecule 
was found to function in a toxin-antitoxin system in mycobacteria, but was able to complement a secB 
mutant in E. coli (Bordes et al. 2011).  
 To learn more about the function of the IniB protein, it would be interesting to look at M. 
smegmatis. M. smegmatis does not have the iniB gene. However, it does contain functional copies of 
iniR, iniA and iniC. Although we showed that M. smegmatis can serve as a host for iniBAC induction 
experiments (chapter 4), we are not sure whether the native iniAC and iniR genetic routes allow for 
functional stress signaling in M. smegmatis. Besides the absence of iniB, there are additional 
differences in the iniAC genetic region of M. smegmatis as compared with M. marinum and M. 
tuberculosis. For instance, MSMEG_0692c is inserted directly in front of iniR. This gene encodes a 
DnaK-like protein and shows the highest similarity to an Hsp70-type protein (20% amino acid 
similarity, as assessed by Phyre2). Moreover, there are two genes between the copies of iniA and iniC 
in M. smegmatis. These proteins likely encode holin-like molecules. If M. smegmatis has a functional 
cell wall stress-transducing system (IniAC/IniR), there must be an alternative entity to fulfil the role of 
the IniB protein. One protein that could replace a possible shuttling molecule or transport molecule is 
the outer membrane porin MspA. MspA is specific for the fast-growing M. smegmatis and is involved 
in nutrient uptake (Ates et al. 2015). The protein would therefore allow the uptake of trehalose or 
trehalose derivatives by diffusing through the pore, effectively circumventing the lack of IniB. This 
theory is also supported by our observations that the induction of the iniBAC operon by trehalose is 
amplified when MspA is introduced into M. marinum. An alternative theory is that the two holins that 
are present between iniA and iniC in M. smegmatis play a role in the uptake of the substrate. Holins 
are usually found in bacteriophages to allow the formation endolysin-holin complexes. These protein 
complexes are known to influence cell wall integrity by degrading cell wall structures, partially 
permeabilizing the bacterial cell wall in the process (Payne & Hatfull 2012). If these two proteins have 
a similar function in M. smegmatis, they could circumvent the need for transport of the signalling 
molecules through IniB. It would therefore be interesting to introduce these two genes in an iniB-
lacking M. marinum strain. This is something we are currently pursuing.  
   
Other proteins associated with the operon 
  Directly downstream of iniR there is a possible additional member of the iniBAC operon, 
encoded by Rv0340 in M. tuberculosis (MMAR_0613 in M. marinum and MSMEG_0693 in M. 
smegmatis). In M. marinum the gene shows some homology with iniB (32%), which led us to coin it 
iniB* (Chapter 4). The gene product of MMAR_0613 is a short protein (180 amino acids) of unknown 
function. Phyre2 predictions did not lead to the identification of protein folds or domains. Although 
the short gene is conserved between M. tuberculosis, M. smegmatis and M. marinum, the amino acid 
sequence homology is low (only 63% sequence identity between M. tuberculosis and M. marinum, 
67% between M.smegmatis and M. marinum). In our RNA sequencing database of drug-treated M. 
marinum (Chapter 6), we can find that MMAR_0613 is partially co-transcribed with the iniBAC genes 
in response to treatment with EMB and INH. After 24 hours of EMB or INH treatment, we can see a 
10-fold upregulation for EMB and 34-fold upregulation for INH, respectively, for MMAR_0613. This 
suggests a role for the protein in the stress response that is deployed upon antibiotic treatment. Perhaps 
the short protein binds or interacts with IniB, which could also explain the observed size shift on SDS-
PAGE gels.  
 
Heterogeneic cytochrome bd expression in zebrafish embryo brain tissue 
  In chapter 7 we discuss a cydBD stress reporter and its use as a genetic tool to study the 
expression of cytochrome bd in response to antibiotics. Moreover, we used the reporter to assess levels 
of cytBD during mouse macrophage infection, and in vivo in a zebrafish embryo infection model. Our 
data indicates that cytBD expression during exponential growth in culture is low. We found that 
antibiotics that target the respiratory chain of M. marinum, like bedaquiline, clofazimine and Q203 can 
induce the operon. In contrast, during cell infection and in vivo experiments we found that cytochrome 
bd is highly transcribed by default. Evidence that CytBD plays a role during infection comes from a 
study where deletion of the genes encoding the terminal oxidase in M. tuberculosis led to a decrease in 
bacterial counts that could be retrieved from infected mice (Shi et al. 2005). Our data strongly 
suggests that cytBD is highly transcribed and therefore important for bacterial cell homeostasis during 
infection. This is underscored by the high induction of fluorescence that we observed almost directly 
after injection of M. marinum in the hindbrain of zebrafish embryos. It is surprising to see that some 
regions of the hindbrain displayed an altered ratio of mEos3.1 (constitutive marker) /mCherry (cytBD 
levels) expression. These high cytBD-expressing patches of bacteria were seen lining the periphery of 
the hindbrain. It could be that this heterogenic expression is caused by different microenvironments in 
regions the brain. Research on the exact of role of infection on local brain homeostasis has not been 
performed yet. However, it is likely that there are differences in local immune responses depending on 
which compartment of the brain is infected. This is excellently reviewed by Weiss et al (Weiss et al. 
2009). Further experiments are required to confirm and assess the heterogenic expression of the cytBD 
reporter during local infection in different brain tissues. It would be interesting to find out whether 
transcriptional induction directly translates into functional CytBD complexes. Since the discovery of 
bedaquiline, the respiratory chain of mycobacteria has become an attractive target for antimicrobial 
compounds; it could therefore also be worthwhile to analyze the dynamic range of cydBD expression 
levels and the effects of these levels on the efficacy of antibiotic treatment. 
 
Concluding remarks 
Overall, this thesis provides several studies on the (previously uncharacterized) stress responses of 
pathogenic mycobacteria to antibiotics and environmental stresses. Based on this work, molecular 
tools, such as stress reporters, can be developed that allow us to address fundamental questions 
regarding the induction parameters of a gene of interest. In this thesis, we show four different studies 
that utilized genetic reporters to address several fundamental questions regarding dynamics of 
phosphate limitation in vivo (Chapter 2) and the molecular requirements of the iniBAC and cytBD 
operons (Chapter 3 and Chapter 7) as well as the corresponding genetic regulatory network (Chapter 
4). These reporters also allowed us to briefly address more clinically relevant issues like the amount of 
heterogeneity in response to antibiotic treatment. With these reporters, we hope to aid anti-TB drug 
discovery by identifying essential stress coping mechanisms and drug-induced key players that can 
serve as a target for novel therapeutic interventions to combat TB.  
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